false2022Q30001910851December 31R1 RCM Inc. /DEP3MP1YP1YP1YP1YP1YP3Y00019108512022-01-012022-09-3000019108512022-11-04xbrli:shares00019108512022-09-30iso4217:USD00019108512021-12-310001910851srt:AffiliatedEntityMember2022-09-300001910851srt:AffiliatedEntityMember2021-12-31iso4217:USDxbrli:shares00019108512022-07-012022-09-3000019108512021-07-012021-09-3000019108512021-01-012021-09-300001910851us-gaap:CommonStockMember2021-12-310001910851us-gaap:TreasuryStockCommonMember2021-12-310001910851us-gaap:AdditionalPaidInCapitalMember2021-12-310001910851us-gaap:RetainedEarningsMember2021-12-310001910851us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001910851us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-3100019108512022-01-012022-03-310001910851us-gaap:CommonStockMember2022-01-012022-03-310001910851us-gaap:TreasuryStockCommonMember2022-01-012022-03-310001910851us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001910851us-gaap:RetainedEarningsMember2022-01-012022-03-310001910851us-gaap:CommonStockMember2022-03-310001910851us-gaap:TreasuryStockCommonMember2022-03-310001910851us-gaap:AdditionalPaidInCapitalMember2022-03-310001910851us-gaap:RetainedEarningsMember2022-03-310001910851us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-3100019108512022-03-310001910851us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-3000019108512022-04-012022-06-300001910851us-gaap:CommonStockMember2022-04-012022-06-300001910851us-gaap:TreasuryStockCommonMember2022-04-012022-06-300001910851us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001910851us-gaap:RetainedEarningsMember2022-04-012022-06-300001910851us-gaap:CommonStockMember2022-06-300001910851us-gaap:TreasuryStockCommonMember2022-06-300001910851us-gaap:AdditionalPaidInCapitalMember2022-06-300001910851us-gaap:RetainedEarningsMember2022-06-300001910851us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-3000019108512022-06-300001910851us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001910851us-gaap:AdditionalPaidInCapitalMemberah:CoyCo2Member2022-07-012022-09-300001910851ah:CoyCo2Member2022-07-012022-09-300001910851us-gaap:CommonStockMember2022-07-012022-09-300001910851us-gaap:TreasuryStockCommonMember2022-07-012022-09-300001910851us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300001910851us-gaap:RetainedEarningsMember2022-07-012022-09-300001910851us-gaap:CommonStockMember2022-09-300001910851us-gaap:TreasuryStockCommonMember2022-09-300001910851us-gaap:AdditionalPaidInCapitalMember2022-09-300001910851us-gaap:RetainedEarningsMember2022-09-300001910851us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300001910851us-gaap:CommonStockMember2020-12-310001910851us-gaap:TreasuryStockCommonMember2020-12-310001910851us-gaap:AdditionalPaidInCapitalMember2020-12-310001910851us-gaap:RetainedEarningsMember2020-12-310001910851us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-3100019108512020-12-310001910851us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-3100019108512021-01-012021-03-310001910851us-gaap:CommonStockMember2021-01-012021-03-310001910851us-gaap:TreasuryStockCommonMember2021-01-012021-03-310001910851us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001910851us-gaap:RetainedEarningsMember2021-01-012021-03-310001910851us-gaap:CommonStockMember2021-03-310001910851us-gaap:TreasuryStockCommonMember2021-03-310001910851us-gaap:AdditionalPaidInCapitalMember2021-03-310001910851us-gaap:RetainedEarningsMember2021-03-310001910851us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-3100019108512021-03-310001910851us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-3000019108512021-04-012021-06-300001910851us-gaap:CommonStockMember2021-04-012021-06-300001910851us-gaap:TreasuryStockCommonMember2021-04-012021-06-300001910851us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300001910851us-gaap:RetainedEarningsMember2021-04-012021-06-300001910851us-gaap:CommonStockMember2021-06-300001910851us-gaap:TreasuryStockCommonMember2021-06-300001910851us-gaap:AdditionalPaidInCapitalMember2021-06-300001910851us-gaap:RetainedEarningsMember2021-06-300001910851us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-3000019108512021-06-300001910851us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300001910851us-gaap:CommonStockMember2021-07-012021-09-300001910851us-gaap:TreasuryStockCommonMember2021-07-012021-09-300001910851us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300001910851us-gaap:RetainedEarningsMember2021-07-012021-09-300001910851us-gaap:CommonStockMember2021-09-300001910851us-gaap:TreasuryStockCommonMember2021-09-300001910851us-gaap:AdditionalPaidInCapitalMember2021-09-300001910851us-gaap:RetainedEarningsMember2021-09-300001910851us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-3000019108512021-09-300001910851ah:CoyCo2Member2022-01-012022-09-300001910851ah:CoyCo2Member2021-01-012021-09-300001910851ah:CloudmedMember2022-01-012022-09-300001910851ah:CloudmedMember2021-01-012021-09-300001910851ah:VisitPayIncMember2022-01-012022-09-300001910851ah:VisitPayIncMember2021-01-012021-09-300001910851ah:SeniorTermLoanMember2022-01-012022-09-300001910851ah:SeniorTermLoanMember2021-01-012021-09-300001910851us-gaap:RevolvingCreditFacilityMember2022-01-012022-09-300001910851us-gaap:RevolvingCreditFacilityMember2021-01-012021-09-300001910851ah:CloudmedMember2022-06-21xbrli:pure0001910851ah:CloudmedMember2022-06-212022-06-210001910851us-gaap:SubsequentEventMemberah:CloudmedMember2022-10-012022-10-310001910851us-gaap:AccountingStandardsUpdate202108Memberah:CloudmedMember2022-04-010001910851ah:CloudmedAcquisitionMember2022-06-212022-06-210001910851us-gaap:RestrictedStockUnitsRSUMemberah:CloudmedAcquisitionMember2022-06-212022-06-210001910851ah:CloudmedMemberah:CloudmedAcquisitionMember2022-06-212022-06-210001910851ah:CloudmedAcquisitionMember2022-06-210001910851us-gaap:CustomerRelationshipsMemberah:CloudmedAcquisitionMember2022-06-212022-06-210001910851us-gaap:TechnologyBasedIntangibleAssetsMemberah:CloudmedAcquisitionMember2022-06-212022-06-210001910851ah:CloudmedAcquisitionMemberus-gaap:LeasesAcquiredInPlaceMarketAdjustmentMember2022-06-212022-06-210001910851ah:CloudmedAcquisitionMember2022-07-012022-09-300001910851ah:CloudmedAcquisitionMember2022-01-012022-09-300001910851ah:RevWorksAcquisitionMember2021-07-012021-09-300001910851ah:RevWorksAcquisitionMember2022-08-012022-08-310001910851ah:RevWorksAcquisitionMember2020-12-31ah:payment0001910851ah:RevWorksAcquisitionMember2020-01-012020-12-310001910851ah:RevWorksAcquisitionMember2022-09-300001910851ah:CloudmedAndVisitPayAcquisitionsMember2022-07-012022-09-300001910851ah:CloudmedAndVisitPayAcquisitionsMember2021-07-012021-09-300001910851ah:CloudmedAndVisitPayAcquisitionsMember2022-01-012022-09-300001910851ah:CloudmedAndVisitPayAcquisitionsMember2021-01-012021-09-300001910851us-gaap:CustomerRelationshipsMember2022-09-300001910851us-gaap:CustomerRelationshipsMember2021-12-310001910851us-gaap:TechnologyBasedIntangibleAssetsMember2022-09-300001910851us-gaap:TechnologyBasedIntangibleAssetsMember2021-12-310001910851us-gaap:TradeNamesMember2022-09-300001910851us-gaap:TradeNamesMember2021-12-310001910851us-gaap:LeasesAcquiredInPlaceMarketAdjustmentMember2022-09-300001910851us-gaap:LeasesAcquiredInPlaceMarketAdjustmentMember2021-12-310001910851ah:NetOperatingFeesMember2022-07-012022-09-300001910851ah:NetOperatingFeesMember2021-07-012021-09-300001910851ah:NetOperatingFeesMember2022-01-012022-09-300001910851ah:NetOperatingFeesMember2021-01-012021-09-300001910851ah:IncentiveFeesMember2022-07-012022-09-300001910851ah:IncentiveFeesMember2021-07-012021-09-300001910851ah:IncentiveFeesMember2022-01-012022-09-300001910851ah:IncentiveFeesMember2021-01-012021-09-300001910851ah:ModularAndOtherMember2022-07-012022-09-300001910851ah:ModularAndOtherMember2021-07-012021-09-300001910851ah:ModularAndOtherMember2022-01-012022-09-300001910851ah:ModularAndOtherMember2021-01-012021-09-300001910851us-gaap:InvestorMember2022-09-300001910851us-gaap:InvestorMember2021-12-310001910851ah:ContractWithCustomerLiabilityIncludingAdvancedBillingsMember2022-01-012022-09-300001910851ah:ContractWithCustomerLiabilityIncludingAdvancedBillingsMember2021-01-012021-09-300001910851us-gaap:AccountsReceivableMember2022-09-300001910851us-gaap:AccountsReceivableMember2021-09-300001910851ah:NetOperatingFeesMember2022-10-012022-09-3000019108512022-10-01ah:IncentiveFeesMember2022-09-300001910851ah:NetOperatingFeesMember2023-01-012022-09-3000019108512023-01-01ah:IncentiveFeesMember2022-09-300001910851ah:NetOperatingFeesMember2024-01-012022-09-300001910851ah:IncentiveFeesMember2024-01-012022-09-300001910851ah:NetOperatingFeesMember2025-01-012022-09-3000019108512025-01-01ah:IncentiveFeesMember2022-09-300001910851ah:NetOperatingFeesMember2026-01-012022-09-300001910851ah:IncentiveFeesMember2026-01-012022-09-300001910851ah:NetOperatingFeesMember2027-01-012022-09-3000019108512027-01-01ah:IncentiveFeesMember2022-09-300001910851ah:NetOperatingFeesMember2028-01-012022-09-300001910851ah:IncentiveFeesMember2028-01-012022-09-300001910851ah:NetOperatingFeesMember2022-09-300001910851ah:IncentiveFeesMember2022-09-3000019108512022-10-012022-09-3000019108512023-01-012022-09-3000019108512024-01-012022-09-3000019108512025-01-012022-09-3000019108512026-01-012022-09-3000019108512027-01-012022-09-3000019108512028-01-012022-09-300001910851ah:PhysicianCustomerMember2022-07-012022-09-300001910851ah:PhysicianCustomerMember2022-09-300001910851ah:CloudmedMemberus-gaap:AccountingStandardsUpdate201613Member2022-06-300001910851ah:CloudmedMemberus-gaap:AccountingStandardsUpdate201613Member2021-06-300001910851ah:CloudmedMemberus-gaap:AccountingStandardsUpdate201613Member2021-12-310001910851ah:CloudmedMemberus-gaap:AccountingStandardsUpdate201613Member2020-12-310001910851us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2022-09-300001910851us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2021-12-310001910851ah:SeniorSecuredTermLoanAMemberus-gaap:LineOfCreditMember2022-09-300001910851ah:SeniorSecuredTermLoanAMemberus-gaap:LineOfCreditMember2021-12-310001910851ah:SeniorSecuredTermLoanBMemberus-gaap:LineOfCreditMember2022-09-300001910851ah:SeniorSecuredTermLoanBMemberus-gaap:LineOfCreditMember2021-12-310001910851us-gaap:LetterOfCreditMemberus-gaap:LineOfCreditMember2022-09-300001910851us-gaap:LineOfCreditMemberah:SecondARCreditAgreementMemberah:ExistingSeniorSecuredTermLoanAMember2022-06-210001910851ah:IncrementalSeniorSecuredTermLoanAMemberus-gaap:LineOfCreditMemberah:SecondARCreditAgreementMember2022-06-210001910851ah:SeniorSecuredTermLoanBMemberus-gaap:LineOfCreditMemberah:SecondARCreditAgreementMember2022-06-210001910851us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberah:SecondARCreditAgreementMember2022-06-210001910851ah:IncrementalSeniorSecuredTermLoanAMemberus-gaap:LineOfCreditMemberah:SecondARCreditAgreementMember2022-06-212022-06-210001910851ah:SeniorSecuredTermLoanBMemberus-gaap:LineOfCreditMemberah:SecondARCreditAgreementMember2022-06-212022-06-210001910851us-gaap:LineOfCreditMemberah:SecondARCreditAgreementMember2022-06-21ah:offer0001910851us-gaap:LineOfCreditMemberah:SecondARCreditAgreementMemberus-gaap:FederalFundsEffectiveSwapRateMember2022-06-212022-06-210001910851ah:InterestRateOptionBasisSpreadOneMemberus-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberah:SecondARCreditAgreementMember2022-06-212022-06-210001910851ah:InterestRateOptionBasisSpreadOneMembersrt:MinimumMemberus-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberah:SecondARCreditAgreementMember2022-06-212022-06-210001910851ah:InterestRateOptionBasisSpreadOneMemberus-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberah:SecondARCreditAgreementMembersrt:MaximumMember2022-06-212022-06-210001910851ah:InterestRateOptionBasisSpreadOneMemberah:SeniorSecuredTermLoanAMemberus-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberah:SecondARCreditAgreementMember2022-06-212022-06-210001910851ah:InterestRateOptionBasisSpreadOneMemberah:SeniorSecuredTermLoanBMemberus-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberah:SecondARCreditAgreementMember2022-06-212022-06-210001910851ah:SeniorSecuredTermLoanAMemberah:InterestRateOptionBasisSpreadTwoMemberus-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberah:SecondARCreditAgreementMember2022-06-212022-06-210001910851ah:SeniorSecuredTermLoanBMemberah:InterestRateOptionBasisSpreadTwoMemberus-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberah:SecondARCreditAgreementMember2022-06-212022-06-210001910851ah:SeniorSecuredTermLoanBMemberah:InterestRateOptionBasisSpreadTwoMembersrt:MinimumMemberus-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberah:SecondARCreditAgreementMember2022-06-212022-06-210001910851ah:SeniorSecuredTermLoanBMemberah:InterestRateOptionBasisSpreadTwoMemberus-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberah:SecondARCreditAgreementMembersrt:MaximumMember2022-06-212022-06-210001910851ah:SeniorSecuredTermLoanAMemberus-gaap:LineOfCreditMemberah:SecondARCreditAgreementMember2022-09-300001910851ah:SeniorSecuredTermLoanBMemberus-gaap:LineOfCreditMemberah:SecondARCreditAgreementMember2022-09-300001910851us-gaap:RevolvingCreditFacilityMembersrt:MinimumMemberus-gaap:LineOfCreditMemberah:SecondARCreditAgreementMember2022-06-212022-06-210001910851us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberah:SecondARCreditAgreementMembersrt:MaximumMember2022-06-212022-06-210001910851us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2022-01-012022-09-300001910851us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2022-07-012022-09-300001910851us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2021-07-012021-09-300001910851us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2021-01-012021-09-300001910851us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2022-09-300001910851us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2022-01-012022-09-300001910851us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2022-07-012022-09-300001910851us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2021-07-012021-09-300001910851us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2021-01-012021-09-300001910851us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2022-09-300001910851us-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2021-12-310001910851us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2021-12-3100019108512021-01-012021-12-310001910851ah:ThirdPartyMember2022-07-052022-07-050001910851us-gaap:CostOfSalesMember2022-07-012022-09-300001910851us-gaap:CostOfSalesMember2021-07-012021-09-300001910851us-gaap:CostOfSalesMember2022-01-012022-09-300001910851us-gaap:CostOfSalesMember2021-01-012021-09-300001910851us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-07-012022-09-300001910851us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-07-012021-09-300001910851us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-09-300001910851us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-09-300001910851ah:OtherMember2022-07-012022-09-300001910851ah:OtherMember2021-07-012021-09-300001910851ah:OtherMember2022-01-012022-09-300001910851ah:OtherMember2021-01-012021-09-300001910851us-gaap:RestrictedStockUnitsRSUMember2021-12-310001910851us-gaap:PerformanceSharesMember2021-12-310001910851us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-09-300001910851us-gaap:PerformanceSharesMember2022-01-012022-09-300001910851us-gaap:RestrictedStockUnitsRSUMember2022-09-300001910851us-gaap:PerformanceSharesMember2022-09-300001910851us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-09-300001910851us-gaap:PerformanceSharesMember2021-01-012021-09-300001910851ah:RestrictedStockUnitsRSUsAndPerformanceSharesMemberah:CloudmedAcquisitionMember2022-06-212022-06-210001910851srt:MinimumMemberus-gaap:PerformanceSharesMember2022-01-012022-09-300001910851us-gaap:PerformanceSharesMembersrt:MaximumMember2022-01-012022-09-300001910851ah:FormerClassPUnitsMember2022-06-212022-06-210001910851ah:ManagementUnitsMember2022-06-212022-06-210001910851ah:ManagementUnitsMember2022-01-012022-09-300001910851us-gaap:InvestorMemberus-gaap:WarrantMember2022-01-012022-09-300001910851us-gaap:InvestorMemberus-gaap:WarrantMember2022-07-012022-09-300001910851ah:IntermountainMemberus-gaap:WarrantMember2022-07-012022-09-300001910851ah:IntermountainMemberus-gaap:WarrantMember2022-01-012022-09-300001910851us-gaap:InvestorMemberus-gaap:WarrantMember2021-07-012021-09-300001910851ah:IntermountainMemberus-gaap:WarrantMember2021-01-012021-09-300001910851us-gaap:PendingLitigationMemberah:TCPASCRecapitalizationLitigationMember2021-04-132021-04-19ah:claim0001910851ah:TCPASCACHISeriesLLLPMemberus-gaap:CommonStockMembersrt:AffiliatedEntityMember2021-05-272021-05-280001910851ah:TCPASCACHISeriesLLLPMemberus-gaap:CommonStockMembersrt:AffiliatedEntityMember2021-05-280001910851ah:TCPASCACHISeriesLLLPMembersrt:AffiliatedEntityMember2021-05-280001910851ah:TCPASCACHISeriesLLLPMembersrt:MinimumMembersrt:AffiliatedEntityMember2021-05-280001910851ah:TCPASCACHISeriesLLLPMembersrt:AffiliatedEntityMembersrt:MaximumMember2021-05-28ah:segment0001910851us-gaap:SalesRevenueNetMemberah:AscensionMemberus-gaap:CustomerConcentrationRiskMember2022-07-012022-09-300001910851us-gaap:SalesRevenueNetMemberah:AscensionMemberus-gaap:CustomerConcentrationRiskMember2021-07-012021-09-300001910851us-gaap:SalesRevenueNetMemberah:AscensionMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-09-300001910851us-gaap:SalesRevenueNetMemberah:AscensionMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-09-300001910851us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberah:CustomerNotAffiliatedwithAscensionHealthMember2022-07-012022-09-300001910851us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberah:CustomerNotAffiliatedwithAscensionHealthMember2021-07-012021-09-300001910851us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberah:CustomerNotAffiliatedwithAscensionHealthMember2022-01-012022-09-300001910851us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberah:CustomerNotAffiliatedwithAscensionHealthMember2021-01-012021-09-300001910851us-gaap:AccountsReceivableMemberah:AscensionMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-09-300001910851us-gaap:AccountsReceivableMemberah:AscensionMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-12-31


UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q

(Mark One)

☑    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
    For the quarterly period ended September 30, 2022
OR
☐    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
    For the transition period from to
COMMISSION FILE NUMBER: 001-41428
R1 RCM INC.
(Exact name of registrant as specified in its charter)
Delaware87-4340782
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification Number)
434 W. Ascension Way
84123
6th Floor
Murray
Utah
(Address of principal executive offices)(Zip code)
(312) 324-7820
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, par value $0.01 per shareRCMNASDAQ
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes þ     No 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes þ    No  
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filerý
Accelerated filerNon-accelerated filerSmaller reporting companyEmerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ☐     No 
As of November 4, 2022, the registrant had 416,510,858 shares of common stock, par value $0.01 per share, outstanding.






Table of Contents
 
 
 
 
  




PART I — FINANCIAL INFORMATION
Item 1.Financial Statements
3


R1 RCM Inc.
Consolidated Balance Sheets
(In millions, except share and per share data)

(Unaudited)
 September 30,December 31,
 20222021
Assets
Current assets:
Cash and cash equivalents$131.1 $130.1 
Accounts receivable, net of $14.5 million and $2.4 million allowance as of September 30, 2022 and December 31, 2021, respectively
209.0 131.3 
Accounts receivable, net of $0.1 million and $0.1 million allowance - related party as of September 30, 2022 and December 31, 2021, respectively
29.7 26.1 
Current portion of contract assets74.4 — 
Prepaid expenses and other current assets96.9 77.2 
Total current assets541.1 364.7 
Property, equipment and software, net163.0 94.7 
Operating lease right-of-use assets98.9 48.9 
Non-current portion of contract assets30.8 — 
Non-current portion of deferred contract costs27.5 23.4 
Intangible assets, net1,567.5 265.4 
Goodwill2,549.3 554.7 
Non-current deferred tax assets9.4 51.8 
Other assets93.6 45.7 
Total assets$5,081.1 $1,449.3 
Liabilities
Current liabilities:
Accounts payable$25.0 $17.7 
Current portion of customer liabilities67.8 41.5 
Current portion of customer liabilities - related party5.6 7.9 
Accrued compensation and benefits105.7 97.0 
Current portion of operating lease liabilities20.8 13.5 
Current portion of long-term debt49.5 17.5 
Other accrued expenses71.6 59.1 
Total current liabilities346.0 254.2 
Non-current portion of customer liabilities5.3 3.3 
Non-current portion of customer liabilities - related party14.1 15.4 
Non-current portion of operating lease liabilities99.2 53.4 
Long-term debt1,728.1 754.9 
Non-current deferred tax liabilities98.2 4.2 
Other non-current liabilities22.4 17.2 
Total liabilities2,313.3 1,102.6 
Stockholders’ equity:
Common stock, $0.01 par value, 750,000,000 shares authorized, 439,386,709 shares issued and 417,722,143 shares outstanding at September 30, 2022; 500,000,000 shares authorized, 298,320,928 shares issued and 278,226,242 shares outstanding at December 31, 2021
4.4 3.0 
Additional paid-in capital3,104.4 628.5 
Accumulated deficit(84.8)(64.3)
Accumulated other comprehensive loss(4.0)(5.3)
Treasury stock, at cost, 21,664,566 shares as of September 30, 2022; 20,094,686 shares as of December 31, 2021
(252.2)(215.2)
Total stockholders’ equity2,767.8 346.7 
Total liabilities and stockholders’ equity$5,081.1 $1,449.3 
See accompanying notes to consolidated financial statements.
4


R1 RCM Inc.
Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)
(In millions, except share and per share data)

 
 Three Months Ended September 30,Nine Months Ended September 30,
 2022202120222021
Net services revenue ($218.1 million and $657.8 million for the three and nine months ended September 30, 2022, respectively, and $227.5 million and $661.4 million for the three and nine months ended September 30, 2021, respectively, from related party)
$496.0 $379.7 $1,273.6 $1,075.7 
Operating expenses:
Cost of services403.1 304.0 1,009.7 858.2 
Selling, general and administrative60.8 33.2 120.6 87.8 
Other expenses30.1 11.4 136.1 34.2 
Total operating expenses494.0 348.6 1,266.4 980.2 
Income from operations2.0 31.1 7.2 95.5 
Net interest expense23.7 6.5 35.3 13.8 
Income (loss) before income tax provision (benefit)(21.7)24.6 (28.1)81.7 
Income tax provision (benefit)7.8 7.6 (7.6)20.5 
Net income (loss)$(29.5)$17.0 $(20.5)$61.2 
Net income (loss) per common share:
Basic$(0.07)$0.06 $(0.06)$(2.03)
Diluted$(0.07)$0.05 $(0.06)$(2.03)
Weighted average shares used in calculating net income (loss) per common share:
Basic417,700,782 278,655,269 330,877,880 262,209,929 
Diluted417,700,782 320,617,086 330,877,880 262,209,929 
Consolidated statements of comprehensive income (loss)
Net income (loss)$(29.5)$17.0 $(20.5)$61.2 
Other comprehensive income (loss):
Net change on derivatives designated as cash flow hedges, net of tax9.2 0.5 8.1 0.9 
Foreign currency translation adjustments(2.2)— (6.8)(1.0)
Total other comprehensive income (loss), net of tax$7.0 $0.5 $1.3 $(0.1)
Comprehensive income (loss)$(22.5)$17.5 $(19.2)$61.1 
Basic:
Net income (loss)$(29.5)$17.0 $(20.5)$61.2 
Less dividends on preferred shares— — — (592.3)
Net income (loss) available/allocated to common shareholders - basic$(29.5)$17.0 $(20.5)$(531.1)
Diluted:
Net income (loss)$(29.5)$17.0 $(20.5)$61.2 
Less dividends on preferred shares— — — (592.3)
Net income (loss) available/allocated to common shareholders - diluted$(29.5)$17.0 $(20.5)$(531.1)
See accompanying notes to consolidated financial statements.
5


R1 RCM Inc.
Consolidated Statements of Stockholders’ Equity (Unaudited)
(In millions, except share and per share data)

 Common StockTreasury StockAdditional
Paid-In
Capital
Accumulated
Deficit
Accumulated
Other
Comprehensive
Loss
Total
 SharesAmountSharesAmount    
Balance at December 31, 2021298,320,928 $3.0 (20,094,686)$(215.2)$628.5 $(64.3)$(5.3)$346.7 
Share-based compensation expense— — — — 10.2 — — 10.2 
Issuance of common stock related to share-based compensation plans1,757,955 — — — — — — — 
Exercise of vested stock options77,438 — — — 0.4 — — 0.4 
Acquisition of treasury stock related to share-based compensation plans— — (727,768)(18.7)— — — (18.7)
Repurchases of common stock— — (8,000)(0.2)— — — (0.2)
Net change on derivatives designated as cash flow hedges, net of tax of $0.0 million
— — — — — — 0.1 0.1 
Foreign currency translation adjustments— — — — — — (1.4)(1.4)
Net income— — — — — 29.4 — 29.4 
Balance at March 31, 2022300,156,321 $3.0 (20,830,454)$(234.1)$639.1 $(34.9)$(6.6)$366.5 
Share-based compensation expense— — — — 11.6 — — 11.6 
Issuance of common stock related to share-based compensation plans505,371 — — — — — — — 
Issuance of common stock135,929,742 1.4 — — 2,386.1 — — 2,387.5 
Replacement awards issued in conjunction with acquisitions— — — — 11.3 — — 11.3 
Exercise of vested stock options395,425 — (2,282)(0.1)2.1 — — 2.0 
Acquisition of treasury stock related to share-based compensation plans— — (153,157)(3.5)— — — (3.5)
Net change on derivatives designated as cash flow hedges, net of tax of $0.4 million
— — — — — — (1.2)(1.2)
Foreign currency translation adjustments— — — — — — (3.2)(3.2)
Net loss— — — — — (20.4)— (20.4)
Balance at June 30, 2022436,986,859 $4.4 (20,985,893)$(237.7)$3,050.2 $(55.3)$(11.0)$2,750.6 
Share-based compensation expense— — — — 24.8 — — 24.8 
CoyCo 2 share-based compensation expense— — — — 3.0 — — 3.0 
Issuance of common stock related to share-based compensation plans189,566 — — — — — — — 
Issuance of common stock1,403,687 — — — 24.3 — — 24.3 
Exercise of vested stock options806,597 — — — 2.1 — — 2.1 
Acquisition of treasury stock related to share-based compensation plans— — (84,547)(1.9)— — — (1.9)
Repurchases of common stock— — (594,126)(12.6)— — — (12.6)
Net change on derivatives designated as cash flow hedges, net of tax of $3.1 million
— — — — — — 9.2 9.2 
Foreign currency translation adjustments— — — — — — (2.2)(2.2)
Net loss— — — — — (29.5)— (29.5)
Balance at September 30, 2022439,386,709 $4.4 (21,664,566)$(252.2)$3,104.4 $(84.8)$(4.0)$2,767.8 
See accompanying notes to consolidated financial statements.
6


R1 RCM Inc.
Consolidated Statements of Stockholders’ Equity (Unaudited)
(In millions, except share and per share data)

 Common StockTreasury StockAdditional
Paid-In
Capital
Accumulated
Deficit
Accumulated
Other
Comprehensive
Loss
Total
 SharesAmountSharesAmount    
Balance at December 31, 2020137,812,559 $1.4 (16,668,521)$(139.2)$393.7 $(161.5)$(6.5)$87.9 
Share-based compensation expense— — — — 12.8 — — 12.8 
Issuance of common stock related to share-based compensation plans6,497 — — — — — — — 
Issuance of common stock324,212 — — — 7.0 — — 7.0 
Exercise of vested stock options539,795 — — — 3.5 — — 3.5 
Acquisition of treasury stock related to share-based compensation plans— — (2,201)— — — — — 
Net change on derivatives designated as cash flow hedges, net of tax of $0.2 million
— — — — — — 0.5 0.5 
Foreign currency translation adjustments— — — — — — (0.4)(0.4)
Conversion of preferred shares117,706,400 1.2 — — 250.3 — — 251.5 
Inducement dividend— — — — (592.3)— — (592.3)
Issuance of common stock related to inducement21,582,800 0.2 — — 487.1 — — 487.3 
Net income— — — — — 25.8 — 25.8 
Balance at March 31, 2021277,972,263 $2.8 (16,670,722)$(139.2)$562.1 $(135.7)$(6.4)$283.6 
Share-based compensation expense— — — — 24.0 — — 24.0 
Issuance of common stock related to share-based compensation plans539,884 — — — — — — — 
Exercise of vested stock options396,250 — — — 1.3 — — 1.3 
Acquisition of treasury stock related to share-based compensation plans— — (167,832)(4.5)— — — (4.5)
Net change on derivatives designated as cash flow hedges, net of tax of $0.0 million
— — — — — — (0.1)(0.1)
Foreign currency translation adjustments— — — — — — (0.6)(0.6)
Exercise of warrants pursuant to cashless provisions16,750,000 0.2 — — (0.2)— — — 
Net income— — — — — 18.4 — 18.4 
Balance at June 30, 2021295,658,397 $3.0 (16,838,554)$(143.7)$587.2 $(117.3)$(7.1)$322.1 
Share-based compensation expense— — — — 25.8 — — 25.8 
Issuance of common stock related to share-based compensation plans54,524 — — — — — — — 
Exercise of vested stock options172,587 — — — 0.7 — — 0.7 
Acquisition of treasury stock related to share-based compensation plans— — (16,555)(0.3)— — — (0.3)
Repurchases of common stock— — (1,538,077)(31.7)— — — (31.7)
Net change on derivatives designated as cash flow hedges, net of tax of $0.1 million
— — — — — — 0.5 0.5 
Net income— — — — — 17.0 — 17.0 
Balance at September 30, 2021295,885,508 $3.0 (18,393,186)$(175.7)$613.7 $(100.3)$(6.6)$334.1 
See accompanying notes to consolidated financial statements.
7


R1 RCM Inc.
Consolidated Statements of Cash Flows (Unaudited)
(In millions)

 Nine Months Ended September 30,
 20222021
Operating activities
Net income (loss)$(20.5)$61.2 
Adjustments to reconcile net income (loss) to net cash (used in) provided by operations:
Depreciation and amortization107.8 56.8 
Amortization of debt issuance costs2.2 0.8 
Share-based compensation46.5 62.0 
CoyCo 2 share-based compensation3.0 — 
(Gain)/loss on disposal and right-of-use asset write-downs3.9 (0.3)
Provision for credit losses10.7 0.6 
Deferred income taxes(9.1)18.0 
Non-cash lease expense10.5 7.4 
Other1.5 0.8 
Changes in operating assets and liabilities:
Accounts receivable and related party accounts receivable(29.7)(18.8)
Contract assets(12.8)— 
Prepaid expenses and other assets(38.3)(19.8)
Accounts payable(23.9)4.5 
Accrued compensation and benefits(79.6)34.3 
Lease liabilities(11.4)(9.9)
Other liabilities(3.2)(8.9)
Customer liabilities and customer liabilities - related party2.9 30.1 
Net cash (used in) provided by operating activities(39.5)218.8 
Investing activities
Purchases of property, equipment, and software(74.6)(33.4)
Acquisition of Cloudmed, net of cash acquired(847.7)— 
Acquisition of VisitPay, net of cash acquired— (294.7)
Proceeds from disposal of assets0.4 2.6 
Net cash used in investing activities(921.9)(325.5)
Financing activities
Issuance of senior secured debt, net of discount and issuance costs1,016.6 698.6 
Borrowings on revolver30.0 120.0 
Payment of debt issuance costs(1.0)(1.9)
Repayment of senior secured debt(13.1)(484.6)
Repayments on revolver(30.0)(90.0)
Payment of contingent consideration liability
— (4.8)
Deferred payment related to acquisition of RevWorks— (12.5)
Inducement of preferred stock conversion— (105.0)
Payment of equity issuance costs(2.0)— 
Exercise of vested stock options4.6 6.3 
Purchase of treasury stock(12.5)(29.5)
Shares withheld for taxes(26.9)(4.8)
Other(0.2)(0.1)
Net cash provided by financing activities965.5 91.7 
Effect of exchange rate changes in cash, cash equivalents and restricted cash(3.1)(0.6)
Net increase (decrease) in cash, cash equivalents and restricted cash1.0 (15.6)
Cash, cash equivalents and restricted cash, at beginning of period130.1 174.8 
Cash, cash equivalents and restricted cash, at end of period$131.1 $159.2 
Supplemental disclosures of cash flow information
Property, equipment and software purchases not paid$27.4 $25.7 
See accompanying notes to consolidated financial statements.
8



R1 RCM Inc.
Notes to Consolidated Financial Statements (Unaudited)
(Dollars in millions, except per share data)

1. Business Description and Basis of Presentation
Business Description
R1 RCM Inc. (the “Company”) is a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers. The Company helps healthcare providers generate sustainable improvements in their operating margins and cash flows while also enhancing patient, physician, and staff satisfaction for its customers.

Cloudmed Acquisition

On June 21, 2022, pursuant to the Transaction Agreement and Plan of Merger (the “Transaction Agreement”), dated as of January 9, 2022, among R1 RCM Inc. (f/k/a Project Roadrunner Parent Inc.), R1 RCM Holdco Inc. (f/k/a R1 RCM Inc.), a wholly-owned subsidiary of the Company (“Old R1 RCM”), Project Roadrunner Merger Sub Inc., formerly a wholly-owned subsidiary of the Company (“R1 Merger Sub”), Revint Holdings, LLC (“Cloudmed”), CoyCo 1, L.P. (“CoyCo 1”), CoyCo 2, L.P. (“CoyCo 2” and, together with CoyCo 1, the “Sellers”), and, solely for certain purposes set forth therein, NMC Ranger Holdings, LLC, the Company purchased Cloudmed, a leader in Revenue Intelligence™ solutions for healthcare providers, and affiliated entities (collectively, the “Cloudmed entities”), through (i) a merger of R1 Merger Sub with and into Old R1 RCM with Old R1 RCM as the surviving entity, which resulted in Old R1 RCM becoming a wholly-owned subsidiary of the Company (the “Holding Company Reorganization”) and (ii) the Sellers contributing 100% of the equity of a blocker parent corporation of the Cloudmed entities in exchange for an aggregate of 135,929,742 shares of common stock, par value $0.01 per share, of the Company (“Company Common Stock”), subject to certain adjustments following the closing as set forth in the Transaction Agreement (the “Cloudmed Acquisition”, and together with the Holding Company Reorganization, the “Transactions”). For further details on the total consideration paid, refer to Note 2, Acquisitions. In October 2022, the Company finalized those adjustments, resulting in an additional 55,846 shares issued to the Sellers.

Cloudmed’s revenue intelligence platform combines cloud-based data architecture and deep domain expertise with intelligent automation to analyze large volumes of medical records, payment data, and complex medical insurance models to identify opportunities to deliver additional revenue to customers. The Company believes this transaction will enable the Company to further its ability to deliver transformative value to healthcare providers through a more fulsome platform of differentiated capabilities by creating a scaled leader across both end-to-end revenue cycle management (“RCM”) and technology-driven revenue intelligence.

Holding Company Reorganization

Pursuant to the Transaction Agreement, immediately prior to the completion of the Cloudmed Acquisition, Old R1 RCM implemented the Holding Company Reorganization, which resulted in the Company owning all of the capital stock of Old R1 RCM. Each share of Old R1 RCM’s common stock that was issued and outstanding immediately prior to the Holding Company Reorganization was automatically exchanged into an equivalent corresponding share of Company Common Stock, having the same designations, rights, powers, and preferences and the qualifications, limitations, and restrictions as the corresponding share of common stock of Old R1 RCM being converted. Accordingly, upon consummation of the Holding Company Reorganization, all Old R1 RCM stockholders became stockholders of the Company. Immediately prior to the consummation of the Holding Company Reorganization, the name of Old R1 RCM was changed to “R1 RCM Holdco Inc.” and the name of the Company was changed to “R1 RCM Inc.” The Company is the successor issuer to Old R1 RCM pursuant to Rule 12g-3(a) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The shares of Company Common Stock, as successor to Old R1 RCM, began trading on The Nasdaq Global Select Market (“Nasdaq”) under the symbol “RCM” on June 22, 2022.

9


Basis of Presentation
The accompanying unaudited consolidated financial statements reflect the Company’s financial position as of September 30, 2022, the results of operations of the Company for the three and nine months ended September 30, 2022 and 2021, and the cash flows of the Company for the nine months ended September 30, 2022 and 2021. These financial statements include the accounts of R1 RCM Inc. and its wholly-owned subsidiaries, including Cloudmed and its subsidiaries since the date of the acquisition. All material intercompany amounts have been eliminated in consolidation. These financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) for interim financial reporting and as required by the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”). Accordingly, certain information and footnote disclosures required for complete financial statements are not included herein. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the interim financial information, have been included. Operating results for the three and nine months ended September 30, 2022 are not necessarily indicative of the results that may be expected for any other interim period or for the fiscal year ending December 31, 2022.
When preparing financial statements in conformity with GAAP, the Company makes a number of significant estimates, assumptions, and judgments in the preparation of the financial statements. Actual results could differ from those estimates. For a more complete discussion of the Company’s significant accounting policies and other information, the unaudited consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements included in the Company’s 2021 Form 10-K.
Recently Issued Accounting Standards and Disclosures

In October 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”). ASU 2021-08 requires companies to apply Topic 606, Revenue from Contracts with Customers, to recognize and measure contract assets and contract liabilities obtained in a business combination. The ASU amendments will generally result in the recognition of contract assets and contract liabilities by the acquirer at amounts consistent with those recorded by the acquiree immediately before the acquisition date. The Company prospectively adopted ASU 2021-08 effective April 1, 2022 and preliminarily recognized contract assets of $92.4 million and contract liabilities of $3.3 million as part of the Cloudmed Acquisition.

In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”). ASU 2022-03 clarifies that a contractual sale restriction on an equity security should not be considered in measuring the security’s fair value. The Company will adopt ASU 2022-03 prospectively effective January 1, 2024 and is currently evaluating the impact of the standard on its consolidated financial statements.

2. Acquisitions

Assets acquired and liabilities assumed in a business combination are recorded at their estimated fair value on the date of the acquisition. The difference between the purchase price amount and the net fair value of assets acquired and liabilities assumed is recognized as goodwill on the balance sheet if the purchase price exceeds the estimated net fair value or as a bargain purchase gain on the income statement if the purchase price is less than the estimated net fair value. The allocation of the purchase price may be modified up to one year after the acquisition date as more information is obtained about the fair value of assets acquired and liabilities assumed.

Cloudmed

On June 21, 2022, the Company completed the acquisition of Cloudmed for a purchase price of $3.3 billion. The following table summarizes the fair value of the total consideration paid:

10


Fair Value
Stock consideration transferred to the Sellers (1)$2,389.5 
Cash consideration (2)879.8 
Replacement awards issued to Cloudmed equity award holders (3)11.3 
Total consideration3,280.6 

(1) The stock consideration fair value includes a preliminary discount for lack of marketability factor related to an 18-month lock-up period during which the Sellers may not sell their Company common stock.
(2) Cash consideration includes the repayment of Cloudmed’s pre-existing credit facility that was paid off at closing and was not assumed by the Company.
(3) Represents the pre-acquisition service portion of the fair value of 1,536,220 replacement restricted stock units (“RSUs”) issued to Cloudmed equity award holders at closing.

The Company funded the cash consideration component and the Company’s associated transaction expenses with a combination of cash on hand and the incurrence of additional indebtedness (see Note 8, Debt).

The purchase price has been provisionally allocated to assets acquired and liabilities assumed based on their fair value as of the acquisition date. The fair value estimate of assets acquired and liabilities assumed is pending the completion of various elements, including gathering further information about the identification and completeness of all assets and liabilities acquired, the finalization of an independent appraisal and valuation of the fair value of the assets acquired and liabilities assumed, and final review by the Company’s management. Some of the more significant amounts that are not yet finalized relate to the fair value of intangible assets (including goodwill), contract assets, contract liabilities, and income and non-income related taxes. Accordingly, management considers the balances shown in the following table to be preliminary, and there could be adjustments to the consolidated financial statements, including changes in our amortization expense related to the valuation of intangible assets acquired and their respective useful lives, among other adjustments.

The preliminary fair value of assets acquired and liabilities assumed is:
11


Purchase Price Allocation
Total purchase consideration$3,280.6 
Allocation of consideration to assets acquired and liabilities assumed:
Cash and cash equivalents$32.1 
Accounts receivable61.8 
Current portion of contract assets68.5 
Property, equipment and software5.0 
Operating lease right-of-use assets25.3 
Non-current portion of contract assets23.9 
Intangible assets1,370.1 
Goodwill1,994.7 
Other assets6.4 
Accounts payable(31.9)
Customer liabilities(3.3)
Accrued compensation and benefits(91.8)
Operating lease liabilities(25.4)
Deferred income tax liabilities(142.0)
Other liabilities(12.8)
Net assets acquired$3,280.6 

The intangible assets identified in conjunction with the Cloudmed Acquisition and their preliminary fair values are as follows:

Useful LifeGross Carrying Value
Customer Relationships
18 years
$318.0 
Technology
7 years
$1,052.0 
Favorable leasehold interestsLife of lease$0.1 

The goodwill recognized is primarily attributable to growth and cost reduction synergies that are expected to be achieved from the integration of Cloudmed. None of the goodwill is expected to be deductible for income tax purposes.

Included in the Consolidated Statements of Operations and Comprehensive Income (Loss) for the three and nine months ended September 30, 2022 are net sales of $120.2 million and $133.5 million, respectively, and net income before taxes of $1.3 million and $0.9 million, respectively, related to the operations of Cloudmed since the acquisition date of June 21, 2022.

Measurement period adjustments

The Company had various measurement period adjustments due to additional information received since the Cloudmed Acquisition, none of which were material.

12


Prior Acquisitions

During 2021, the Company acquired the following business:

Company NameDescription of the BusinessDescription of the Acquisition
iVinci Partners, LLC d/b/a VisitPay (“VisitPay”)
Provider of digital payment solutions
Purchased all outstanding equity interests

In 2020, the Company purchased certain assets relating to the RevWorks services business from Cerner Corporation. In accordance with the purchase agreement, the Company paid the first deferred payment of $12.5 million in the third quarter of 2021. The remaining deferred payment of $12.5 million was payable on the second anniversary of the closing date (August 2022) and is included in other accrued expenses on the Consolidated Balance Sheet as of September 30, 2022 as it had not been paid as of such date.

The two deferred payments related to the RevWorks acquisition were contractual obligations of the Company; however, they are refundable to the Company if certain RevWorks customer revenue targets defined in the purchase agreement for the first two years following the acquisition are not achieved. At the time of the acquisition, the Company recorded an asset for the fair value of the contingently refundable consideration of $22.3 million. As of September 30, 2022, the entire amount of the contingently refundable consideration of $25.0 million is included in prepaid expenses and other current assets on the Consolidated Balance Sheet. The parties are currently engaging in arbitration to finalize the remaining deferred payment and contingently refundable consideration amounts.

Pro Forma Results

The following table summarizes, on a pro forma basis, the combined results of the Company as though the Cloudmed Acquisition had occurred as of January 1, 2021 and the VisitPay acquisition had occurred as of January 1, 2020. These pro forma results are not necessarily indicative of the actual consolidated results had the acquisitions occurred as of those dates or of the future consolidated operating results for any period. Pro forma results are:

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Net services revenue$496.0 $464.6 $1,476.9 $1,321.5 
Net loss$(22.9)$(20.3)$(21.5)$(112.4)

Adjustments were made to earnings to adjust depreciation and amortization to reflect the fair value of identified assets acquired, to adjust share-based compensation expense for awards granted in connection with the acquisitions, to record the effects of extinguishing the debt of the acquired companies and replacing it with the debt of the Company, to adjust timing of acquisition related costs incurred by the Company, and to record the income tax effect of these adjustments.

3. Intangible Assets

The following table provides the gross carrying value and accumulated amortization for each major class of definite-lived intangible assets at September 30, 2022 and December 31, 2021:

13


September 30, 2022December 31, 2021
Gross Carrying ValueAccumulated AmortizationNet Book ValueGross Carrying ValueAccumulated AmortizationNet Book Value
Customer relationships$418.0 $(30.4)$387.6 $100.0 $(20.8)$79.2 
Technology1,267.5 (88.3)1,179.2 215.5 (30.2)185.3 
Tradename1.0 (0.4)0.6 1.0 (0.1)0.9 
Favorable leasehold interests0.1 — 0.1 — — — 
Total intangible assets$1,686.6 $(119.1)$1,567.5 $316.5 $(51.1)$265.4 

Intangible asset amortization expense was $49.2 million and $68.0 million for the three and nine months ended September 30, 2022, respectively, and $7.1 million and $15.8 million for the three and nine months ended September 30, 2021, respectively. Amortization expense for intangible assets is included in cost of services on the Company’s Consolidated Statements of Operations and Comprehensive Income (Loss). The Company has no indefinite-lived intangible assets.

Estimated annual amortization expense related to intangible assets with definite lives as of September 30, 2022 is as follows:

Remainder of 2022$49.0 
2023196.3 
2024194.5 
2025192.9 
2026192.9 
2027192.9 
Thereafter549.0 
Total$1,567.5 

4. Goodwill

Changes in the carrying amount of goodwill for the nine months ended September 30, 2022 were:

Goodwill
Balance as of December 31, 2021
$554.7 
Cloudmed Acquisition1,994.7 
Change in foreign currency rates(0.1)
Balance as of September 30, 2022
$2,549.3 

5. Revenue Recognition
Revenue is measured based on consideration specified in a contract with a customer, and presented net of any sales incentives and amounts collected on behalf of third parties. The Company recognizes revenue when it satisfies a performance obligation by transferring control over a service to a customer, which is typically over the contact term. Estimates of variable consideration are included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once the uncertainty is resolved.

Disaggregation of Revenue

In the following table, revenue is disaggregated by source of revenue:
14



Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Net operating fees$324.2 $308.5 $965.3 $879.8 
Incentive fees20.8 41.5 80.9 108.0 
Modular and other (1)151.0 29.7 227.4 87.9 
Net services revenue$496.0 $379.7 $1,273.6 $1,075.7 

(1) Modular and other revenue primarily consists of service fees related to Cloudmed and R1 EntriTM Pay, physician advisory services (“PAS”), practice management (“PM”) services, and software subscription revenue.

Contract Balances

The following table provides information about contract assets and contract liabilities from contracts with customers:

September 30, 2022December 31, 2021
Contract assets
Current$74.4 $— 
Non-current30.8 — 
Total contract assets$105.2 $— 
Contract liabilities
Current (1)$28.4 $10.3 
Non-current (2)19.4 18.7 
Total contract liabilities$47.8 $29.0 

(1) Current contract liabilities include $26.5 million and $7.8 million classified in the current portion of customer liabilities and $1.9 million and $2.5 million classified in the current portion of customer liabilities - related party as of September 30, 2022 and December 31, 2021, respectively.
(2) Non-current contract liabilities include $5.3 million and $3.3 million classified in the non-current portion of customer liabilities and $14.1 million and $15.4 million classified in the non-current portion of customer liabilities - related party as of September 30, 2022 and December 31, 2021, respectively.

The contract assets balance will increase or decrease based on the timing of invoices and recognition of revenue. Prior to the Cloudmed Acquisition, the Company did not have significant contract assets. Significant changes in the carrying amount of contract assets for the three months ended September 30, 2022 were as follows:

Contract Assets
Balance as of June 30, 2022$89.6 
Revenue recognized84.4 
Amounts billed(73.0)
Other (1)4.2 
Balance as of September 30, 2022
$105.2 

(1) Other primarily includes measurement period adjustments to the contract assets acquired from the Cloudmed Acquisition.
15



The Company recognized revenue of $93.4 million and $99.7 million during the nine months ended September 30, 2022 and 2021, which amounts were included in contract liabilities on January 1 of the respective periods. These revenue amounts include $85.8 million and $88.1 million for the nine months ended September 30, 2022 and 2021, respectively, related to advanced billings which become accounts receivable and contract liabilities on the first day of the respective service period.

Refer to Note 2, Acquisitions, for the preliminary contract assets acquired and contract liabilities assumed as part of the Cloudmed Acquisition.

Transaction Price Allocated to the Remaining Performance Obligation

The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. The estimated revenue does not include amounts of variable consideration that are constrained.

Net operating feesIncentive fees
Remainder of 2022$36.1 $17.8 
2023109.6 23.3 
202491.2 — 
202539.2 — 
202638.5 — 
202732.9 — 
Thereafter122.0 — 
Total$469.5 $41.1 
    
The amounts presented in the table above include variable fee estimates of the Company’s physician groups RCM services contracts, fixed fees, and forecasted incentive fees. Fixed fees are typically recognized ratably as the performance obligation is satisfied and forecasted incentive fees are measured cumulatively over the contractually defined performance period.

Estimates of revenue expected to be recognized in future periods exclude unexercised customer options to purchase services within the Company’s PAS contracts that do not represent material rights to the customer.

The Company does not disclose information about remaining performance obligations with an original expected duration of one year or less and has elected an exemption to the disclosure requirements related to estimate variable consideration and an exemption where the Company has a right to consideration from a customer in an amount that corresponds directly with the value to the customer of the entity’s performance completed to date.

6. Accounts Receivable and Allowance for Credit Losses

Accounts receivable is comprised of unpaid balances pertaining to modular services and end-to-end RCM customers, net receivable balances for end-to-end RCM customers after considering cost reimbursements owed to such customers, including related accrued balances, and amounts due from physician RCM and PM customers.

16


The Company evaluates its accounts receivable for expected credit losses quarterly. The Company maintains an estimated allowance for credit losses to reduce its accounts receivable to the amount that it believes will be collected. This allowance is based on the Company’s historical experience, its assessment of each customer’s ability to pay, the length of time a balance has been outstanding, input from key Company resources assigned to each customer, the status of any ongoing operations with each applicable customer, and business and industry factors such as significant shifts in the healthcare environment which the Company believes may have impacted or will impact its customers’ financial health and ability to pay.

During the three months ended September 30, 2022, the Company increased the allowance for credit losses related to a physician customer by $9.5 million due to the customer facing financial challenges and its resulting inability to make a contractually required payment on September 30, 2022. As a result of reviewing the potential expected outcomes related to this customer, the Company recorded an allowance for credit losses of $10.0 million related to an overall receivable balance of $33.3 million as of September 30, 2022.

The Company has presented the rollforward below on a consolidated basis as the currently expected credit losses for its large integrated healthcare system customers are not anticipated to be material.

Movements in the allowance for credit losses are as follows (in millions):

 Three Months Ended September 30,Nine Months Ended September 30,
 2022202120222021
Beginning balance$4.4 $2.3 $2.5 $3.8 
Cumulative effect of Cloudmed ASC 326 adoption
— — 1.8 — 
Provision (recoveries)10.4 0.4 10.7 0.6 
Write-offs(0.2)(0.3)(0.4)(2.0)
Ending balance$14.6 $2.4 $14.6 $2.4 

7. Leases

The components of lease costs are as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Operating lease cost$6.9 $4.0 $16.8 $12.1 
Sublease income(0.4)(0.6)(1.3)(1.7)
Total lease cost$6.5 $3.4 $15.5 $10.4 

Supplemental cash flow information related to leases are as follows:

Nine Months Ended September 30,
20222021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases$17.6 $18.6 
Right-of-use assets obtained in exchange for operating lease obligations:67.6 13.6 

Refer to Note 2, Acquisitions, for the preliminary right-of-use assets acquired and lease liabilities assumed as part of the Cloudmed Acquisition.

Maturities of lease liabilities as of September 30, 2022 are as follows:
17



Operating Leases
Remainder of 2022$9.3 
202324.6 
202423.9 
202522.6 
202616.8 
202710.8 
Thereafter40.8 
Total148.8 
Less:
Imputed interest(28.8)
Present value of lease liabilities$120.0 
.

8. Debt

The carrying amounts of debt consist of the following:

September 30, 2022December 31, 2021
Senior Revolver (1)$80.0 $80.0 
Term A Loans1,222.5 695.6 
Term B Loan500.0 — 
Unamortized discount and issuance costs(24.9)(3.2)
Total debt1,777.6 772.4 
Less: Current maturities(49.5)(17.5)
Total long-term debt$1,728.1 $754.9 

(1) As of September 30, 2022, the Company had $80.0 million in borrowings, $0.9 million letters of credit outstanding, and $519.1 million of availability under the Senior Revolver.

Second Amended and Restated Senior Secured Credit Facilities

On June 21, 2022, the Company, Old R1 RCM, and certain of its subsidiaries entered into a second amended and restated senior credit agreement (the “Second A&R Credit Agreement”) with Bank of America, N.A., as administrative agent, and the lenders named therein, governing the Company’s second amended and restated senior secured credit facilities (the “Senior Secured Credit Facilities”), consisting of the $691.3 million existing senior secured term loan A facility (the “Existing Term A Loan”), a $540.0 million senior secured incremental term loan A facility (the “Incremental Term A Loan”, and together with the Existing Term A Loan, the “Term A Loans”), a $500.0 million senior secured term loan B facility (the “Term B Loan”, and together with the Term A Loans, the “Senior Term Loans”), and a $600.0 million senior secured revolving credit facility (the “Senior Revolver”). In conjunction with entering into the Second A&R Credit Agreement, the Company incurred $7.2 million and capitalized $6.4 million of debt issuance costs.

The Incremental Term A Loan has a five-year maturity and the Term B Loan has a seven-year maturity. The Existing Term A Loan and Senior Revolver mature on July 1, 2026. The Second A&R Credit Agreement provides that the Company may make one or more offers to the lenders, and consummate transactions with individual lenders that accept the terms contained in such offers, to extend the maturity date of the lender’s term loans and/or revolving commitments, subject to certain conditions, and any extended term loans or revolving commitments will constitute a separate class of term loans or revolving commitments.
18



Borrowings under the Senior Secured Credit Facilities bear interest, at the Company’s option, at: (i) an Alternate Base Rate (“ABR”) equal to the greater of (a) the prime rate of Bank of America, N.A., (b) the federal funds rate plus 0.50% per annum, and (c) the Term Secured Overnight Financing Rate (“SOFR”) for an interest period of one-month beginning on such day plus 100 basis points, plus between 0.25% and 1.50% dependent on the Company’s total net leverage ratio (provided that the Term SOFR rate applicable to the Term A Loans shall not be less than 0.00% per annum, and the Term SOFR rate applicable to the Term B Loan shall not be less than 0.50% per annum); or (ii) the Term SOFR rate (provided that the Term SOFR rate applicable to the Term A Loans shall not be less than 0.00% per annum, and the Term SOFR rate applicable to the Term B Loan shall not be less than 0.50% per annum), plus between 1.25% and 2.50%, dependent on the Company’s total net leverage ratio. The interest rate as of September 30, 2022 was 5.28% for the Term A Loans and Senior Revolver and 6.03% for the Term B Loan. The Company is also required to pay an unused commitment fee to the lenders under the Senior Revolver at a rate between 0.20% and 0.40% of the average daily unutilized commitments thereunder dependent on the Company’s total net leverage ratio.

The Second A&R Credit Agreement requires the Company to make mandatory prepayments, subject to certain exceptions, with: (i) beginning with fiscal year ending December 31, 2023, 50% (which percentage will be reduced upon the Company’s achievement of certain total net leverage ratios) of the Company’s annual excess cash flow, (ii) 100% of net cash proceeds of all non-ordinary course asset sales or other dispositions of property or casualty events, subject to certain exceptions and thresholds, and (iii) 100% of the net cash proceeds of any debt incurrence, other than debt permitted under the Second A&R Credit Agreement.

The Second A&R Credit Agreement contains a number of financial and non-financial covenants. The Company was in compliance with all of the covenants in the Second A&R Credit Agreement as of September 30, 2022. The obligations under the Second A&R Credit Agreement are secured by a pledge of 100% of the capital stock of certain domestic subsidiaries owned by the Company and a security interest in substantially all of the Company’s tangible and intangible assets and the tangible and intangible assets of certain domestic subsidiaries.

The proceeds from the new Senior Secured Credit Facilities were or will be used, in addition to cash on hand, (1) to refinance, in full, all existing indebtedness under the Amended and Restated Credit Agreement, dated as of July 1, 2021, by and among Old R1 RCM and certain of its subsidiaries, Bank of America, N.A., as administrative agent, and the lenders named therein, and amend and restate all commitments thereunder (the “Refinancing”), (2) to pay certain fees and expenses incurred in connection with the entry into the Second A&R Credit Agreement and the Refinancing, (3) to fund the Transactions, and to pay the fees, premiums, expenses, and other transaction costs incurred in connection therewith, and (4) to finance working capital needs of the Company and its subsidiaries for general corporate purposes. Debt amounts presented as of December 31, 2021 were incurred under the 2021 Amended and Restated Credit Agreement.

Debt Maturities

Scheduled maturities of the Company’s long-term debt are summarized as follows:

19


Scheduled Maturities
Remainder of 2022$12.4 
202353.9 
202467.0 
202567.0 
2026698.3 
2027430.2 
Thereafter473.7 
Total$1,802.5 

For further details on the Company’s 2021 Amended and Restated Credit Agreement, refer to Note 10 of the Company’s 2021 Form 10-K.
9. Derivative Financial Instruments

The Company utilizes cash flow hedges to manage its currency risk arising from its global business services centers. As of September 30, 2022, the Company has recorded $1.2 million of unrealized losses in accumulated other comprehensive loss related to foreign currency hedges. The Company estimates that $1.1 million of losses reported in accumulated other comprehensive loss are expected to be reclassified into earnings within the next 12 months. Amounts reclassified into cost of services were a net loss of $0.7 million and $0.6 million during the three and nine months ended September 30, 2022, respectively, and a net gain of $0.4 million and $1.0 million during the three and nine month periods ended September 30, 2021, respectively. As of September 30, 2022, the Company’s currency forward contracts have maturities extending no later than December 31, 2023, and had a total notional value of $76.8 million.

The Company also utilizes cash flow hedges to reduce variability in interest cash flows from its outstanding debt. As of September 30, 2022, the Company has recorded $12.9 million of unrealized gains in accumulated other comprehensive loss related to interest rate swaps. The Company estimates that $3.7 million of gains reported in accumulated other comprehensive loss are expected to be reclassified into earnings within the next 12 months. Amounts reclassified into interest expense were a net loss of $0.4 million and $0.9 million during the three and nine months ended September 30, 2022, respectively and a net loss of $0.3 million and $1.1 million during the three and nine month periods ended September 30, 2021, respectively. As of September 30, 2022, the Company’s interest rate swaps extend no later than June 30, 2025, and had a total notional value of $500.0 million.

The location and fair value of derivative instruments designated as hedges in the Consolidated Balance Sheets as of September 30, 2022 and December 31, 2021 are as follows:

September 30, 2022December 31, 2021
Foreign currency forward contracts
Prepaid expenses and other current assets$— $1.7 
Other accrued expenses1.2 — 
Total foreign current forward contracts$1.2 $1.7 
Interest rate swaps
Prepaid expenses and other current assets$3.7 $— 
Other assets9.2 — 
Other accrued expenses— 0.7 
Total interest rate swaps$12.9 $0.7 
20



As of September 30, 2022 and December 31, 2021, the accumulated gain, net of tax, recognized in accumulated other comprehensive loss was $8.8 million and $0.7 million, respectively.

The Company classifies cash flows from its derivative programs as cash flows from operating activities in the consolidated statements of cash flows. Fair values for derivative financial instruments are based on prices computed using third-party valuation models and are classified as Level 2 in accordance with the three-level hierarchy of fair value measurements.
On July 5, 2022, the Company entered into an agreement with a third party regarding the potential purchase of a business that would expand the service capabilities of the Company. This agreement is effective through approximately the end of 2023 and allows the other party to sell the business to the Company for $150.0 million, subject to the negotiation of a definitive agreement and the satisfaction of agreed upon closing conditions, including the requirement that the purchase price be deemed to be fair value at the time of the potential transaction. The parties, assuming an agreement is reached, would also need to reach agreement as to whether the purchase price would be paid in cash or shares of common stock of the Company.

10. Share-Based Compensation

The share-based compensation expense relating to the Company’s stock options, RSUs, and performance-based restricted stock units (“PBRSUs”) for the three months ended September 30, 2022 and 2021 was $27.8 million and $25.5 million, respectively, with related tax benefits of approximately $4.6 million and $5.1 million, respectively. The share-based compensation expense relating to the Company’s stock options, RSUs, and PBRSUs for the nine months ended September 30, 2022 and 2021 was $49.5 million and $62.0 million, respectively, with related tax benefits of approximately $8.5 million and $12.2 million, respectively.

The Company accounts for forfeitures as they occur. Excess tax benefits and shortfalls for share-based payments are recognized in income tax expense (benefit) and included in operating activities. The Company recognized $4.3 million and $0.6 million of income tax benefit from windfalls associated with vesting and exercises of equity awards for the three months ended September 30, 2022 and 2021, respectively. The Company recognized $9.2 million and $7.2 million of income tax benefit from windfalls associated with vesting and exercises of equity awards for the nine months ended September 30, 2022 and 2021, respectively.
Total share-based compensation costs that have been included in the Company’s consolidated statements of operations were as follows:
 Three Months Ended September 30,Nine Months Ended September 30,
 2022202120222021
Share-Based Compensation Expense Allocation Details:
Cost of services$12.3 $15.8 $21.7 $38.8 
Selling, general and administrative15.4 9.7 27.7 23.2 
Other0.1 — 0.1 — 
Total share-based compensation expense$27.8 $25.5 $49.5 $62.0 
The Company uses the Black-Scholes option pricing model to estimate the fair value of its service-based options as of their grant dates. The Company assesses current performance on performance-based PBRSUs by reviewing historical performance to date, along with any adjustments which have been approved to the reported performance, and changes to the projections to determine the probable outcome of the awards. The current estimates are then compared to the scoring metrics and any necessary adjustments are reflected in the current period to update share-based compensation expense to the current performance expectations.
21


Stock options
A summary of the options activity during the nine months ended September 30, 2022 is shown below:

OptionsWeighted-
Average
Exercise
Price
Outstanding at December 31, 20214,386,205 $3.37 
Granted24,344 22.19 
Exercised(1,279,460)3.67 
Canceled/forfeited(13,408)4.59 
Expired(7,500)8.71 
Outstanding at September 30, 20223,110,181 $3.38 
Outstanding, vested and exercisable at September 30, 20223,084,188 $3.22 
Outstanding, vested and exercisable at December 31, 20214,365,759 $3.33 
Restricted stock units and performance-based restricted stock units    
A summary of the RSU and PBRSU activity during the nine months ended September 30, 2022 is shown below:
Weighted-
Average Grant
Date Fair Value
RSUsPBRSUsRSUPBRSU
Outstanding and unvested at December 31, 20212,218,651 3,203,013 $16.28 $16.45 
Granted2,249,157 5,230,483 20.62 19.83 
Performance factor adjustment— 876,109 — 10.46 
Vested(574,564)(1,878,328)14.49 11.19 
Forfeited(164,414)(201,544)17.41 19.87 
Outstanding and unvested at September 30, 20223,728,830 7,229,733 $19.12 $19.44 
Shares surrendered for taxes for the nine months ended September 30, 2022
182,080 783,392 
Cost of shares surrendered for taxes for the nine months ended September 30, 2022 (in millions)
$4.1 $20.0 
Shares surrendered for taxes for the nine months ended September 30, 2021
186,588 — 
Cost of shares surrendered for taxes for the nine months ended September 30, 2021 (in millions)
$4.8 $— 
Upon consummation of the Holding Company Reorganization, outstanding restricted units of Cloudmed were replaced by an aggregate 1,536,220 RSUs of the Company. The Company also issued an aggregate of 3,173,184 inducement RSUs and PBRSUs to certain employees of Cloudmed under Nasdaq Listing Rule 5635(c)(4) pursuant to its newly adopted 2022 Inducement Plan.

The Company’s RSU and PBRSU agreements allow employees to surrender to the Company shares of common stock upon vesting of their RSUs and PBRSUs in lieu of their payment of the required personal employment-related taxes. Shares surrendered for payment of personal employment-related taxes are held in treasury.
22



Outstanding PBRSUs vest upon satisfaction of both time-based and performance-based conditions. Depending on the award, performance condition targets may include cumulative adjusted EBITDA, end-to-end RCM agreement growth, modular sales revenue, or other specific performance factors. Depending on the percentage level at which the performance-based conditions are satisfied, the number of shares vesting could be between 0% and 200% of the number of PBRSUs originally granted. Based on the established targets, the maximum number of shares that could vest for all outstanding PBRSUs is 14,412,591.
CoyCo 2, L.P. Limited Partnership Units    

As part of the transactions contemplated by the Transaction Agreement, equity awards held by certain employees of Cloudmed (“Former Class P Units”) were modified, through a series of transactions, into awards (“Management Units”) of CoyCo 2. The Management Units issued by CoyCo 2 are treated as share-based compensation under ASC 718, Compensation —Stock Compensation.

The Former Class P Units were originally issued to employees of Cloudmed and its affiliates (“Participants”) in connection with and as a part of the compensation and incentive arrangements between Cloudmed and such Participants prior to the consummation of the Cloudmed Acquisition. A portion of the Former Class P Units immediately vested upon the closing of the Cloudmed Acquisition; however, certain Former Class P Units that were subject to performance-based vesting conditions did not become vested upon the closing of the Cloudmed Acquisition (“Unvested Units”). However, in connection with the Cloudmed Acquisition, Cloudmed caused the Former Class P Units, including the Unvested Units, to be converted into Management Units. At the time of the closing of the Cloudmed Acquisition, 97,875 Unvested Units were converted into 514,986 Management Units.

In general, Unvested Units vest upon the achievement of certain performance criteria, including achievement by the Sellers’ owner, New Mountain Capital, L.L.C. (“New Mountain”), of (i) specified multiples of Base Equity Value (“BEV”) (i.e., generally the aggregate equity value of New Mountain’s investment in Cloudmed as of the original grant date), or (ii) specified Multiples on Invested Capital (“MIC”) with respect to New Mountain Capital’s pre-Cloudmed Acquisition investment in Cloudmed, and subject to continued service with the Company and its affiliates, including Cloudmed through the applicable vesting date. The awards are not awards of the Company and the Participants will receive no additional shares of the Company upon satisfaction of the vesting criteria. However, GAAP requires the Company recognize the cost of share-based compensation granted by an investor (CoyCo 2) to the Company’s employees and service providers for services that benefit the Company’s operations, and a corresponding capital contribution because the costs are incurred on the Company’s behalf.

A Monte Carlo simulation was used to estimate the fair value of the Unvested Units which is being amortized over a period of 4 years on a straight-line basis.
11. Other Expenses

Other expenses are incurred in connection with acquisition and integration costs, various exit activities, transformation initiatives, and organizational changes to improve our business alignment and cost structure. The following table summarizes the other expenses (income) recognized for the three and nine months ended September 30, 2022 and 2021.
23


Three Months Ended September 30,Nine Months Ended September 30,
 2022202120222021
Severance and related employee benefits (1)$— $0.3 $— $2.1 
Business acquisition costs (2)0.2 2.3 74.4 4.2 
Integration costs (3)8.8 — 18.3 2.6 
Strategic initiatives (4)6.2 2.5 9.0 6.4 
Global business services center expansion project in the Philippines (5)10.0 — 20.0 — 
Customer employee transition and restructuring expenses (6)— 3.2 (0.4)3.2 
Facility-exit charges (7)1.3 — 7.3 2.9 
Other (8)3.6 3.1 7.5 12.8 
Total other expenses$30.1 $11.4 $136.1 $34.2 
(1) These costs relate to restructuring and business reorganization events.
(2) These are costs, including legal, consulting, and bank fees, that are directly related to the close of the Cloudmed Acquisition on June 21, 2022 and the close of the VisitPay acquisition on July 1, 2021 and include changes to contingent consideration, if applicable.
(3) These costs reflect efforts to integrate acquisitions from a systems, processes, and people perspective. Costs include consulting fees, IT vendor spend, severance, early lease termination of Cloudmed facilities, and certain payroll costs.
(4) These costs relate to performing portfolio and capital structure analyses and transactions and other business transformation projects (including large scale system projects) as part of the Company’s growth strategy. Costs include vendor spend, employee time and expenses spent on activities, severance, and retention amounts.
(5) These costs include legal and consulting fees related to the establishment of the Company’s inaugural global business services center in the Philippines as well as severance costs for personnel whose roles are being relocated. The entry into the Philippines is the first new organic global business services center country expansion by the Company in approximately 15 years.
(6) As part of the transition of customer personnel to the Company under certain operating partner model contracts, the Company agreed to reimburse the customer, or directly pay affected employees, for severance and retention costs related to certain employees who were not transitioned to the Company, or whose jobs were relocated after the employee transitioned to the Company.
(7) As part of evaluating its footprint, the Company has exited certain leased facilities. Costs include asset impairment charges, early termination fees, and other costs related to exited leased facilities.
(8) For the three and nine months ended September 30, 2022, other includes $0.7 million and $1.8 million, respectively, of expenses related to the COVID-19 pandemic. For the three and nine months ended September 30, 2021, other includes $2.7 million and $7.1 million, respectively, of expenses related to the COVID-19 pandemic.
12. Income Taxes

Income tax provisions for interim periods are based on estimated annual income tax rates, adjusted to reflect the effects of any significant and infrequent or unusual items which are required to be discretely recognized within the current interim period. The effective tax rates in the periods presented are largely based upon the projected annual pre-tax earnings by jurisdiction and the allocation of certain expenses in various taxing jurisdictions where the Company conducts its business. These taxing jurisdictions apply a broad range of statutory income tax rates. The global intangible low-taxed income (“GILTI”) provisions impose taxes on foreign income in excess of a deemed return on tangible assets of foreign corporations. The Company elected to account for GILTI tax in the period in which it is incurred.

24


The Company recognized income tax expense for the three months ended September 30, 2022 and income tax benefit for the nine months ended September 30, 2022 on the year-to-date pre-tax loss. The deviation from the federal statutory tax rate of 21% is primarily attributable to recognizing the provisions for foreign taxes, GILTI, non-deductible expenses, and discrete items.

The Company recognized income tax expense for the three and nine months ended September 30, 2021 on the year-to-date pre-tax income. The deviation from the federal statutory tax rate of 21% is primarily attributable to recognizing the provisions for state taxes, GILTI, non-deductible expenses, and discrete items.
The Company and its subsidiaries are subject to U.S. federal income tax as well as income tax of multiple state and foreign jurisdictions. U.S. federal income tax returns since 2018 are currently open for examination. State jurisdictions vary for open tax years. The statute of limitations for most states ranges from three to six years.

At December 31, 2021, the Company had gross deferred tax assets of $123.7 million, of which $54.7 million related to net operating loss (“NOL”) carryforwards. The Company expects to be profitable, allowing the Company to utilize its NOL carryforwards and other deferred tax assets.

13. Earnings (Loss) Per Share
Basic net income (loss) per share is computed by dividing net income (loss), less any dividends, accretion or decretion, redemption or induced conversion on the preferred stock, by the weighted average number of common shares outstanding during the period.
Diluted net income (loss) per share is calculated by adjusting the denominator used in the basic net income (loss) per share computation by potentially dilutive securities outstanding during the period plus, when their effect is dilutive, incremental shares consisting of shares subject to stock options and shares issuable upon vesting of RSUs and PBRSUs.
Basic and diluted net income (loss) per common share are calculated as follows:
Three Months Ended September 30,Nine Months Ended September 30,
 2022202120222021
Basic EPS:
Net income (loss)$(29.5)$17.0 $(20.5)$61.2 
Less dividends on preferred shares (1)— — — (592.3)
Net income (loss) available/(allocated) to common shareholders - basic$(29.5)$17.0 $(20.5)$(531.1)
Diluted EPS:
Net income (loss)$(29.5)$17.0 $(20.5)$61.2 
Less dividends on preferred shares (1)— — — (592.3)
Net income (loss) available/(allocated) to common shareholders - diluted$(29.5)$17.0 $(20.5)$(531.1)
Basic weighted-average common shares417,700,782 278,655,269 330,877,880 262,209,929 
Add: Effect of dilutive equity awards— 7,281,436 — — 
Add: Effect of dilutive warrants— 34,680,381 — — 
Diluted weighted average common shares417,700,782 320,617,086 330,877,880 262,209,929 
Net income (loss) per common share (basic)$(0.07)$0.06 $(0.06)$(2.03)
Net income (loss) per common share (diluted)$(0.07)$0.05 $(0.06)$(2.03)
25


(1) The 2021 dividend on preferred shares includes amounts related to the conversion of the preferred shares. See Note 16 of the Company’s 2021 Form 10-K for more information.
Because of their anti-dilutive effect, 21,251,602 common share equivalents comprised of stock options, PBRSUs, and RSUs have been excluded from the diluted earnings per share calculation for the three and nine months ended September 30, 2022. Additionally, for the three and nine months ended September 30, 2022, TCP-ASC ACHI Series LLLP’s (“TCP-ASC” or the “Investor”) and IHC Health Services, Inc.’s (“Intermountain”) exercisable warrants to acquire up to 40.5 million and 1.5 million shares, respectively, of the Company’s common stock have been excluded from the diluted earnings per share calculation because they were anti-dilutive.
For the three and nine months ended September 30, 2021, 890,717 and 15,155,288 common share equivalents, respectively, have been excluded from the diluted earnings per share calculation because of their anti-dilutive effect. Additionally, for the nine months ended September 30, 2021, the Investor’s and Intermountain’s exercisable warrants to acquire up to 40.5 million and 1.5 million shares, respectively, of the Company’s common stock have been excluded from the diluted earnings per share calculation because they were anti-dilutive.

14. Commitments and Contingencies

Legal Proceedings

Other than as described below, the Company is not presently a party to any material litigation or regulatory proceeding and is not aware of any pending or threatened litigation or regulatory proceeding against the Company which, individually or in the aggregate, could have a material adverse effect on its business, operating results, financial condition or cash flows.

On April 13, 2021 and April 19, 2021, respectively, certain purported stockholders of the Company filed two complaints in the Delaware Court of Chancery regarding the Company’s January 15, 2021 recapitalization transaction with TCP-ASC. Both complaints allege that TCP-ASC, Ascension Health (“Ascension”), and TowerBrook Capital Partners (“TowerBrook”) controlled the Company and breached their fiduciary duties by using that alleged control to force the Company to overpay in redeeming TCP-ASC’s preferred stock as part of the recapitalization transaction. The plaintiffs seek an unspecified amount of damages against TCP-ASC, Ascension, and TowerBrook. The plaintiffs also allege that the Company and TCP-ASC entered into amendments to the Investor Rights Agreement that the plaintiffs contend contains provisions that are void under the Company’s charter, bylaws, and the Delaware General Corporation Law. The cases have since been consolidated into a single action. All defendants have answered the complaint and discovery has commenced.

On February 18, 2022, plaintiffs filed a supplement to their complaint, naming certain additional defendants and asserting additional claims related to the Company’s agreement to acquire Cloudmed, which was announced on January 10, 2022. The additional claims assert that: (i) TCP-ASC, Ascension, and TowerBrook, along with the Company’s directors (“Individual Defendants”), breached their fiduciary duties by causing the Company to enter into and approving the Cloudmed acquisition, respectively, which plaintiffs claim will perpetuate TCP-ASC’s, Ascension’s, and TowerBrook’s control over the Company and entrench the Individual Defendants by virtue of certain agreements entered into as part of the transaction, including a Second Amended Investor Rights Agreement with TCP-ASC (the “Seconded Amended Investor Rights Agreement”) and an Investor Rights Agreement with Cloudmed (the “Cloudmed Investor Rights Agreement”); and (ii) Cloudmed’s stockholders aided and abetted such breaches. Plaintiffs also allege that certain provisions in the Cloudmed Investor Rights Agreement and the Second Amended Investor Rights Agreement are void under the Company’s charter, bylaws, and the Delaware General Corporation law. The plaintiffs seek a declaratory judgment and an unspecified amount of damages, as well as attorneys’ fees and costs. The Company believes it has meritorious defenses to all claims against it and intends to vigorously defend itself against these claims.

26


In May 2016, the Company was served with a False Claims Act case brought by a former emergency department service associate who worked at a hospital of one of the Company’s customers, MedStar Inc.’s Washington Hospital Center (“WHC”), along with WHC and three other hospitals that were PAS customers and a place holder, John Doe hospital, representing all PAS customers (U.S. ex rel. Graziosi vs. Accretive Health, Inc. et. al.), and seeking money damages, False Claims Act penalties, and plaintiff’s attorneys’ fees. The Third Amended Complaint alleges that the Company’s PAS business violates the federal False Claims Act. The case was originally filed under seal in 2013 in the federal district court in Chicago and presented to the U.S. Attorney in Chicago, and the U.S. Attorney declined to intervene. The Company believes that it has meritorious defenses to all claims in the case and intends to vigorously defend itself against these claims. Both the Company’s and plaintiff’s motions for summary judgment were denied in December 2020, and the parties have completed damage and expert discovery. Additional dispositive motions are expected to extend through 2022, with trial, if necessary, in June 2023.
15. Related Party Transactions
This note encompasses transactions between Ascension and its affiliates, including AMITA Health, and the Company pursuant to the Master Professional Services Agreement, including all supplements, amendments, and other documents entered into in connection therewith. For further details on the Company’s agreements with Ascension, see Note 1 and Note 19 of the Company’s 2021 Form 10-K. In conjunction with the Cloudmed Acquisition, New Mountain became a new related party. There were no material transactions with New Mountain subsequent to the Cloudmed Acquisition.
Net services revenue from services provided to Ascension, as well as corresponding accounts receivable and customer liabilities are presented in the Consolidated Statements of Operations and Comprehensive Income (Loss) and the Consolidated Balance Sheets. Since Ascension is the Company’s largest customer, a significant percentage of the Company’s cost of services is associated with providing services to Ascension. However, due to the nature of the Company’s global business services and information technology operations, it is impractical to assign the dollar amount associated with services provided to Ascension.

On May 27, 2021 and May 28, 2021, the Company issued 16,750,000 shares of common stock to TCP-ASC upon the cashless exercise of a warrant to purchase 19,535,145 shares of common stock at an exercise price of $3.50 per share based upon a market value of $24.54 to $24.64 per share as determined under the terms of the warrant.
16. Segments and Customer Concentrations
The Company has determined that it has a single operating segment in accordance with the way that management operates and views the business. All of the Company’s significant operations are organized around the single business of providing end-to-end management services of revenue cycle operations for U.S.-based healthcare providers. Accordingly, for purposes of segment disclosures, the Company has only one operating and reportable segment.
Customers comprising greater than 10% of net services revenue are as follows:
Three Months Ended September 30,
Nine Months Ended September 30,
Customer Name2022202120222021
Ascension and its affiliates44 %60 %52 %61 %
Intermountain Healthcare11 %14 %13 %14 %
The loss of customers within the Ascension health system or Intermountain network could have a material adverse impact on the Company’s operations.
As of September 30, 2022 and December 31, 2021, the Company had a concentration of credit risk with Ascension, representing 12% and 17% of accounts receivable, respectively.
27


17. Supplemental Financial Information
The following table summarizes the allocation of depreciation and amortization expense related to property, equipment and software between cost of services and selling, general and administrative expenses:
 Three Months Ended September 30,Nine Months Ended September 30,
 2022202120222021
Cost of services$14.7 $13.6 $39.0 $38.8 
Selling, general and administrative0.3 0.6 0.8 2.2 
Total depreciation and amortization$15.0 $14.2 $39.8 $41.0 
28



Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations
Unless the context indicates otherwise, references in this Quarterly Report on Form 10-Q to “R1,” “the Company,” “we,” “our,” and “us” mean R1 RCM Inc., and its subsidiaries.

The following discussion and analysis is an integral part of understanding our financial results and is provided as an addition to, and should be read in connection with, our consolidated financial statements and the accompanying notes.

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Undue reliance should not be placed on these statements. All statements, other than statements of historical facts, included in this Quarterly Report on Form 10-Q are forward-looking statements. The words “anticipate,” “believe,” “designed,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “will” or “would” and similar expressions or variations are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such forward-looking statements include, among other things, statements about the acquisition of Cloudmed, our strategic initiatives, our capital plans, our costs, our ability to successfully implement new technologies, our future financial performance, and our liquidity. Such forward-looking statements are based on management’s current expectations about future events as of the date hereof and involve many risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in our forward-looking statements. Subsequent events and developments, including actual results or changes in our assumptions, may cause our views to change. We do not undertake to update our forward-looking statements except to the extent required by applicable law. Readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements included herein are expressly qualified in their entirety by these cautionary statements. Our actual results and outcomes could differ materially from those included in these forward-looking statements as a result of various factors, including, but are not limited to, geopolitical, economic, and market conditions, including heightened inflation, slower growth or recession, changes to fiscal and monetary policy, higher interest rates, currency fluctuations, and challenges in the supply chain; our ability to retain existing customers or acquire new customers; the development of markets for our revenue cycle management offering; variability in the lead time of prospective customers; our ability to integrate Cloudmed’s business into our operations in a timely and efficient manner; failure to realize the anticipated benefits of the Cloudmed acquisition; volatility in our stock price, including in connection with the integration and results of Cloudmed; competition within the market; breaches or failures of our information security measures or unauthorized access to customer’s data; delayed or unsuccessful implementation of our technologies or services, or unexpected implementation costs; disruptions in or damages to our global business services centers and third-party operated data centers; the ongoing impact of the 2019 Novel Coronavirus (“COVID-19”) pandemic on our business, operating results, and financial condition; and the factors discussed elsewhere in this Quarterly Report on Form 10-Q, and those set forth in Part I, Item 1A of our 2021 Form 10-K and our other filings with the SEC. The forward-looking statements in this Quarterly Report on Form 10-Q represent our views as of the date of this Quarterly Report on Form 10-Q. Subsequent events and developments may cause our views to change. While we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Quarterly Report on Form 10-Q.
Overview
Our Business
We are a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers. Our services help healthcare providers generate sustainable improvements in their operating margins and cash flows while also enhancing patient, physician, and staff satisfaction for our customers.
29



We achieve these results for our customers by managing healthcare providers’ revenue cycle operations, which encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, bill preparation, and collections from patients and payers. We do so by leveraging our extensive healthcare domain experience, innovative technology and intelligent automation, and process excellence. We assist our revenue cycle management (“RCM”) customers in managing their revenue cycle operating costs while simultaneously increasing the portion of the maximum potential services revenue they receive. Together, these benefits can generate significant and sustainable improvements in operating margins and cash flows for our customers.
Our primary offerings consist of end-to-end or modular RCM services for health systems, hospitals, and physician groups. We deploy our end-to-end offering through an operating partner relationship or a co-managed relationship. Under an operating partner relationship, we provide comprehensive revenue cycle infrastructure to providers, including all revenue cycle personnel, technology solutions, and process workflow. Under a co-managed relationship, we leverage our customers’ existing RCM staff and processes, and supplement them with our infused management, subject matter specialists, proprietary technology solutions, and other resources. Under the operating partner model, we record higher revenue and expenses due to the fact that almost all of the revenue cycle personnel are our employees and more third-party vendor contracts are controlled by us. Under the co-managed model, the majority of the revenue cycle personnel and third-party vendor contracts remain with the customer and those costs are netted against our co-managed revenue. For the nine months ended September 30, 2022 and 2021, substantially all of our net operating and incentive fees from end-to-end RCM services were generated under the operating partner model.

Our modular offerings allow customers to engage us for specific components of RCM services, such as revenue intelligence solutions (which were enhanced through the acquisition of Revint Holdings, LLC (“Cloudmed”)), automation solutions, patient experience (R1 EntriTM Pay), physician advisory services (“PAS”), clinical documentation integrity (“CDI”), coding management, revenue integrity solutions (“RIS”), business office services, and practice management (“PM”). Our patient experience offering, R1 EntriTM Pay, unifies scheduling, clearance, intake, and payments into one welcoming experience.

Once implemented, our technology solutions, processes, and services are deeply embedded in our customers’ day-to-day revenue cycle operations. We believe our service offerings are adaptable to meet an evolving healthcare regulatory environment, technology standards, and market trends.
We operate our business as a single segment configured with our significant operations and offerings organized around the business of providing revenue cycle operations for healthcare providers.
Leadership Succession
On November 8, 2022, the Company announced that Joseph Flanagan, Chief Executive Officer and member of the Board, will step down from the position of Chief Executive Office effective as of January 1, 2023. Mr. Flanagan will assume the non-executive role of Executive Advisor to the Chief Executive Officer and remain a member of the Board. The Company also announced that Lee Rivas, currently the President of the Company, will succeed Mr. Flanagan in the role of Chief Executive Officer and will become a member of the Board as of January 1, 2023. John Sparby, currently the Executive Vice President, Operations & Delivery and Chief Operating Officer, will succeed Mr. Rivas in the role of President of the Company effective as of January 1, 2023.
30



Macroeconomic Environment

Growth in economic activity and demand for goods and services, alongside labor shortages and supply chain complications, have contributed to high levels of inflation in 2022. We expect inflation to persist in 2023, which would negatively impact our costs for wages and other materials. Inflation may also impact the economic health of our customers, including their ability to pay amounts owed to us. In response to rising inflation, the Federal Reserve Board has raised interest rates and signaled that it will continue to raise rates. Our credit facility interest, in part, is based on a variable interest rate structure which can result in increased cost in periods of rising interest rates. To date, rising interest rates have not had a material impact on our results of operations.

Our incentive fees were impacted by deterioration in payer-reimbursement turnaround times. We currently anticipate continued impact on our performance into 2023 from payer turnaround times. In addition, we are observing the following trends, which we expect will persist in 2023: (i) we expect the inflationary effect on our labor and cost structure to be higher than payer rate increases flowing to our customers’ revenue and cash collections; (ii) we expect reduced growth in our physician business serving emergency department physicians due to regulatory changes that are impacting some of the large groups in the industry; and (iii) with recessionary concerns increasing, we could see potential weakness in consumer collections as healthcare bills are de-prioritized.

Other adverse macroeconomic conditions, including but not limited to changes to fiscal and monetary policy and currency fluctuations, could impact macro-level consumer spending trends, which could affect the amount of volumes processed on our platform and result in fluctuations to our revenue streams. Certain of our customers may be negatively impacted by these events. Further, while patient volumes are largely in line with pre-COVID-19 levels, the COVID-19 pandemic continues to evolve, continuing to affect the population. In addition, our business and customers continue to face challenges relating to a tight labor market and increased turnover rates. The extent to which these macroeconomic conditions will affect our business is uncertain and will depend on political, social, economic, and regulatory forces that are outside of our control. We continue to assess fluctuating macroeconomic events to manage our response.

Cloudmed Acquisition

On June 21, 2022, we completed the acquisition of Cloudmed pursuant to the Transaction Agreement and Plan of Merger, dated as of January 9, 2022, (the “Cloudmed Acquisition”). The purchase price was $3.3 billion. We funded the cash consideration component of the purchase price and the Company’s associated transaction expenses with a combination of cash on hand and the incurrence of additional indebtedness.

Cloudmed’s revenue intelligence platform combines cloud-based data architecture and deep domain expertise with intelligent automation to analyze large volumes of medical records, payment data, and complex medical insurance models to identify opportunities to deliver additional revenue to customers. We believe this transaction will enable us to further our ability to deliver transformative value to healthcare providers through a more fulsome platform of differentiated capabilities by creating a scaled leader across both end-to-end revenue cycle management and technology-driven revenue intelligence.
CONSOLIDATED RESULTS OF OPERATIONS
The following table provides consolidated operating results and other operating data for the periods indicated:
31



 Three Months Ended September 30,2022 vs. 2021
Change
Nine Months Ended September 30,2022 vs. 2021
Change
 20222021Amount%20222021Amount%
 (In millions, except percentages)
Consolidated Statement of Operations Data:
Net operating fees$324.2 $308.5 $15.7 %$965.3 $879.8 $85.5 10 %
Incentive fees20.8 41.5 (20.7)(50)%80.9 108.0 (27.1)(25)%
Modular and other151.0 29.7 121.3 408 %227.4 87.9 139.5 159 %
Total net services revenue496.0 379.7 116.3 31 %1,273.6 1,075.7 197.9 18 %
Operating expenses:
Cost of services403.1 304.0 99.1 33 %1,009.7 858.2 151.5 18 %
Selling, general and administrative60.8 33.2 27.6 83 %120.6 87.8 32.8 37 %
Other expenses30.1 11.4 18.7 164 %136.1 34.2 101.9 298 %
Total operating expenses494.0 348.6 145.4 42 %1,266.4 980.2 286.2 29 %
Income from operations2.0 31.1 (29.1)(94)%7.2 95.5 (88.3)(92)%
Net interest expense23.7 6.5 17.2 265 %35.3 13.8 21.5 156 %
Net income (loss) before income tax provision (benefit)(21.7)24.6 (46.3)(188)%(28.1)81.7 (109.8)(134)%
Income tax provision (benefit)7.8 7.6 0.2 %(7.6)20.5 (28.1)(137)%
Net income (loss)$(29.5)$17.0 $(46.5)(274)%$(20.5)$61.2 $(81.7)(133)%
Adjusted EBITDA (1)$124.0 $89.3 $34.7 39 %$300.5 $248.5 $52.0 21 %

(1) Refer to the Non-GAAP Financial Measures section below for a reconciliation of our financial results reported in accordance with GAAP to non-GAAP financial results.
Use of Non-GAAP Financial Information
In order to provide a more comprehensive understanding of the information used by our management team in financial and operational decision-making, we supplement our consolidated financial statements that have been prepared in accordance with GAAP with the non-GAAP financial measure of adjusted EBITDA. Adjusted EBITDA is utilized by our Board and management team as (i) one of the primary methods for planning and forecasting overall expectations and for evaluating actual results against such expectations; and (ii) as a performance evaluation metric in determining achievement of certain executive incentive compensation programs, as well as for incentive compensation plans for employees.
Adjusted EBITDA
We define adjusted EBITDA as net income (loss) before net interest income/expense, income tax provision/benefit, depreciation and amortization expense, share-based compensation expense, CoyCo 2, L.P. (“CoyCo 2”) share-based compensation expense, and other expense items detailed in Note 11, Other Expenses, to the Consolidated Financial Statements included in this Quarterly Report on Form 10-Q, including business acquisition costs, integration costs, strategic initiatives, and the global business services center expansion project in the Philippines.
We understand that, although non-GAAP measures are frequently used by investors, securities analysts, and others in their evaluation of companies, these measures have limitations as analytical tools, and you should not consider them in isolation or as a substitute for analysis of our results of operations as reported under GAAP. Some of these limitations are:
Adjusted EBITDA does not reflect:
32



Changes in, or cash requirements for, our working capital needs;
Share-based compensation expense (including CoyCo 2 share-based compensation expense);
Income tax expenses or cash requirements to pay taxes;
Interest expenses or cash required to pay interest;
Certain other expenses which may require cash payments;
Although depreciation and amortization charges are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and adjusted EBITDA does not reflect cash requirements for such replacements or other purchase commitments, including lease commitments; and
Other companies in our industry may calculate adjusted EBITDA differently than we do, limiting its usefulness as a comparative measure.
Reconciliation of GAAP and Non-GAAP Measures
The following table represents a reconciliation of adjusted EBITDA to net income (loss), the most closely comparable GAAP measure, for each of the periods indicated:
 Three Months Ended September 30,2022 vs. 2021
Change
Nine Months Ended September 30,2022 vs. 2021
Change
 20222021Amount%20222021Amount%
 (In millions, except percentages)
Net income (loss)$(29.5)$17.0 $(46.5)(274)%$(20.5)$61.2 $(81.7)(133)%
  Net interest expense23.7 6.5 17.2 265 %35.3 13.8 21.5 156 %
  Income tax provision (benefit)7.8 7.6 0.2 %(7.6)20.5 (28.1)(137)%
  Depreciation and amortization expense 64.2 21.3 42.9 201 %107.8 56.8 51.0 90 %
  Share-based compensation expense (1)24.7 25.5 (0.8)(3)%46.4 62.0 (15.6)(25)%
CoyCo 2 share-based compensation expense (2)3.0 — 3.0 100 %3.0 — 3.0 100 %
  Other expenses (3)30.1 11.4 18.7 164 %136.1 34.2 101.9 298 %
Adjusted EBITDA (non-GAAP)$124.0 $89.3 $34.7 39 %$300.5 $248.5 $52.0 21 %
(1)        Share-based compensation expense represents the expense associated with stock options, restricted stock units, and performance-based restricted stock units granted, as reflected in our Consolidated Statements of Operations and Comprehensive Income (Loss). See Note 10, Share-Based Compensation, to the consolidated financial statements included in this Quarterly Report on Form 10-Q for the detail of the amounts of share-based compensation expense.
(2) CoyCo 2 share-based compensation expense represents the expense associated with CoyCo 2 limited partnership units, as reflected in our Consolidated Statements of Operations and Comprehensive Income (Loss). See Note 10, Share-Based Compensation, to the consolidated financial statements included in this Quarterly Report on Form 10-Q for the detail of the amounts of CoyCo 2 share-based compensation expense.
(3)        Other expenses are incurred in connection with acquisition and integration costs, various exit activities, transformation initiatives, and organizational changes to improve our business alignment and cost structure. See Note 11, Other Expenses, to the consolidated financial statements included in this Quarterly Report on Form 10-Q for the detail of the amounts included in other expenses.
Three Months Ended September 30, 2022 Compared to Three Months Ended September 30, 2021
Net Services Revenue
Net services revenue increased by $116.3 million, or 31%, from $379.7 million for the three months ended September 30, 2021, to $496.0 million for the three months ended September 30, 2022. The increase was driven by a $120.2 million contribution from Cloudmed and $15.7 million increase in net operating fees driven by new customers, partially offset by lower incentive fees of $20.7 million due to longer payer-reimbursement turnaround times and execution issues at two operating partner customers.
33



Cost of Services
Costs of services primarily consists of wages and benefits of personnel that perform services for our customers and any related supplies, equipment, or facility costs utilized by these employees. It also includes cost of services provided to our customers by vendors directly contracted by R1 or assigned to R1 at contract inception. Cost of services increased by $99.1 million, or 33%, from $304.0 million for the three months ended September 30, 2021, to $403.1 million for the three months ended September 30, 2022. The increase in cost of services was primarily driven by the Cloudmed Acquisition, expansion of deployment capacity, and onboarding of new customers.
Selling, General and Administrative Expenses
Selling, general and administrative expenses increased by $27.6 million, or 83%, from $33.2 million for the three months ended September 30, 2021, to $60.8 million for the three months ended September 30, 2022. The increase was driven by the Cloudmed Acquisition, higher share-based compensation expense, and a $9.5 million increase in allowance for credit losses related to a physician customer that was unable to make a contractually required payment on September 30, 2022, is currently facing financial challenges, and is in an active debt refinancing process. As a result of reviewing the potential expected outcomes related to this customer, we recorded an allowance for credit losses of $10.0 million related to an overall receivable balance of $33.3 million as of September 30, 2022.
Other Expenses
Other expenses increased by $18.7 million, or 164%, from $11.4 million for the three months ended September 30, 2021, to $30.1 million for the three months ended September 30, 2022. See Note 11, Other Expenses, to the consolidated financial statements included in this Quarterly Report on Form 10-Q for the details of the costs included in this total for the comparative periods.
Income Taxes
Income tax provision increased by $0.2 million from $7.6 million for the three months ended September 30, 2021, to $7.8 million for the three months ended September 30, 2022, primarily due to higher GILTI and non-deductible expenses. Our effective tax rate (including discrete items) was approximately (36)% and 31% for the three months ended September 30, 2022 and 2021, respectively. Our tax rate is also affected by discrete items that may occur in any given year but are not necessarily consistent from year to year.
Nine Months Ended September 30, 2022 Compared to Nine Months Ended September 30, 2021
Net Services Revenue
Net services revenue increased by $197.9 million, or 18%, from $1,075.7 million for the nine months ended September 30, 2021, to $1,273.6 million for the nine months ended September 30, 2022. The increase was driven by a $133.5 million contribution from Cloudmed and net operating fees from new end-to-end customers, partially offset by lower incentive fees.
Cost of Services
Costs of services primarily consists of wages and benefits of personnel that perform services for our customers and any related supplies, equipment, or facility costs utilized by these employees. It also includes cost of services provided to our customers by vendors directly contracted by R1 or assigned to R1 at contract inception. Cost of services increased by $151.5 million, or 18%, from $858.2 million for the nine months ended September 30, 2021, to $1,009.7 million for the nine months ended September 30, 2022. The increase in cost of services was primarily driven by the Cloudmed Acquisition and onboarding of new customers, which are reflected in our current revenue growth.
34



Selling, General and Administrative Expenses
Selling, general and administrative expenses increased by $32.8 million, or 37%, from $87.8 million for the nine months ended September 30, 2021, to $120.6 million for the nine months ended September 30, 2022. The increase was driven by the Cloudmed Acquisition, higher share-based compensation expense, and a $9.5 million increase in allowance for credit losses related to a physician customer that was unable to make a contractually required payment on September 30, 2022, is currently facing financial challenges, and is in an active debt refinancing process. As a result of reviewing the potential expected outcomes related to this customer, we recorded an allowance for credit losses of $10.0 million related to an overall receivable balance of $33.3 million as of September 30, 2022. These increases were partially offset by lower accrued compensation expense.
Other Expenses
Other expenses increased by $101.9 million, or 298%, from $34.2 million for the nine months ended September 30, 2021, to $136.1 million for the nine months ended September 30, 2022. See Note 11, Other Expenses, to the consolidated financial statements included in this Quarterly Report on Form 10-Q for the details of the costs included in this total for the comparative periods.
Income Taxes
Income tax benefit improved by $28.1 million from a $20.5 million income tax provision for the nine months ended September 30, 2021, to a $7.6 million income tax benefit for the nine months ended September 30, 2022, primarily due to pre-tax loss. Our effective tax rate (including discrete items) was approximately 27% and 25% for the nine months ended September 30, 2022 and 2021, respectively. Our tax rate is also affected by discrete items that may occur in any given year, but are not necessarily consistent from year to year.
CRITICAL ACCOUNTING ESTIMATES
Management considers an accounting estimate to be critical if the accounting estimate requires management to make particularly difficult, subjective, or complex judgments about matters that are inherently uncertain. A summary of our critical accounting estimates is included in Part II, Item 7 “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Application of Critical Accounting Estimates” of our 2021 Form 10-K. There have been no material changes to the critical accounting estimates disclosed in our 2021 Form 10-K.
NEW ACCOUNTING PRONOUNCEMENTS
For additional information regarding new accounting guidance, see Note 1, Business Description and Basis of Presentation, to our consolidated financial statements included in this Quarterly Report on Form 10-Q, which provides a summary of our recently adopted accounting standards and disclosures.
LIQUIDITY AND CAPITAL RESOURCES
Our primary sources of liquidity include our cash flows from operations and borrowings under our second amended and restated senior credit agreement (the “Second A&R Credit Agreement”). As of September 30, 2022 and December 31, 2021, we had total available liquidity of $650.2 million and $499.6 million, respectively, reflecting our cash and cash equivalents as well as remaining availability under our senior secured revolving credit facility (the “Senior Revolver”).
Our liquidity is influenced by many factors, including timing of revenue and corresponding cash collections, the amount and timing of investments in strategic initiatives, our investments in property, equipment and software, and the use of cash to pay tax withholding obligations upon surrender of shares upon vesting of equity awards. We continue to invest capital in order to achieve our strategic initiatives and successfully integrate acquired companies. In addition, we plan to enhance customer service by continuing our investment in technology to enable our systems to more effectively integrate with our customers’ existing technologies in connection with our strategic initiatives.
35



We plan to continue to deploy resources to strengthen our information technology infrastructure, including automation, in order to drive additional value for our customers. We also expect to continue to invest in our global business services infrastructure and capabilities, including by expanding into the Philippines, and selectively pursue acquisitions and/or strategic relationships that will enable us to broaden or further enhance our offerings. New business development remains a priority as we plan to continue to boost our sales and marketing efforts. Additionally, we expect to incur costs associated with implementation and transition costs to onboard new customers.
We expect cash and cash equivalents, cash flows from operations, and our availability under the Senior Revolver to continue to be sufficient to fund our operating activities and cash commitments for investing and financing activities, including debt maturities and material capital expenditures, for at least the next 12 months and beyond. Similar to previous material acquisitions, future potential acquisitions may be funded through the incurrence of additional debt if our current credit facilities do not have the required capacity.
Our material cash requirements include the following contractual and other obligations:
Debt
Our indebtedness materially increased as a result of the Cloudmed Acquisition. As of September 30, 2022, we had outstanding debt of $1.8 billion with contractual payments extending through 2029, with $49.5 million payable within 12 months. Future interest payments associated with our debt total $463.0 million, with $99.1 million payable within the next 12 months, based on the floating rates as of September 30, 2022.
Leases
Our significant leasing activity encompasses leases for real estate, including corporate offices, operational facilities, and global business services centers. As of September 30, 2022, we had fixed future lease payments of $148.8 million, with $27.7 million payable within 12 months.
Software Purchase and Services Obligations
Our primary purchase obligations relate to contracts entered into with vendors that supply various software services and products. As of September 30, 2022, we had purchase obligations related to software and service contracts of $233.5 million, with $70.6 million payable within 12 months.
As of September 30, 2022 and December 31, 2021, we had cash and cash equivalents of $131.1 million and $130.1 million, respectively. Cash flows from operating, investing, and financing activities, as reflected in our consolidated statements of cash flows, are summarized in the following table:
 Nine Months Ended September 30,
 20222021
 (In millions)
Net cash used in (provided by) operating activities$(39.5)$218.8 
Net cash used in investing activities$(921.9)$(325.5)
Net cash provided by financing activities$965.5 $91.7 
Cash Flows from Operating Activities
Cash used in operating activities increased by $258.3 million from cash provided of $218.8 million for the nine months ended September 30, 2021, to cash used of $39.5 million for the nine months ended September 30, 2022. Cash used in operating activities increased due to a larger cash bonus payout related to the 2021 bonus plan compared to the 2020 bonus plan, payment of Cloudmed compensation amounts, and decreased net income of $81.7 million.
36



Cash Used in Investing Activities
Cash used in investing activities primarily includes our investments in property, equipment and software and our inorganic growth initiatives. Outflows for significant acquisitions are typically offset by cash inflows from financing activities related to obtaining new debt.
Cash used in investing activities increased by $596.4 million from $325.5 million for the nine months ended September 30, 2021, to $921.9 million for the nine months ended September 30, 2022. The increase in cash usage is primarily due to the difference in cash payments for the Cloudmed Acquisition in 2022 compared to the VisitPay acquisition in 2021 and the timing of payments for property, equipment and software.
Cash Flows from Financing Activities
Cash flows from financing activities primarily relate to borrowings and repayments of debt. In conjunction with acquisitions, we typically borrow additional debt to fund the consideration, either by increasing our existing facilities or refinancing with new facilities. We utilize our revolver to ensure we have sufficient cash on hand to support the needs of the business at any given point in time. Cash flows from financing activities also include cash received from exercises of stock options and the use of cash to pay tax withholding obligations upon surrender of shares upon vesting of equity awards, as well as other financing activities.
Cash provided by financing activities increased by $873.8 million from $91.7 million for the nine months ended September 30, 2021, to $965.5 million for the nine months ended September 30, 2022. This change is primarily due to 2022 borrowings made under the Second A&R Credit Agreement and smaller debt repayments in 2022, partially offset by higher amounts of cash required to pay tax withholding obligations upon surrender of shares upon vesting of equity awards in 2022. In addition, there were no inducement payments made during the nine months ended September 30, 2022, compared to $105.0 million used during the nine months ended September 30, 2021 to pay for the inducement of the conversion of our preferred stock
Debt and Financing Arrangements
On June 21, 2022, we entered into a Second A&R Credit Agreement with Bank of America, N.A., as administrative agent, and the lenders named therein, governing the Company’s second amended and restated senior secured credit facilities (the “Senior Secured Credit Facilities”), consisting of the $691.3 million existing senior secured term loan A facility (the “Existing Term A Loan”), a $540.0 million senior secured incremental term loan A facility (the “Incremental Term A Loan”, and together with the Existing Term A Loan, the “Term A Loans”), a $500.0 million senior secured term loan B facility (the “Term B Loan”, and together with the Term A Loans, the “Senior Term Loans”), and a $600.0 million Senior Revolver. The Existing Term A Loan requires quarterly payments. Commencing December 31, 2022, we are also required to repay the Incremental Term A Loan and Term B Loan in quarterly principal installments. The Senior Secured Credit Facilities bear interest at a floating rate, which was 5.28% for the Term A Loans and Senior Revolver and 6.03% for the Term B Loan as of September 30, 2022.

As of September 30, 2022, we had drawn $80.0 million and had $519.1 million of remaining availability on our Senior Revolver.

The proceeds from the new Senior Secured Credit Facilities were or will be used, in addition to cash on hand, (1) to refinance, in full, all existing indebtedness under the Amended and Restated Credit Agreement, dated as of July 1, 2021, by and among Old R1 RCM and certain of its subsidiaries, Bank of America, N.A., as administrative agent, and the lenders named therein, and amend and restate all commitments thereunder (the “Refinancing”), (2) to pay certain fees and expenses incurred in connection with the entry into the Second A&R Credit Agreement and the Refinancing, (3) to fund the Cloudmed Acquisition and a holding company reorganization, and to pay the fees, premiums, expenses and other transaction costs incurred in connection therewith, and (4) to finance our working capital needs for general corporate purposes.

37



The Second A&R Credit Agreement contains a number of financial and non-financial covenants. We are required to maintain minimum consolidated total net leverage and consolidated interest coverage ratios. The Company was in compliance with all of the covenants in the Second A&R Credit Agreement as of September 30, 2022.

See Note 8, Debt, to our consolidated financial statements included in this Quarterly Report on Form 10-Q for additional information.

Item 3.Qualitative and Quantitative Disclosures about Market Risk
Interest Rate Sensitivity. Our results of operations and cash flows are subject to fluctuations due to changes in interest rates due to our debt and banking arrangements, which can result in fluctuations in our interest income and expense. As of September 30, 2022, we have hedged $500.0 million of our $1.8 billion outstanding floating rate debt to a fixed rate of 3.01% plus the applicable spread defined in the Second A&R Credit Agreement. The remaining $1.3 billion outstanding is subject to average variable rates of 5.28% for the Term A Loans and Senior Revolver and 6.03% for the Term B Loan as of September 30, 2022. Assuming the current level of borrowings, a one percentage point increase or decrease in interest rates would increase or decrease our annual interest expense on the $1.3 billion subject to variable rates by approximately $13.0 million.
Our interest income is primarily generated from variable rate interest earned on operating cash accounts.
Foreign Currency Exchange Risk. Our results of operations and cash flows are subject to fluctuations due to changes in the Indian rupee and Philippine peso because a portion of our operating expenses are incurred by our subsidiaries in India and the Philippines and are denominated in Indian rupees and Philippine pesos, respectively. We do not generate significant revenues outside of the United States. For the nine months ended September 30, 2022 and 2021, 8% and 9% of our expenses were denominated in foreign currencies, respectively. As of September 30, 2022 and 2021, we had net assets of $77.6 million and $65.6 million in foreign entities, respectively. Before the impact of our foreign currency hedging activities discussed below, the reduction in earnings from a 10% change in foreign currency spot rates would be $11.9 million and $9.6 million at September 30, 2022 and 2021, respectively.
For designated cash flow hedges, gains and losses currently recorded in accumulated other comprehensive loss will be reclassified into earnings at the time when certain anticipated intercompany charges are accrued as cost of services. As of September 30, 2022, it was anticipated that approximately $0.8 million of losses, net of tax, currently recorded in accumulated other comprehensive loss will be reclassified into cost of services within the next 12 months.

We use sensitivity analysis to determine the effects that market foreign currency exchange rate fluctuations may have on the fair value of our hedge portfolio. The sensitivity of the hedge portfolio is computed based on the market value of future cash flows as affected by changes in exchange rates. This sensitivity analysis represents the hypothetical changes in value of the hedge position and does not reflect the offsetting gain or loss on the underlying exposure. A 10% change in the levels of foreign currency exchange rates against the U.S. dollar (or other base currency of the hedge if not a U.S. dollar hedge) with all other variables held constant would have resulted in a change in the fair value of our hedge instruments of approximately $6.2 million as of September 30, 2022.

38



Item 4.Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) are designed to ensure that information required to be disclosed by us in reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms and that such information is accumulated and communicated to management including its principal executive officer and principal financial officer to allow timely decisions regarding required disclosures.

In connection with the preparation of this report, our management, under the supervision and with the participation of the Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2022. Our Chief Executive Officer and Chief Financial Officer concluded that, as of September 30, 2022, our disclosure controls and procedures were effective.

Changes in Internal Control Over Financial Reporting

There have been no changes in our internal control over financial reporting during the third quarter of 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

39



PART II — OTHER INFORMATION
Item 1.Legal Proceedings

Other than the litigation described in Note 14, Commitments and Contingencies, to our consolidated financial statements included in this Quarterly Report on Form 10-Q, we are presently not a party to any material litigation or regulatory proceeding and are not aware of any pending or threatened litigation or regulatory proceeding against us which, individually or in the aggregate, could have a material adverse effect on our business, operating results, financial condition or cash flows.

Item 1A.Risk Factors

In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in Part I, Item 1A of our 2021 Annual Report on Form 10-K. Except as set forth below, there have been no material changes in our risk factors from those disclosed in our 2021 Form 10-K.

Risks Related to the Acquisition of Cloudmed

If we do not integrate the businesses successfully, we may lose customers and fail to achieve our financial objectives.

Achieving the benefits of the Cloudmed Acquisition will depend in part on the successful integration of Cloudmed’s business into our operations in a timely and efficient manner. In order for us to provide our customers with the same level of service after the Cloudmed Acquisition, we will need to integrate our product lines and development organizations with those of Cloudmed. This may be difficult, unpredictable, and subject to delay because the businesses have been developed independently and were designed without regard to such integration. In addition, Cloudmed is still in the process of integrating certain of its recent acquisitions. If we cannot successfully integrate the businesses and products and continue to provide customers with products and new product features in the future on a timely basis, we may lose customers and our business and operating results may be harmed.

We may not realize the anticipated benefits from the Cloudmed Acquisition.

The Cloudmed Acquisition involves the integration of two companies that have previously operated independently. We expect the combined company to result in financial and operational benefits, including increased cost savings and other financial and operating benefits from the Cloudmed Acquisition. There can be no assurance, however, regarding when or the extent to which we will be able to realize these increased cost savings or benefits. The companies must integrate or, in some cases, replace numerous systems, including those involving management information, purchasing, accounting and finance, sales, billing, employee benefits, payroll, and regulatory compliance, many of which are dissimilar. Difficulties associated with integrating the post-acquisition entity could have a material adverse effect on us and the market price of our common stock.

We have incurred significant transaction and merger-related costs in connection with the Cloudmed Acquisition and will remain liable for significant transaction costs, including legal, accounting, and other costs.

We have incurred and expect to continue to incur a number of non-recurring costs associated with combining the operations of the two companies which cannot be estimated accurately at this time. Although we expect that the elimination of duplicative costs, as well as the realization of other efficiencies related to the integration of the businesses, may offset incremental transaction and transaction-related costs over time, this net benefit may not be achieved in the near term, or at all.

40



The Cloudmed Acquisition could cause us to lose key personnel, which could materially affect our business and require us to incur substantial costs to recruit replacements for lost personnel.

As a result of the Cloudmed Acquisition, current and prospective R1 employees could experience uncertainty about their future roles within the combined company. This uncertainty may adversely affect our ability to attract and retain key management and operational personnel. Any failure to attract and retain key personnel could have a material adverse effect on our business.

The trading price of our common stock has been volatile and may continue to be volatile.

Since March 1, 2020, our common stock has traded at a price per share as high as $31.28 and as low as $7.12. Market prices for securities of companies that have undergone significant acquisitions may be volatile. The trading price of our common stock may be highly volatile in the future and could be subject to wide fluctuations in response to various factors. In addition to the risks described in this section, factors that may cause the market price of our common stock to fluctuate include: fluctuations in our quarterly financial results or the quarterly financial results of companies perceived to be similar to us; changes in estimates of our financial results or recommendations by securities analysts, if any, who cover our common stock, or failure to meet expectations of such securities analysts; the loss of service agreements with customers; lawsuits filed against us by governmental authorities or stockholders; unfavorable publicity concerning our operations or business practices; investors’ general perception of us; changes in local, regional or national economic conditions; changes in demographic trends; increased labor costs, including healthcare, unemployment insurance, and minimum wage requirements; the entry into, or termination of, material agreements; changes in general economic, industry, regulatory, and market conditions not related to us or our business; the availability of experienced management and hourly-paid employees; issues in operating the company; future sales of our securities, including sales by our significant stockholders; and other potentially negative financial announcements, including delisting of our common stock from The Nasdaq Global Select Market, changes in accounting treatment or restatement of previously reported financial results, delays in our filings with the SEC or failure to maintain effective internal control over financial reporting.

In addition, if the stock market in general experiences a loss of investor confidence, the trading price of our common stock could decline for reasons unrelated to our business, financial condition, or operating results.

Our consolidated indebtedness has increased substantially following completion of the Cloudmed Acquisition. This increased level of indebtedness could adversely affect us, including by decreasing our business flexibility.

Our consolidated indebtedness as of December 31, 2021 was approximately $775.6 million. In conjunction with the Cloudmed Acquisition, we entered into the Second A&R Credit Agreement, which increased our consolidated indebtedness by $1.0 billion. The increased indebtedness has had the effect of increasing our interest payments and could have the effect of, among other things, reducing our flexibility to respond to changing business and economic conditions. The increased level of indebtedness could also reduce funds available for capital expenditures, share repurchases and dividends, and other activities and may create competitive disadvantages for us relative to other companies with lower debt levels.

Item 2.Unregistered Sales of Equity Securities and Use of Proceeds
Unregistered Sale of Equity Securities
On July 5, 2022, the Company issued 1,403,687 shares of its common stock to Sutter Health as consideration for certain real property acquired by the Company from an affiliate of Sutter Health at a value of $24.3 million. The foregoing securities were issued in reliance upon the exemption from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended.
41



Issuer Purchases of Equity Securities
The following table provides information about our repurchases of common stock during the periods indicated:
PeriodNumber of Shares  Purchased (1) Average Price Paid per Share (1), (2)Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (2)  Maximum Dollar Value of Shares that May Yet be Purchased Under Publicly Announced Plans or Programs (in millions) (2)
July 1, 2022 through July 31, 2022 157,133   $22.26 73,976   $490.3 
August 1, 2022 through August 31, 202237,380 22.38 35,990 489.5 
September 1, 2022 through September 30, 2022484,160 20.92 484,160 479.3 
Total purchases678,673 $21.31 
(1)Includes the surrender of shares of our common stock related to employees’ tax withholding upon vesting of restricted stock or option exercise. See Note 10, Share-Based Compensation, to our consolidated financial statements included in this Quarterly Report on Form 10-Q.
(2)On October 22, 2021, the Board authorized the repurchase of up to $200.0 million of our common stock from time to time in the open market or in privately negotiated transactions (the “2021 Repurchase Program”). On January 9, 2022, the Board increased the authorization under the 2021 Repurchase Program to an aggregate amount of up to $500.0 million. The average price paid per share of common stock repurchased under the 2021 Repurchase Program is the execution price, including commissions paid to brokers. The timing and amount of any shares repurchased under the 2021 Repurchase Program will be determined by our management based on its evaluation of market conditions and other factors. The 2021 Repurchase Program may be suspended or discontinued at any time.

42



Item 6.Exhibits

The following are filed or incorporated by reference as a part of this Quarterly Report on Form 10-Q:

(a)
Exhibit NumberExhibit Description
101.INSXBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCHXBRL Taxonomy Extension Schema Document
101.CALXBRL Taxonomy Extension Calculation Linkbase Document
101.LABXBRL Taxonomy Extension Label Linkbase Document
101.DEFXBRL Taxonomy Extension Definition Linkbase Document
101.PREXBRL Taxonomy Extension Presentation Linkbase Document
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

*Furnished herewith.
+Certain portions of this exhibit have been redacted pursuant to Item 601(b)(10)(iv) of Regulation S-K. The Company agrees to furnish supplementally an unredacted copy of the exhibit to the Securities and Exchange Commission upon request.
43



SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
R1 RCM INC.
By:/s/ Joseph Flanagan
Joseph Flanagan
Chief Executive Officer
By:/s/ Rachel Wilson
Rachel Wilson
Chief Financial Officer and Treasurer
Date: November 8, 2022
    

44
Exhibit 10.1
CONFIDENTIAL
FINAL

AMENDMENT NO. 6 TO
AMENDED AND RESTATED MASTER PROFESSIONAL SERVICES AGREEMENT
BY AND BETWEEN
ASCENSION HEALTH AND R1 RCM INC.
    This Amendment No. 6 to the Master Professional Services Agreement (this “Amendment”) by and between Ascension Health (d/b/a Ascension Healthcare) (“Ascension Health”) and R1 RCM Holdco Inc. (f/k/a R1 RCM Inc., f/k/a Accretive Health, Inc.) (“Supplier”) is entered into as of the last date of execution hereof, and effective as of July 1, 2022 (the “Amendment Effective Date”). Ascension Health and Supplier are sometimes referred to in herein as a “Party” or collectively as the “Parties”. All capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Ascension MPSA or AMITA MPSA (as each is defined below).
    WHEREAS, the Parties entered into that certain Amended and Restated Master Professional Services Agreement, dated February 16, 2016, as amended, restated, supplemented or otherwise modified (the “Ascension MPSA”), which sets out a framework pursuant to which Supplier and Ascension Health and other Eligible Recipients may enter into Supplements for the provision of Services by Supplier;
    WHEREAS, the Parties, together with Alexian Brothers − AHS Midwest Region Health Co (doing business as AMITA Health) (“AMITA”) and Adventist Health System Sunbelt Healthcare Corporation (“AdventHealth”) entered into that certain Master Professional Services Agreement, dated November 1, 2018, as amended, restated, supplemented, or otherwise modified (the “AMITA MPSA”), which sets out a framework under which Supplier:
(a) provides Dependent Acute Services and Physician Advisory Services for the benefit of Acute Care facilities that are owned or controlled by Legacy Presence, pursuant to Supplement One to the AMITA MPSA (“Supplement #1”),
(b) provides Dependent Acute Services and Physician Advisory Services for the benefit of Acute Care facilities that are owned or controlled by certain Alexian Affiliates, pursuant to Supplement Two to the AMITA MPSA (“Supplement #2”);
(c) provides Dependent Provider Services for the benefit of Owned Eligible Medical Groups owned, controlled or employed by Legacy Presence, pursuant to Supplement Three to the AMITA MPSA (“Supplement #3”),
(d) provides Dependent Provider Services for the benefit of Owned Eligible Medical Groups owned, controlled or employed by certain Alexian Affiliates, pursuant to Supplement Four to the AMITA MPSA (“Supplement #4”);
    WHEREAS, as of even date herewith, the Parties, together with AMITA and AdventHealth, entered into that certain Contract Migration Agreement (“Contract Migration Agreement”), pursuant to which the Parties agreed to terminate the AMITA MPSA and migrate Supplier’s obligations with respect to the Presence Acute Group (including under Supplement #1), the Alexian Acute Group (including under Supplement #2), the Presence Provider Group (including under Supplement #3), and the Alexian Provider Group (including under Supplement #4), from the AMITA MPSA to the Ascension MPSA in accordance with the terms and conditions set forth herein; and
    WHEREAS, the Parties now desire to add new Supplements to be governed under the Ascension MPSA and make certain other related changes as set forth in this Amendment.
    NOW THEREFORE, in consideration of the mutual promises and covenants contained in this Amendment, and of other good and valid consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows:
1.Additional Definitions and Eligible Recipients
1.01For the avoidance of doubt, the Alexian Acute Group, the Presence Acute Group, the Alexian Provider Group and the Presence Provider Group, as well as any Entities that control any Migrated Group, are each Eligible Recipients under the Ascension MPSA. However, the Presence Acute Group and the Alexian Acute Group are neither Additional Book Eligible Recipients nor Current Book Eligible Recipients under the Ascension MPSA.
.- 1 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


1.02The definition of “Cost to Collect Factor,” as set forth in Exhibit 1 of the Ascension MPSA, is hereby deleted and replaced in its entirety with the following:

Cost to Collect Factor” means the Additional Book Cost to Collect Factor, the Current Book Cost to Collect Factor, the Presence Acute Cost to Collect Factor or the Alexian Acute Cost to Collect Factor as applicable.

1.03The following definitions are hereby added to Exhibit 1 of the Ascension MPSA:

Acute Group” means either the Presence Acute Group or the Alexian Acute Group.

Alexian Acute Cost to Collect Factor” has the meaning given in Supplement 29.

Alexian Acute Group” means the Entities set forth on Schedule A to this Amendment, each of which is, as of the Amendment Effective Date, Controlled by Alexian Brothers.

Alexian Brothers” means Alexian Brothers Hospital Network.

Alexian Provider Group” has the meaning given in EMG Services Addendum [#13] to Supplement 26 to the Ascension MPSA.

Legacy Presence” means Presence Care Transformation Corporation (or any successor Entity thereto) or any Covered Affiliate that is Controlled by Presence Care Transformation Corporation (or any successor Entity thereto).

Migrated Group” means any of (a) the Alexian Acute Group, (b) the Presence Acute Group, (c) the Presence Provider Group or (d) the Alexian Provider Group.

Presence Acute Group” means the Entities set forth on Schedule A to this Amendment, each of which is, as of the Amendment Effective Date, Controlled by Legacy Presence.

Presence/Alexian Acute Care Units” shall mean the Acute Care facilities included in the Acute Presence/Alexian Group.

Presence Acute Cost to Collect Factor” has the meaning given in Supplement 28.

Presence/Alexian Acute Group” shall mean, collectively, the Alexian Acute Group and the Presence Acute Group.

Presence/Alexian Cost to Collect Factor” shall mean either (a) the Alexian Acute Cost to Collect Factor or (b) the Presence Acute Cost to Collect Factor.

Presence Provider Group” has the meaning given in EMG Services Addendum [#14] to Supplement 26.

2.Addition of Supplements and Exhibits to Ascension MPSA and EMG Services Addenda and Exhibits to Supplement 26.
2.01     New Supplements and EMG Services Addenda - Effective as of the Amendment Effective Date, the Parties have entered into Supplement 28 to the Ascension MPSA (for the Presence Acute Group), Supplement 29 to the Ascension MPSA (for the Alexian Acute Group), EMG Services Addendum #13 to Supplement 26 to the Ascension MPSA (for the Presence Provider Group) and EMG Services Addendum #14 to Supplement 26 to the Ascension MPSA (for the Alexian Provider Group).
.- 2 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


2.02     EMG Services for the Alexian Provider Group and Presence Provider Group - Effective as of the Amendment Effective Date, Exhibit 1-A to Supplement 26 (EMG Services – For the Alexian Provider Group and the Presence Provider Group) is hereby added to Supplement 26, as set forth in Addendum 1 attached hereto. For the avoidance of doubt, Exhibit 1-A to Supplement 26 will apply solely to the Alexian Provider Group and the Presence Provider Group and will not apply to any other Eligible Medical Groups.
2.03    Acute Care Service Levels for the Alexian Acute Group and Presence Acute GroupEffective as of the Amendment Effective Date (but without limiting the retroactive effect of certain Services Levels as expressly set forth in Addendum 2), Exhibit 3-A (Service Levels - For the Alexian Acute Care Group and Presence Acute Care Group) is hereby added to the Ascension MPSA, as set forth in Addendum 2 attached hereto. For the avoidance of doubt, Exhibit 3-A will apply solely to the Presence Acute Group and the Alexian Acute Group and will not apply to the Current Book Eligible Recipients or the Additional Book Eligible Recipients.
2.04    EMG Service Levels for the Alexian Provider Group and Presence Provider GroupEffective as of the Amendment Effective Date (but without limiting the retroactive effect of certain Services Levels as expressly set forth in Addendum 3), Exhibit 4-A to Supplement 26 (Service Levels – For the Alexian Provider Group and the Presence Provider Group) is hereby added to Supplement 26, as set forth in Addendum 3 attached hereto. For the avoidance of doubt, Exhibit 4-A to Supplement 26 will apply solely to the Alexian Provider Group and the Presence Provider Group and will not apply to any other Eligible Medical Groups.
2.05     EMG Incentive Fees - Effective as of the Amendment Effective Date, Exhibit 3-A to Supplement 26 (EMG Incentive Fees – For the Alexian Provider Group and the Presence Provider Group) is hereby added to Supplement 26, as set forth in Addendum 4 attached hereto. For the avoidance of doubt, Exhibit 3-A to Supplement 26 will apply solely to the Alexian Provider Group and the Presence Provider Group and will not apply to any other Eligible Medical Groups and, in lieu of the calculations set forth in Exhibit 3 to the AMG Supplement, the EMG Incentive Fees for each of the Alexian Provider Group and Presence Provider Group will be determined in accordance with Addendum 4 attached hereto; provided that (a) the Appendices to Exhibit 3 to Supplement 26 will apply to the Alexian Provider Group and the Presence Provider Group, and (b) for purposes of Appendix B of Exhibit 3 of Supplement 26, the Alexian Provider Group and Presence Provider Group shall be deemed included in the “Phase 1 Group”.
3.Acute Services - Modifications to Dependent Services Exhibit for Presence Acute Group and Alexian Acute Group.
Effective as of the Amendment Effective Date, the following is hereby added as Dependent Services to Section 1(a) of Exhibit 2-A (Dependent Services) to the Ascension MPSA that Supplier is obligated to provide solely for the Presence Acute Group and the Alexian Acute Group and for no other Eligible Recipients, except to the extent otherwise agreed by the Parties in writing:
Scheduling (including inpatient, outpatient, and diagnostics) – In accordance with Ascension Health Standards and each individual hospital’s technical systems, policies, and practices ensure that critical information and all core set of data elements are obtained from either the patient or the referring physician practice to enable successful subsequent front end processes. To aid scheduling processes, provide patient in advance with instructions based on the scheduled medical procedure, manage physician orders as directed by such physician for scheduled medical procedures, manage Ascension Health medical procedure facility schedule as directed, and provide follow up or reminders of scheduled visits.
BCBSIL UPP Reimbursement Management” -- Supplier shall undertake the following activities solely for the benefit of the Presence Acute Group and the Alexian Acute Group: Utilize Blue Cross Blue Shield Illinois experience reports as provided by Ascension Health or the Presence/Alexian Acute Care Units to validate actual reimbursements compared to expected reimbursement for underpayment and denial recovery
.- 3 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


.IL Medicaid and State Payor AR Management -- Supplier shall undertake the following activities solely for the benefit of the Presence Acute Group and the Alexian Acute Group: As made available by State of Illinois programs defined as traditional Medicaid, managed care organizations, and all commercial payors funded by the State. Supplier will request, monitor and maintain payor ‘promise to pay’ status on adjudicated but unpaid claims for accounts receivable management and reporting to finance departments of the Presence Acute Group and the Alexian Acute Group to assist with identifying accounts receivable with delayed payment due to State funding.
4.Acute Incentive Fees - Modifications to Incentive Fees for Alexian Acute Group and Presence Acute Group
4.01     Subject to the Performance Targets, Metric Weights and Upper Bounds and Lower Bounds for each Operating Metric set forth in Supplement 28 and Supplement 29, respectively, and Sections 4.02 through 4.04 below, the Incentive Payment for each of the Presence Acute Group and the Alexian Acute Group will be determined in accordance with Exhibit 4-B to the MPSA (as amended); provided that the changes to Exhibit 4-B described in Section 4.02 through 4.04 below will only apply through [*****]. For the avoidance of doubt, the [*****] that is planned to become effective on [*****].

4.02     Notwithstanding Section 1.2 of Exhibit 4-B to the MPSA, from [*****] through [*****], with respect to each of the Presence Acute Group and the Alexian Acute Group, the numeral in sub-clause (ii) in each of the definitions of “Balance Sheet Incentive Payment” and “Income Statement Incentive Payment” in Exhibit 4-B is hereby modified to be [*****] instead of [*****].
4.03     Notwithstanding Section 6 of Exhibit 4-B to the MPSA, from [*****] through [*****], with respect each of the Presence Acute Group and the Alexian Acute Group, the definitions of “Performance Score” and “Performance Target” are hereby revised as follows.
Performance Score” means the percentage value assigned to the Operating Metric based on the relationship of the Actual Performance for the Operating Metric as compared to the Performance Target and the Lower Bound and the Upper Bound. For any Operating Metric, the Performance Score resulting from Actual Performance shall equal the result of the following equation (expressed as a percentage): the sum of (A) the result of (x) the difference of the Actual Performance with respect to such Operating Metric minus the Performance Target, divided by (y) the difference of the applicable Upper Bound minus the applicable Performance Target, which result will be multiplied by (z) [*****], and (B) [*****].
[*****] = Performance Score

For example, an Actual Performance of [*****] for an Operating Metric that has a Lower Bound of [*****], a Performance Target of [*****] and an Upper Bound of [*****] would result in a Performance Score of [*****] since:
[*****]
Notwithstanding the foregoing, the maximum Performance Score is [*****] and the minimum Performance Score is [*****]
Performance Target” means, with respect to any Operating Metric, the Actual Performance for such Operating Metric that would result in a Performance Score for such Operating Metric of the fraction [*****] expressed as a percentage.
4.04     Notwithstanding Section 8.5 of Exhibit 4-B to the MPSA, from [*****] through [*****], with respect to each of the Presence Acute Group and the Alexian Acute Group, the table in Section 8.5 to Exhibit 4-B is hereby revised as shown below.
.- 4 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


#Metric0% Target[*****]100% Target
1)Metric Removed
2)[*****][*****]
Pursuant to Section 3.3
[*****]
3)[*****]
4)[*****][*****]
Pursuant to Section 3.3
[*****]
5)[*****][*****]
Pursuant to Section 3.3
[*****]
6)[*****]
7)[*****][*****]
Pursuant to Section 3.3
[*****]
8a)[*****][*****]
Pursuant to Section 3.3
[*****]
8b)[*****][*****]
Pursuant to Section 3.3
[*****]
9)[*****][*****]
Pursuant to Section 3.3
[*****]
10)[*****]

5.Implementation Fees for Legacy Presence and Alexian Brothers
5.01     During the period running from [*****] through [*****], if Legacy Presence, Alexian Brothers or any Entity in the Presence Acute Group or Alexian Acute Group acquires a new Eligible Recipient Unit for Acute Care, then the references to [*****] in Section 5 of Exhibit 4-A to the Ascension MPSA will be modified to be [*****] for purposes of calculating the Implementation Fee. For clarity, with respect to any Eligible Recipient Unit acquired by any Entity in the Presence Acute Group or Alexian Acute Group after [*****], (a) the foregoing modification will not apply, and (b) the [*****] from Section 5 of Exhibit 4-A to the Ascension MPSA shall be used for purposes of calculating the Implementation Fee.
6.Limitation of Liability.
Effective as of the Amendment Effective Date, Section 18.2(b) of the Ascension MPSA is hereby deleted and replaced in its entirety with the below.
Liability Cap. Except as provided in this Section 18.2, the total aggregate liability of either Party, for claims asserted by the other Party under or in connection with this Agreement, regardless of the form of the action or the theory of recovery, shall be limited to [*****] per calendar year. For avoidance of doubt, this annual liability cap is an aggregate liability cap for this Agreement and all Supplements.”

7.Compliance.
Effective as of the Amendment Effective Date, Section 3.2 of Exhibit 11 of the Ascension MPSA is hereby deleted in its entirety.
8.Approved Data Subcontractors for Legacy Presence and Alexian Brothers.
8.01     Ascension Health hereby approves Supplier’s use of [*****] as Data Subcontractors under the Ascension MPSA, in each case, subject to the terms and conditions set forth in the Data Subcontractor Acknowledgements entered into between AMITA and Supplier on [*****] and [*****], respectively, but solely for the provision of the applicable approved categories of services (as set forth in each Data Subcontractor Acknowledgment) for Legacy Presence and Alexian Brothers.

9.Miscellaneous.
.- 5 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


9.01    The Parties agree and acknowledge that, except as otherwise expressly amended by this Amendment, (a) the Ascension MPSA remains in full force and effect according to its terms and conditions, (b) except as expressly set forth herein, this Amendment shall not affect any rights of a Party that accrued with respect to the Ascension MPSA prior to the Amendment Effective Date and (c) this Amendment shall not release a Party from any obligations, liabilities, or other claims that may have arisen under the Ascension MPSA prior to the Amendment Effective Date. The Parties agree that this Amendment represents compliance with all obligations relating to the Presence and Alexian Contract Migration, as defined in and set forth in the Contract Migration Agreement.
9.02    Prior to [*****], the Parties agree to discuss in good faith potential amendments to the MPSA for purposes of: (a) simplifying the Subcontractor approval process, while maintaining all relevant controls currently specified therein; and (b) modernizing the terms related to information security and each Party’s Intellectual Property Rights (e.g., to reflect the delivery of certain technologies as software-as-a-service).
9.03    This Amendment may be executed in several counterparts, all of which taken together will constitute one single agreement between the Parties.

[signature page follows]

.- 6 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15



IN WITNESS WHEREOF, the Parties have caused this Amendment to be executed by their respective duly authorized representatives as of the Amendment Effective Date.

Agreed to and Accepted by:
R1 RCM Holdco Inc. (f/k/a R1 RCM Inc.)

By:    /s/ John Sparby

Name:    John Sparby

Title: Executive Vice President and Chief Operating Officer


Date: July 1, 2022
Ascension Health (d/b/a Ascension Healthcare)

By:    /s/ Jon Sohn

Name:    Jon Sohn

Title: Senior Vice President, Chief Revenue Officer, Ascension, on behalf of Ascension Health d/b/a Ascension Healthcare

Date: July 1, 2022


.- 7 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


Schedule A
List of Entities in Presence Acute Group and Alexian Acute Group
Presence Acute Group:

1.Presence Chicago Hospitals Network d/b/a Presence Holy Family Medical Center;
2.Presence Chicago Hospitals Network d/b/a Presence Resurrection Medical Center
3.Presence Chicago Hospitals Network d/b/a Presence Saint Francis Hospital
4.Presence Chicago Hospitals Network d/b/a Presence Saint Joseph Hospital – Chicago
5.Presence Chicago Hospitals Network d/b/a Presence Saint Elizabeth Hospital
6.Presence Chicago Hospitals Network d/b/a Presence Saint Mary of Nazareth Hospital
7.Presence Central and Suburban Hospitals Network d/b/a Presence Mercy Medical Center
8.Presence Central and Suburban Hospitals Network d/b/a Presence Saint Joseph Hospital – Elgin
9.Presence Central and Suburban Hospitals Network d/b/a Presence Saint Joseph Medical Center
10.Presence Central and Suburban Hospitals Network d/b/a Presence St. Mary’s Hospital – Kankakee

Alexian Acute Group:

1.Alexian Brothers Medical Center
2.St. Alexius Medical Center
3.Alexian Brothers Behavioral Health Hospital



.- 8 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


Addendum 1
Exhibit 1-A to Supplement 26
(EMG Services– For the Alexian Provider Group and the Presence Provider Group)
The EMG Services described below are being undertaken for the purposes of optimizing the Revenue Cycle Operations process to maximize compliant collections from the amounts billable as a result of operations of the Alexian Provider Group or Presence Provider Group, as applicable. None of the EMG Services described below are being undertaken to manage medical decisions or business operations of the Alexian Provider Group or Presence Provider Group, nor are any of the Services intended to increase the volume of operations of the Alexian Provider Group or Presence Provider Group.

With respect to each function in the revenue cycle operations of the Alexian Provider Group or Presence Provider Group, Annex A to this Exhibit 1-A attached hereto sets forth ownership, applicable technology, and whether Supplier is responsible for implementing related processes and performance improvement.

1.EMG Services. In accordance with Section 4.1 of the MPSA, Supplier shall provide the following EMG Services, subject to the allocation of tasks set forth in Annex A to this Exhibit 1-A.
a.Medical Group Market Services. For purposes of this Addendum, “Medical Group Market Services” shall include the following functional areas:
i.PRE-SERVICE – Supplier will provide leadership, management oversight, staffing and technical expertise of:

Authorization/Referral (Verification) – Supplier will (i) perform authorization clearance services for patients to verify that an authorization is in place, and (ii) document all required authorizations.

Insurance Eligibility Verification (Financial Clearance) – Once the payer is identified, check benefit eligibility and obtain verification from insurance (governmental or commercial) that the patient reported insurance for the applicable service is still in force and will reimburse the provider for the service.

ii.TIME OF SERVICE - Supplier will directly provide leadership, management oversight, staffing and technical expertise of, or indirectly support through implementation of “best practices” and process standardization, the following services:

Self-Pay Financial Advocacy and Eligibility of Services (e.g., self-pay conversions) (Financial Counseling) – For those patients that are unaware of what insurance they have, or declare they have no insurance, work diligently and use proprietary tools to gather information to understand what might be an acceptable source of reimbursement.

Registration – Obtaining all required patient liability (i.e., outstanding balance), clinical, demographic, and financial information from patients that was not obtained during scheduling or pre-registration when the patient is present for service regardless of status (scheduled or walk-in). Obtaining information necessary to obtain financial clearance at time of service (to include collection of co-pay, deductible, or co-insurance).

.- 9 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


Collection of Residuals – Support and monitor the patient education and communication process, present the opportunity for patients to pay their patient balances as both a convenience and improvement to patient flow at the point of service.

iii.CHARGING/CODING - Supplier will directly provide leadership, management oversight, staffing and technical expertise of, or indirectly support through implementation of “best practices” and process standardization, the following services:

Physician Coding Review/Audit – For operations that result in reviewing of medical records; Medical records are reviewed in order to determine appropriate charges billed, CPT and/or ICD-10 coding, and that providers are in accordance with any and all regulatory guidelines.

Physician Education-  For operations that result in educating and training providers based on audit findings and trends to ensure proper coding and supported documentation. In addition, ensuring that providers are educated on applicable regulatory coding changes.

Abstract Coding- Ensuring that once a medical record of service is completed, coders have used the appropriate ICD- 10 CM, CPT, HCPCS codes and modifiers as supported by documentation.

iv.POST-SERVICE - Supplier will directly provide leadership, management oversight, staffing and technical expertise of, or indirectly (depending on the applicable patient accounting system) support through implementation of “best practices” and process standardization, the following services:

Coding Supported Accounts Receivable Management – Once a medical record coding and/or charge entry is completed and submitted for billing, identify and remedy billing deficiencies in accordance with payer requirements and compliant billing practices. When required, utilize certified coding professional to review and correct billing editor rejections and payer denials to correct and resubmit claims.

Charge Capture/ Pre-Bill, Post-Bill (Charge Optimization) - Use automated and manual methods, including retrospectively, to correctly bill gross revenue and to capture applicable and authorized charges on the bill that is sent to the payer/ patient, while remaining in compliance with all applicable laws and guidelines. For retrospective review, analyze claims after the bill has been sent to look for incorrect or missing charges or codes, and initiate confirmation and rebill processes to ensure all applicable and authorized charges have been captured by clinical departments and re-billed to the payer/ patient.

b.Platform-Specific Services – For purposes of this Addendum, “Platform-Specific Services” shall include the following functional areas:

POST-SERVICE – Supplier will directly provide leadership, management oversight, staffing and technical expertise of, or indirectly (depending on the applicable patient accounting system) support through implementation of “best practices” and process standardization, the following services:

.- 10 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


Billing/Claims Processing, Claims Scrubbing/Preparation/Claims Submission - Send all required information to the billing editor application or system so that a claim proceeds to the applicable payer. Though the goal is to have no bill editor rejects, Supplier shall oversee processes to resolve all discrepancies in a timely manner for resubmission of the bill to the applicable payer. Once the insurance balance is resolved, confirm that the applicable patient billing system sends a bill for the residual patient responsibility. Recommend billing edits and bridge routines to improve the number of claims sent to the payer without intervention and/or to reduce denials.

Credits (Refund Processing) - Research credit balances and reasons for credit balances (e.g., over-contractualization, system processing issues, actual over-payments, etc.), and prepare appropriate payment alterations where no refund is due. Supplier shall process credit balances for refund payment for Ascension Affiliates’ review and consent. Implement processes necessary to comply with state escheatment laws for uncashed refund payments.

Unpostables – Research and gather all information necessary to support posting an “Unpostable” to the correct account. “Unpostables” are unidentified remittances, whether made by check, cash payment, remit or individual account balance, which do not contain sufficient information to accurately process and post such payments to a patient account.

Credit Card Processing – Manage and/or support processes for patient and payer credit card processing.
Cash Posting and Processing (Lockbox and Payment Posting) – Electronically and manually post cash from both payers’ and patients’ accounts and reconcile outstanding accounts receivable in a timely and accurate manner. Reconcile daily cash at patient account level to the extent reasonably feasible (except Ascension will be responsible for general ledger and patient accounting reconciliation). Post payments not processed electronically (e.g., over-the-counter deposits, payroll deductions, returned lockbox items, bank credit/debit adjustments, credit card chargebacks) on the day such items are received or in a longer timeframe determined by Ascension to be proper. Identify and reconcile unidentified cash receipts and daily lockbox deposits to payment posting in the patient accounting system on a daily basis.

Third Party Collections and Self-Pay Follow-Up (internal and external collection activities) (AR Follow-up) - Manage the collection process in accordance with Ascension Health Standards, federal, state and local hospital policies and practices. Coordinate with third party collectors for debt in default. Attempt to resolve all issues (e.g. registration, coding, billing, clinical, etc.) which have caused a partial or full denial. Perform denial and appeal service on third party claims, including review Remittance Advice and/or Explanation of Benefits and determine payment discrepancies between actual payment and expected payment. Create and send appeal letters for accounts that have been denied by the insurance payer. As necessary, resubmit all applicable bills to the payer and make improvements to attempt reduction or elimination of re-occurrence of such events. This service includes all non-zero balances.

.- 11 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


Denial Management (Operational and Clinical) - Attempt to resolve all issues (e.g., registration, coding, billing, clinical, etc.) which have caused a partial or full denial. Resubmit the applicable bill to the payer as necessary and make systemic improvements to reduce or eliminate re-occurrence. Implement process improvements to reduce future denials based on root cause analysis of current denials.

Customer Service (Patient Billing/Patient Financial Services) – Provide an inbound call center capability and mail response capabilities for patient inquires, complaints, and possible payment/resolutions via a phone number and address listed on the patient bill. Customer service agent shall handle and resolve a wide range of questions or issues to include disputes. Supplier shall record all relevant customer service calls and maintain recordings for a period of a least ninety (90) days after the date of call, making such recordings available to Ascension upon request. Manage all correspondence received by the call center or patient correspondence sent to a physician group within the Alexian Provider Group’s or Presence Provider Group’s lockbox. This function will also include processing post-service financial assistance applications, Medicaid applications, and other patient liability functions (e.g. bankruptcy, attorney requests, etc). This call center will receive calls for both acute care and professional fee patient balances at the mutual agreement of the Alexian Provider Group or Presence Provider Group, as applicable.

Patient Statement/Pre-Collect – Manage processing of patient statements and perform patient/ authorized guarantor non-defaulted receivables collection services.

Bad Debt Management (Self-Pay Collections) - Manage patient bad debt through internal means and/or third party vendors and maintain documentation to support bad debt logging.

Underpayment Review/Recovery – Use a contract management system and other tools or vendors to identify claims (after all efforts related to AR follow-up have been exhausted) that were not technically paid correctly (commonly due to a payer mistake or a misinterpretation of or a vague contractual term). Once such claims have been identified, appeal such claims and follow-up until either the claim is paid correctly or the contract is clarified for re-modeling or changed.

Patient Billing / Secondary Billing – Identified as part of the registration process (preferred) or subsequently from the patient at time of patient billing. Send a secondary payer bill for the patient responsibility portion of such bill after the primary insurance is settled to gain reimbursement from a secondary insurance payer.

AR Oversight Support as Appropriate to Support General Operations – Provide oversight of open accounts receivable and escalate items as appropriate to assist the Alexian Provider Group and Presence Provider Group to timely resolve items and maximize collections.

c.OTHER SERVICES – The Platform-Specific Services and the Medical Group Market Services will include the additional services listed below, which Supplier will provide across all Pre-Service, Time of Service and Post-Service functional areas:

.- 12 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


Revenue Cycle Analytics and Reporting - Provide detailed reports and analytical support to revenue cycle functions through data mining, analysis and report creation.

Revenue Cycle Technology and Support - Revenue cycle support services including, but not limited to, technology support, training and special projects.

Revenue Cycle Training - Conduct training and quality assurance across all revenue cycle processes.

Vendor Management - Contracting for and management of vendor relationships specializing in revenue cycle sub-functions including areas such as authorization management, coding and debt collection.

IL Medicaid and State Payor AR Management - As made available by State of Illinois programs defined as traditional Medicaid, managed care organizations, and all commercial payors funded by the State. Upon the request of the finance departments of the Alexian Provider Group or Presence Provider Group, Supplier will request, monitor and maintain payor ‘promise to pay’ status on adjudicated but unpaid claims for accounts receivable management and reporting to finance departments of the Alexian Provider Group or Presence Provider Group to assist with identifying accounts receivable with delayed payment due to State funding.

2.Out of Scope Services.
Without limiting Section 4.1 of the MPSA, the Parties agree that any services that are not described in Section 1 of this Exhibit 1-A shall be considered to be out-of-scope services unless agreed to in writing by Supplier and the Alexian Provider Group or Presence Provider Group, as applicable. Notwithstanding the foregoing, the Parties acknowledge that (i) Supplier shall be responsible for overall performance improvement across the entire revenue cycle with respect to the Alexian Provider Group or the Presence Provider Group and will be accountable for revenue cycle performance of the Alexian Provider Group and Presence Provider Group through the Provider Incentive Fee Payments and Provider Service Levels and (ii) in the future, certain out-of-scope services may be provided by Supplier for the Alexian Provider Group or Presence Provider Group in accordance with Section 4.3(a) of the MPSA.

.- 13 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15



Annex A to Exhibit 1-A

image_2a.jpg


.- 14 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15




Addendum 2
Exhibit 3-A
(Service Levels - For the Alexian Acute Care Group and Presence Acute Care Group)
This Exhibit 3-A shall govern all Service Levels with respect to Dependent Services, solely to the extent provided to the Presence/Alexian Acute Care Units, which comprise the Presence/Alexian Acute Group. Exhibit 3 (excluding, for clarity, this Exhibit 3-A) shall continue to apply to Dependent Services provided to all other Acute Care Eligible Recipients.
1.Definitions.
For purposes of this Exhibit 3-A, the Alexian Acute Group and the Presence Acute Group will be treated as one single Acute Group, known as the Presence/Alexian Acute Group.
Acute Service Level Default” means, in accordance with this Exhibit 3-A, Supplier’s level of performance for a particular Service Level fails to meet the applicable Acute Target Level during the applicable Measurement Window (which Measurement Window starts and ends after the applicable Acute Service Level Effective Date) with respect to an applicable Acute Group.
Acute Service Level Effective Date” means, with respect to each Service Level as applied to a particular Acute Group, in accordance with this Exhibit 3-A, the date that such Service Level will be effective and enforced, which shall be the date that is [*****] after the Acute SLA Measurement Commencement Date applicable to such Service Level; provided that the Acute Service Level Effective Date will be deemed to be: (i) for Service Levels 5 (provided that sub-components of Service Level 5 will [*****], as set forth in Section 3.5 below) and 13, [*****]; (ii) for Service Levels 1, 2, 6, 7, 8 and 10, [*****]; (iii) for Service Levels 4, 11 and 12, [*****]; and (iv) for Service Levels 3 and 9, [*****].
Acute SLA Measurement Commencement Date” means, with respect to each Service Level as applied to a particular Acute Group(s), the date that such Service Level will start to be measured, tracked, and recorded, which shall be the Commencement Date for the Dependent Service against which the applicable Service Level is applied.
Service Level” means, with respect to this Exhibit 3-A only, any service level described in one of the following Sections (and any additional service levels agreed to by the Parties): Section 3.1 (“Service Level 1”), Section 3.2 (“Service Level 2”), Section 3.3 (“Service Level 3”), Section 3.4 (“Service Level 4”), Section 3.5 (“Service Level 5”), Section 3.6 (“Service Level 6”), Section 3.7 (“Service Level 7”), Section 3.8 (“Service Level 8”), Section 3.9 (“Service Level 9”), Section 3.10 (“Service Level 10”), Section 3.11 (“Service Level 11”), Section 3.12 (“Service Level 12”) and Section 3.13 (“Service Level 13”).
2.General.
2.1 As of the Acute SLA Measurement Commencement Date with respect to each Service Level for an Acute Group(s), Supplier will perform the Dependent Services with the intention to meet or exceed the Acute Target Levels (as defined below) for the Service Levels by its applicable Acute Service Level Effective Date, in accordance with this Exhibit 3-A. For the avoidance of doubt, in no event shall Supplier be liable for any Acute Service Level Default (including any Acute Service Level Credits) with respect to any Service Level prior to the applicable Acute Service Level Effective Date for any Acute Group.
As of the Acute SLA Measurement Commencement Date for each Service Level and continuing through the remainder of the applicable Supplement Term, Supplier shall, in accordance with this Exhibit 3-A, monitor, measure, collect, record and report Supplier’s performance of certain Dependent Services with respect to the metric applicable to each Service Level.
.- 15 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


2.2 Supplier shall report to Ascension Health and the Presence/Alexian Acute Group regarding Supplier’s performance, with respect to the applicable Acute Group, against each of the Service Levels for each Measurement Window.
2.3 Ascension Health, with respect to each applicable Acute Group, will have the right to receive Acute Service Level Credits, to be applied against the applicable portion of the Acute Base Fee in accordance with Section 7 below.
2.4 Supplier shall provide Ascension Health and each Acute Group with the performance reporting for the Dependent Services, as specified in Section 6 below and as set forth in Section 9.2 of the MPSA.
The Parties acknowledge and agree that, for purposes of this Exhibit 3-A, the Acute Target Levels and Service Level metrics are intended to reflect rational and reasonable standards of performance in line with industry standards, but are not intended to be in the top quartile of performance standards; provided that the Parties may, in accordance with Section 5, mutually agree to increase any Acute Target Levels or Service Level metrics during the applicable Supplement Term to be in such top quartile.
3.Service Level Criteria - Supplier will measure Supplier’s performance against the following Service Levels.
3.1 Service Level 1 - This Service Level will apply to all existing and new Supplier’s In-Scope Shared Service Centers that receive patient calls and will be composed of the following two (2) equally-weighted components (the “Acute Service Level 1 Components”):
(a)In-Scope Shared Service Centers Mean Speed to Answer (mean wait time, in seconds, to answer calls at Supplier’s In-Scope Shared Service Centers). This Service Level shall mean for a given Measurement Window for all of the Presence/Alexian Acute Care Units in a particular Acute Group, (i) the SSC Acute Aggregate Hold Time divided by (ii) the number of calls to Supplier’s In-Scope Shared Service Center for all such Presence/Alexian Acute Care Units for which the caller requested to speak with a Supplier representative during the Measurement Window.  For purposes of calculating this Service Level, “SSC Acute Aggregate Hold Time” means the aggregated total amount of time during the Measurement Window that all callers to Supplier’s In-Scope Shared Service Center for all of the Presence/Alexian Acute Care Units in a particular Acute Group (including “hang-ups”) remained on hold or in the interactive voice response unit after such callers requested to speak with a Supplier representative with respect to the applicable In-Scope Shared Service Center.
(b)Scheduling Mean Speed to Answer (mean wait time, in seconds, to answer scheduling calls at scheduling departments owned or managed by Supplier). This Service Level shall mean for a given Measurement Window for all of the Presence/Alexian Acute Care Units in a particular Acute Group, (i) the Scheduling Acute Aggregate Hold Time divided by (ii) the number of calls to the scheduling department owned or managed by Supplier for all such Presence/Alexian Acute Care Units for which the caller requested to schedule service with a Supplier representative during the Measurement Window. For purposes of calculating this Service Level, “Scheduling Acute Aggregate Hold Time” means the aggregated total amount of time during the Measurement Window that all callers to the scheduling department owned or managed by Supplier for all of the Presence/Alexian Acute Care Units in a particular Acute Group (including “hang-ups”) remained on hold or in the interactive voice response unit after such callers requested to speak with a Supplier representative with respect to the scheduling department owned or managed by Supplier with respect to all of the Presence/Alexian Acute Care Units in such Acute Group.
.- 16 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


(c)In-Scope Shared Service Centers Abandonment Rate. This Service Level shall mean for a given Measurement Window for all of the Presence/Alexian Acute Care Units in a particular Acute Group, (i) the number of calls to Supplier’s In-Scope Shared Service Center with respect to all such Presence/Alexian Acute Care Units entering the queue that are abandoned after at least 20 seconds in the queue, divided by (ii) the total number of inbound calls.
(d)Scheduling Abandonment Rate. This Service Level shall mean for a given Measurement Window for all of the Presence/Alexian Acute Care Units in a particular Acute Group, (i) the number of calls to Supplier’s scheduling department with respect to all such Presence/Alexian Acute Care Units entering the queue that are abandoned after at least 20 seconds in the queue, divided by (ii) the total number of inbound calls.
3.2 Service Level 2 - Percentage of scheduled patients who have 100% Financial Clearance completion. This Service Level shall mean, for a given Measurement Window for all of the Presence/Alexian Acute Care Units in a particular Acute Group, (a) the number of patients (both inpatient and outpatient) who had an appointment at such facility which appointment (1) was scheduled 48 hours or more prior to such patient’s appointment, and (2) occurs during such Measurement Window and who had 100% Financial Clearance divided by (b) the number of patients, both inpatient and outpatient, who had an appointment at such facility which appointment (1) was scheduled 48 hours or more prior to such patient’s appointment, and (2) occurs during such Measurement Window, expressed as a percentage. “Financial Clearance” shall mean that (i) contact has been made with the patient when applicable, (ii) the patient’s demographics have been confirmed and updated, (iii) the patient’s eligibility has been identified, and (iv) the requisite insurance authorization has been obtained.
3.3 Service Level 3 - [*****]
3.4 Service Level 4 - [*****]
3.5 Service Level 5 - Patient Experience – Patient Survey Response.
(a)     Metric. This Service Level metric shall mean, for all of the Presence/Alexian Acute Care Units in a particular Acute Group during any Measurement Window, each of (i) the Registration Survey Score and (ii) the PFSS Survey Score.
(b)     Definitions. For purposes hereof, the following terms shall have the meanings ascribed to such terms below:
(1)Registration Survey Score” shall mean, for all Presence/Alexian Acute Care Units in a particular Acute Group during any Measurement Window, the percentage of responses to the Press Ganey Outpatient Survey that indicate a score of 5 (best score) on a scale of 1 to 5 in the “Standard Registration” category. The Registration Survey Score calculations will be measured cumulatively during each Measurement Window.
(2)PFSS Survey Score” shall mean, for all of the Presence/Alexian Acute Care Units in a particular Acute Group during any Measurement Window, the percentage of responses to Supplier’s survey question of “Please rate your satisfaction with today’s call (Satisfied, Neutral, Dissatisfied)” completed during such Measurement Period that indicate a score of “Satisfied,” minus “Dissatisfied”. For clarity, this Service Level includes surveys given to callers to Supplier’s Financial Clearance Center, Medical Financial Solutions division, Customer Service Center and care coverage department. For purposes of measuring this Service Level, scores will be excluded for all of the Presence/Alexian Acute Care Units in a particular Acute Group that has less than thirty (30) survey responses during with Measurement Window.
.- 17 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


(c)    Phase-In. Service Level 5 shall be subject to phase-in process as follows: (i) effective as of [*****], the metrics and targets for Service Level 5 will be modified to account for (A) [*****] and (B) [*****] and (ii) effective as of [*****] the metrics and targets for Service Level 5 will be modified to account for [*****] and (ii) effective as of [*****] the metrics and targets for Service Level 5 will be further modified to account for a [*****], (i) and (ii), that will be defined and assigned appropriate targets to be mutually agreed by the parties.
3.6 Service Level 6 – Credit AR Days. This Service Level shall mean, for a given Measurement Window for all of the Presence/Alexian Acute Care Units in a particular Acute Group, (a) the negative balance accounts receivable with respect to all such Presence/Alexian Acute Care Units as of the last day of the Measurement Window, divided by (b) the average daily GPSR with respect to all such Presence/Alexian Acute Care Units for such Measurement Window. Average daily GPSR is calculated by dividing the total GPSR for the applicable Measurement Window by the number of calendar days during such Measurement Window. The source data for measurement will be the Crowe RCA (or to the extent necessary, such other system or method as agreed by the Parties).
3.7 Service Level 7 – Coding Quality. This Service Level will apply to Supplier Personnel and Subcontractors (including any computer-assisted coding vendor).
(a)    Metric. This Service Level shall mean, for any Measurement Window, the lower of the: (i) Inpatient DRG Coding Accuracy Score, (ii) Inpatient Diagnosis Coding Accuracy Score, (iii) Inpatient Procedure Coding Accuracy Score, (iv) Outpatient Diagnosis “First Listed” Coding Accuracy Score, (v) Outpatient Diagnosis Coding Accuracy Score and (vi) Outpatient Procedure Coding Accuracy Score.
(b)     Definitions. For purposes hereof, the following terms shall have the meanings ascribed to such terms below:
(1)     “Inpatient DRG Accuracy Score” shall mean, for any Measurement Window, the result (expressed as a percentage) of (i) the total number of cases within the Coding Audit for such Measurement Window for which the MS-DRGs or equivalent DRGs that impact payment do not require a re-assignment divided by (ii) the total number of cases within the Coding Audit.
(2)    “Inpatient Diagnosis Coding Accuracy Score” shall mean, for any Measurement Window, the result (expressed as a percentage) of (i) the total number of original ICD-10-CM diagnoses minus the number of ICD-10-CM codes that were changed (defined as replaced, deleted, or added) divided by (ii) the total number of original ICD-10-CM diagnoses within the coding audit with changes identified. Accuracy is reflected in the assignment of any secondary diagnosis to the extent such diagnosis impacts the DRG (APR or MS-DRG), SOI, ROM, or other identified quality requirements. Diagnoses outside of the identified criteria is not reflective of the Inpatient Diagnosis Coding Accuracy Score.
(3)Inpatient Procedure Coding Accuracy Score” shall mean, for any Measurement Window, the result (expressed as a percentage) of (i) the total number of original ICD-10-PCS procedure codes minus the number of ICD-10-PCS procedure codes that were changed (defined as replaced, deleted or added) divided by (ii) the total number of original ICD-10-PCS procedure codes within the coding audit.
(4)Outpatient Diagnosis “First Listed” Coding Accuracy Score” shall mean, for any Measurement Window, the result (expressed as a percentage) of (i) the total number of cases within the Coding Audit for such Measurement Window for which the ICD10 - Primary Diagnoses do not require a change divided by (ii) the total number of cases within the Coding Audit for such Measurement Window.
.- 18 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


(5)Outpatient Diagnosis Coding Accuracy Score” shall mean, for any Measurement Window, the result (expressed as a percentage) of (i) the total number of original ICD-10-CM diagnoses minus the number of ICD-10-CM codes that were changed (defined as replaced, deleted, or added) divided by (ii) the total number of original ICD-10-CM diagnoses within the coding audit with changes identified. Accuracy is reflected in the assignment of any secondary diagnosis to the extent such diagnosis impacts the outpatient encounter related to chronic conditions, impacts the APC, or other identified quality requirements. Diagnoses outside of the identified criteria are not reflective of the Outpatient Diagnosis Coding Accuracy Score.
(6)Outpatient Procedure Coding Accuracy Score” shall mean, for any Measurement Window, the result (expressed as a percentage) of (i) the total number of original CPT/HCPCS procedure codes minus the number of CPT/HCPCS procedure codes that were changed (defined as replaced, deleted or added) divided by (ii) the total number of original CPT/HCPCS procedure codes within the coding audit.
(7)Coding Audit” shall mean:
(i)[*****], random sample-based quality assurance audits, conducted by or on behalf of Supplier, of the accuracy of the billing coding performed by Supplier coder. As part of this [*****], random sample-based audit, each Supplier coder shall be audited.
(ii)[*****], random sample-based quality assurance external audits, performed for Ascension Health, whether engaged by Ascension Health or Supplier.
a.With respect to each of the [*****], an external auditor will be engaged to conduct a random, sample-based audit of the [*****] audits referenced in Section 3.7(b)(7)(i) above. The purpose of this [*****] audit, from [*****], will be to confirm Supplier’s [*****] coder audits meet expectations. Supplier shall engage such auditor for the [*****] and Ascension Health shall engage such auditor for the [*****]. After [*****], the Parties shall reevaluate the scope and structure of any annual, random sample-based quality assurance external audits to be performed on a prospective basis.
b.For clarification, the [*****] random sample-based audits will be deemed separate and distinct from the Parties’ individual or collective risk-based, focused Compliance audits, although such audits may be performed at or during the same period of time.
(iii)Any auditing, including as done by external auditors, will utilize random or probability sampling commensurate with nationally recognized audit standards and practices.
(iv)Cases coded by a Transitioned Employee shall be subject to the Coding Audits only after such Transitioned Employee has been employed by Supplier for [*****]. Thereafter, Transitioned Employee Supplier coders shall be audited at least quarterly, consistent with the quarterly coding assurance audits noted in Section 3.7(b)(7)(i) above.
(v)In conducting the Coding Audits, Supplier shall use only personnel holding the following credentials: Auditors of inpatient coding records must have at least [*****] of hospital inpatient coding experience and auditors of outpatient coding records must have at least [*****] of hospital outpatient coding experience. Additionally, each coding auditor must have any one or more of the following coding credentials: (i) RHIA, (ii) RHIT, (iii) CCS, (iv) CPC or (v) CIC.
.- 19 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


(c)    Reporting. [*****] reporting provided for all areas including (a) Inpatient DRG Coding Accuracy Score, (b) Inpatient Diagnosis Coding Accuracy Score, (c) Inpatient Procedure Coding Accuracy Score, (d) Outpatient Diagnosis “First Listed” Coding Accuracy Score, (e) Outpatient Diagnosis Coding Accuracy Score, (f) Outpatient Procedure Coding Accuracy Score and (g) the Gross Improper Payment Rate (IPR). Any measurement not meeting [*****] accuracy requires a specific corrective action plan for identified opportunities, trends and required action.
3.8 Service Level 8 - Remittance Posting.

(a)     Metric. This Service Level metric shall mean, for all of the Presence/Alexian Acute Care Units in a particular Acute Group during any Measurement Window, the absolute value of the quotient of (i) all such Presence/Alexian Acute Care Units’ aggregated Acute Trailing Period Monthly Average Unposted Cash (as defined below) divided by (ii) all such Presence/Alexian Acute Care Units’ aggregated Acute Trailing Period Daily Average NPSR (as defined below).
(b)    Definitions. For purposes of the foregoing:
(1)     “Acute Trailing Period Monthly Average Unposted Cash” shall mean, for all of the Presence/Alexian Acute Care Units in a particular Acute Group, the result of (i) the sum of the aggregate amount of all such Presence/Alexian Acute Care Units’ Acute Unposted Cash as of the last day of each of the most recent three months ended on or prior to the date of measurement divided by (ii) 3.
(2)     “Acute Trailing Period Daily Average NPSR” shall mean, for all of the Presence/Alexian Acute Care Units in a particular Acute Group for any Measurement Window, the result of (i) the aggregate amount of net patient service revenue generated by all such applicable Presence/Alexian Acute Care Units during such Measurement Window (as indicated at the time of measurement by the Crowe RCA System) divided by (ii) the number of calendar days during such Measurement Window.
(3)     “Acute Unposted Cash” shall mean, for all of the Presence/Alexian Acute Care Units in a particular Acute Group, the sum of the balances of all cash deposits related to patient accounts that have not been posted or transferred; provided that certain unposted balances may be excluded by written agreement of the Parties in the event that Supplier did not have sufficient timely information to post or transfer such cash balances.
(a)Reporting. Supplier will provide Ascension Health leadership with access to Supplier’s dashboard reflecting daily Unposted Cash, real time cash posting progress and any escalation items.
(c)    Section 2.2 and Section 6 and the data and reporting requirements of Section 2.4 shall not apply with respect to this Service Level 8 - Remittance Posting. Ascension Health shall provide Supplier, within [*****] following the end of each month, with reports setting forth for each Acute Group the Trailing Period Daily Average NPSR for each Presence/Alexian Acute Care Unit in such Acute Group together with all supporting data reasonably necessary for Supplier to verify such amounts and calculations.
(d)    Governance. The Parties will meet [*****] to discuss cash posting and reconciliation issues. The Parties agree to form a cash posting steering committee that will be responsible for oversight of cash and reconciliation issues and opportunities. The committee will have the power and duty to develop the future state of cash posting across Ascension Health.
3.9        Service Level 9 - [*****]
3.10        Service Level 10 - Transcription. This Service Level shall mean for a given Measurement Window for all of the Presence/Alexian Acute Care Units in a particular Acute Group, the time that elapses from the time that the applicable dictated file for a patient with respect to any of such Presence/Alexian Acute Care Unit is available to Supplier until the time that the transcription of such file is completed and such time that the transcription is uploaded into such Presence/Alexian Acute Care Unit’s EMR or Supplier provides a printable form of such transcription.
.- 20 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


3.11        Service Level 11 - [*****]
3.12        Service Level 12 - [*****]

3.13             Service Level 13 – Illinois Medicaid A/R Follow Up.
(a)Metric. This Service Level shall mean, for a given Measurement Window for all Presence/Alexian Acute Care Units in a particular Acute Group, each of (a) Unworked/ Overdue Illinois Medicaid A/R In Risk Levels 1-2 and (b) Unworked/ Overdue Illinois Medicaid A/R In Risk Levels 3-5.
(b)Definitions. For purposes hereof, the following terms shall have the meanings ascribed to such terms below:
(1)     “Unworked/ Overdue Illinois Medicaid A/R” shall mean: (x) the sum of the aggregate balances of Unworked and Overdue Medicaid Traditional Accounts Receivable, divided by (y) the Average Daily GPSR for all Payers.
(2)     “Unworked and Overdue Medicaid Traditional Accounts Receivable” shall mean, the balance accounts receivable related to Medicaid Claims, excluding Managed Care Organization (MCO)/Medicaid Managed Care, that are past due to be worked according to existing Supplier technology solutions and workflow management criteria.
(3)     “Medicaid Claims” shall mean claims and/or invoices where the primary insurance billed is “Medicaid”.
(4)     “Risk Levels 1 -2” refers to Medicaid Claims with accounts receivable balances less than [*****].
(5)     “Risk Levels 3 -5” refers to Medicaid Claims with accounts receivable balances greater than or equal to [*****].
(6)     “Average Daily GPSR for all Payers” shall mean the average daily GPSR attributed to Payers with respect to all such Presence/Alexian Acute Care Units for such Measurement Window. Average daily GPSR is calculated by dividing the total GPSR for the applicable Measurement Window by the number of calendar days during such Measurement Window. The source data for measurement will be the Crowe RCA (or to the extent necessary, such other system or method as agreed by the Parties).
.- 21 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


4.Acute Target Levels.
The target level for each of the Service Levels for Dependent Services provided to the Presence/Alexian Group (an “Acute Target Level”), will be set as follows:
a) Service Level 1 - The Acute Target Level for each Acute Service Level 1 Component for each applicable period will be set as follows:
Acute Service Level 1 Component[*****][*****][*****][*****]
[*****] - Remainder of term
In-Scope Shared Service Centers Mean Speed to Answer
Less than or equal to [*****].
Less than or equal to [*****].
Less than or equal to [*****].
Less than or equal to [*****].
Less than or equal to [*****].
In-Scope Shared Service Centers Abandonment Rate
Less than or equal to [*****].
Less than or equal to [*****].
Less than or equal to [*****].
Less than or equal to [*****].
Less than or equal to [*****].
Scheduling Mean Speed to AnswerN/AN/AN/AN/A
Less than or equal to [*****].
Scheduling Abandonment RateN/AN/AN/AN/A
Less than or equal to [*****]

b) Service Level 2 - At least [*****].
c) Service Level 3 - As mutually agreed by the Parties.
d) Service Level 4 – As mutually agreed by the Parties.
e) Service Level 5 – Effective as of [*****]: (a) The Acute Target Level for the Registration Survey Score measurement shall be (i) [*****] for the Alexian Acute Group and (ii) [*****] for the Presence Acute Group; and (b) the Acute Target Level for the PFSS Survey Score measurement shall be [*****] for each of the Acute Groups. Supplier must meet (a) and (b) to achieve the Acute Target Level for this Service Level. For clarity, the Acute Target Levels that apply following [*****] will be as mutually agreed by the Parties, subject to the phase-in of additional sub-components of this Service Level as described in Section 3.5(c) above.
f) Service Level 6 – [*****] or less and compliance with CMS refund rules and regulations.
g)    Service Level 7 – At least [*****]. However, the Acute Target Levels for (b) Inpatient Diagnosis Coding Accuracy Score, (c) Inpatient Procedure Coding Accuracy Score and (e) Outpatient Diagnosis Coding Accuracy Score will have a tiered approach to the [*****] Acute Target Level as follows:
TierTimelineTarget
1[*****][*****]
2[*****][*****]
3[*****][*****]

h)     Service Level 8 – Less than or equal to [*****].
.- 22 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


i)     Service Level 9 - As mutually agreed by the Parties.
j)     Service Level 10
[*****] within [*****] (other than for discharge summaries)

a. [*****] within [*****] (for discharge summaries)
b. [*****] within [*****], other than in connection with:
i.Queries to dictating medical staff: discrepancies within text of report, e.g., right/left, request to clarify proper clinician template use, distorted audio quality requiring physician decision on whether to re-dictate or fill in missing information, and incomplete or partial dictations;
ii.Queries to HIM staff: Missing patient information, signing or dictating physician, or date of service;
iii. Workflows for department of cardiology wherein scanned data is required from the hospital side to transcription to be typed into the report prior to upload;
iv. Technical failures outside the reasonable control of Supplier, including with respect to eScription data center, inbound HL7 interface from hospital, or outbound EMR interface.
k)Service Level 11 - As mutually agreed by the Parties, including (a) a target initially in effect for the period beginning on the Service Level Effective Date and ending on [*****], and (b) a revised target as mutually agreed by the Parties for the period beginning on [*****] through the remainder of the Term.
l)Service Level 12 - As mutually agreed by the Parties.
m)Service Level 13 – (a) The Acute Target Level for Unworked/Overdue Illinois Medicaid A/R In Risk Levels 1-2 will be [*****]; and (b) the Acute Target Level for Unworked/Overdue Illinois Medicaid A/R In Risk Levels 3-5 will be [*****]. Supplier must meet (a) and (b) to achieve the Acute Target Level for this Service Level.
5.Changes to Existing Service Levels.
The number of Service Levels will not exceed [*****]. The Parties will work in good faith during the twelve (12) months prior to the following effective dates to discuss any applicable revisions to the following aspects of the Service Level framework:
(a)effective as of [*****];
(b)effective as of [*****];
(c)effective as of [*****]; and
(d)effective as of [*****].
[*****] and may reflect or be derived from the following as mutually agreed upon information and factors:
-    External benchmarks; and/or
-    Then-current performance.
Any adjustment to any Service Level resulting from this Section 5 must be mutually agreed, shall apply prospectively only and shall not be applied to any period of time preceding the written agreement of the Parties with respect to such adjustment.
6.Measurement and Reporting.
6.1 Supplier’s performance against the Service Levels will be measured for each Measurement Window as of the [*****] (or, if later, the date Supplier assumes responsibility for the applicable Dependent Services in accordance with the Transition Plan).
.- 23 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


6.2 Supplier will implement automated or other measurement and monitoring tools and procedures reasonably acceptable to Ascension Health to measure Supplier’s performance against the Service Levels in a manner and at a level of detail approved by Ascension Health. Supplier will provide Ascension Health and the applicable Acute Group with access to up-to-date problem management data and other data reasonably requested by Ascension Health and the applicable Acute Group regarding the status of failures and/or user inquiries.
6.3 If Supplier fails to measure its performance with respect to a Service Level so that it is not possible to confirm whether the level of performance specified for the Service Level has been achieved for a given Measurement Window, then, unless such failure to measure was previously excused in writing by Ascension Health, such failure will be deemed an Acute Service Level Default for the applicable Measurement Window.
6.4 Supplier shall provide to the applicable Acute Group, as part of Supplier’s monthly performance reports, a set of hard- and soft-copy reports to verify Supplier’s performance and compliance with the Service Levels where data is available monthly.
6.5 Supplier shall provide detailed supporting information for each report to the applicable Acute Group in machine-readable form suitable for use on a personal computer. The data and detailed supporting information shall be Ascension Health Confidential Information, and the applicable Acute Group may access such information online, where technically feasible and permissible under Supplier’s applicable third party agreements, at any time.
7.Acute Service Level Credits.
7.1 If Supplier commits an Acute Service Level Default with respect to any Service Level for an Acute Group(s), then Supplier will pay or credit Ascension Health for the amounts described below (each, a “Acute Service Level Credit”). [*****]. Upon the occurrence of an Acute Service Level Default, Supplier will perform the problem analysis described in Section 8. Supplier will also propose a corrective action plan to improve Supplier’s performance in the upcoming Measurement Window, subject to the approval of the affected Acute Groups. Unless mutually agreed upon by Supplier and the affected Acute Group, the measurement of Supplier’s performance for a Measurement Window will be completed no later than [*****] days after the completion of such Measurement Window.
7.2 If Supplier’s performance within a Measurement Window for such Service Level for any Acute Group does not achieve the applicable Acute Target Level, resulting in an Acute Service Level Default for such Service Level with respect to the applicable Acute Group, then Supplier shall apply an Acute Service Level Credit equal to the product of (i)[*****] divided by the number of Service Levels then in effect with respect to the applicable Acute Group, multiplied by (ii) [*****] which Acute Service Level Credit shall be applied on the [*****] following the applicable Measurement Window (e.g., May 1 for a Service Level Default for the first quarter Measurement Window) for such Acute Service Level Default.
7.3 If more than one Service Level within an Acute Group has experienced an Acute Service Level Default for any Measurement Window, Supplier will apply the sum of the Acute Service Level Credit amounts for each such Service Level that had Acute Service Level Defaults during such Measurement Window as described in this Section 7.2. There shall be up to [*****] of [*****], as applicable, at risk with respect to such Measurement Window, and Supplier shall in no event be liable for Service Level Credits in excess of such at-risk amount.
7.3.1 For Service Level 1, Supplier shall calculate and report performance separately for each component. If Supplier’s performance does not achieve the Target Level for any component, then the Service Level Credit to be applied will be proportional to the number of the Target Levels not achieved. For example, if Supplier does not achieve the In-Scope Shared Service Centers Mean Speed to Answer component, but meets the In-Scope Shared Service Centers Abandonment Rate component, then Supplier shall apply [*****] of the Service Level Credit for one Service Level Default calculated in accordance with Section 7.3 of this Exhibit.
.- 24 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


7.3.2 For Service Level 5, with respect to each Acute Group, Supplier shall calculate and report performance separately for each of: (i) the Registration Survey Score; (ii) the PFSS Survey Score for Supplier’s Financial Clearance Ceter; (iii) the PFSS Survey Score for Supplier’s Medical Financial Solutions division; (iv) the PFSS Survey Score for Supplier’s Customer Service Unit and (v) the PFSS Survey Score for Supplier’s Care Coverage team (each, a “Sub-Service Level”). If Supplier’s performance does not achieve the Target Level for any Sub-Service Level for each Acute Group, then the Service Level Credit to be applied will be proportional to the number of the Target Levels not achieved. For example, if Supplier does not achieve the PFSS Survey Score for the Customer Service Unit, but meets the remaining Sub-Service Levels, then Supplier shall apply [*****] of the Service Level Credit for one Service Level Default calculated in accordance with Section 7.3 of Exhibit 3 for the applicable Eligible Recipient.
7.4 Except as otherwise expressly set forth in Section 20.1(b)(ii) of the MPSA, if Supplier’s performance on the Service Level that experienced an Acute Service Level Default achieves the Acute Target Level in the subsequent Measurement Window, the applicable Acute Group will remit the previously paid applicable Acute Service Level Credit on the [*****] following the next Measurement Window (“Acute Earnback”). However, if Supplier’s performance on such Service Level fails to achieve the Acute Target Level during the next Measurement Window, Supplier will no longer have an opportunity to earn back the applicable Acute Service Level Credit.
7.5 The mechanism for applying Acute Service Level Credits and Acute Earnback credits to the [*****].
8.Problem Analysis and Correction.
Supplier shall promptly investigate and correct each failure to meet a Service Level, by (i) promptly investigating and reporting on the causes of the problem; (ii) providing a Root Cause Analysis of such failure as soon as practicable after such failure or at the request of the affected Acute Groups; (iii) correcting the problem as soon as practicable or coordinate the correction of the problem if Supplier does not have responsibility for the cause of the problem; (iv) advising the affected Acute Group of the status of remedial efforts being undertaken with respect to such problem; (v) demonstrating that the causes of such problem have been or will be corrected on a prospective basis; and (vi) taking corrective actions to prevent any recurrence of such problem. Supplier shall complete the Root Cause Analysis as quickly as possible, but in all events within [*****], and shall notify such affected Acute Group prior to the end of the initial [*****] period as to the status of the Root Cause Analysis and the estimated completion date. The Parties shall report on Acute Service Level Defaults at each meeting of the JRB, including any disputes regarding problem analysis and correction steps, and without limiting any obligations of the Parties to implement any other decision of the JRB, each Party shall promptly implement or facilitate implementation of any resolutions determined by the JRB (e.g., Supplier cooperating with any exercise of step-in rights by Ascension Health as required by Section 4.4 of the MPSA).
9.Windfall Situations; Environmental Changes and Other Issues.
If any of the events described in Section 10.1 or Section 10.2 of Exhibit 4-A to the MPSA occurs, and such event significantly affects the Service Level measurement, Supplier’s performance under any Service Level (including the amount of resources required to maintain such performance) or Supplier’s ability to measure its performance with respect to any of the Service Levels, then either Party shall have the right to request that the other Party consider a fair and appropriate adjustment to the affected Service Levels and/or Acute Target Levels. Upon such a request, the Parties will, in good faith, discuss the impact of such event on (a) Supplier’s performance under each such Service Level; (b) the amount of resources required to maintain performance at or above the applicable Acute Target Levels and (c) Supplier’s ability to measure such Service Levels, with the outcome to equitably reflect the impact of such event(s).
Intentionally Left Blank

.- 25 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15



Addendum 3
Exhibit 3-B to Supplement 26
(Service Levels – For the Alexian Provider Group and the Presence Provider Group)

This Exhibit 3-B shall govern all Service Levels with respect to EMG Services provided to the Presence Provider Group under EMG Services Addendum #13 to Supplement 26 and the Alexian Provider Group under EMG Services Addendum #14 to Supplement 26.
1.Definitions.
Provider Service Level Default” means, in accordance with this Exhibit 3-B, Supplier’s level of performance for a particular Service Level fails to meet the applicable Provider Target Level during the applicable Measurement Window (which Measurement Window starts and ends after the applicable [*****]) with respect to an applicable Provider SLA Group.
“[*****]” means, with respect to each Service Level as applied to a particular Provider SLA Group, in accordance with this Exhibit 3-B, the date that such Service Level will be effective and enforced. For each of the Presence Provider Group and the Alexian Provider Group, the [*****] will be deemed to be (i) for Service Levels 2 and 6, [*****]; (ii) for Service Level 1, 5, 8 and 10, [*****]; and (iii) for Service Level 4, [*****]; (iv) for Service Levels 3 and 9, [*****]; and (v) for Service Levels 11 and 12, [*****] following the quarter in which the Parties mutually agree to the respective Target Levels.
Provider SLA Group” means either the Presence Provider Group or the Alexian Provider Group, provided that effective as of [*****], the Alexian Provider Group and the Presence Provider Group will be treated as one single group for purposes of this Exhibit 3-B.
Provider SLA Measurement Commencement Date” means, with respect to each Service Level as applied to a particular Provider SLA Group, the date that such Service Level will start to be measured, tracked, and recorded, which shall be the Commencement Date for the EMG Service against which the applicable Service Level is applied.
Service Level” means, with respect to this Exhibit 3-B only, any service level described in one of the following Sections (and any additional service levels agreed to by the Parties): Section 3.1 (“Service Level 1”), Section 3.2 (“Service Level 2”), Section 3.3 (“Service Level 3”), Section 3.4 (“Service Level 4”), Section 3.5 (“Service Level 5”), Section 3.6 (“Service Level 6”), Section 3.8 (“Service Level 8”), Section 3.9 (“Service Level 9”), Section 3.10 (“Service Level 10”), Section 3.11 (“Service Level 11”) and Section 3.12 (“Service Level 12”).
1.General.
1.1As of the Provider SLA Measurement Commencement Date with respect to each Service Level for a Provider SLA Group, Supplier will perform the EMG Services with the intention to meet or exceed the Provider Target Levels (as defined below) for each of the Service Levels by its applicable [*****], in accordance with this Exhibit 3-B. For the avoidance of doubt, in no event shall Supplier be liable for any Provider Service Level Default (including any Provider Service Level Credits) with respect to any Service Level prior to the applicable [*****] for any Provider SLA Group.
As of the Provider SLA Measurement Commencement Date for each Service Level and continuing through the remainder of the applicable Supplement Term, Supplier shall, in accordance with this Exhibit 3-B, monitor, measure, collect, record and report Supplier’s performance of certain EMG Services with respect to the metric applicable to each Service Level.
.- 26 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


1.2Supplier shall report to Ascension and each Provider SLA Group regarding Supplier’s performance, with respect to the applicable Provider SLA Group, against each of the Service Levels for each Measurement Window.
1.3Ascension, with respect to each applicable Provider SLA Group, will have the right to receive Provider Service Level Credits, to be applied against the [*****], in accordance with Section 7 below.
1.4Supplier shall provide Ascension and the Provider SLA Group with the performance reporting for the EMG Services, as specified in Section 6 below and as set forth in Section 9.2 of the MPSA.
1.5The Parties acknowledge and agree that, for purposes of this Exhibit 3-B, the Provider Target Levels and Service Level metrics are intended to reflect rational and reasonable standards of performance in line with industry standards, but are not intended to be in the top quartile of performance standards; provided that the Parties may, in accordance with Section 5, mutually agree to increase any Provider Target Levels or Service Level metrics during the applicable Supplement Term to be in such top quartile.
2.Service Level Criteria – Supplier will measure Supplier’s performance against the following Service Levels.
2.1 Service Level 1 - This Service Level will apply to all existing and new Supplier In-Scope Shared Service Centers that receive patient calls. In-Scope Shared Service Centers Mean Speed to Answer (mean wait time, in seconds, to answer calls at Supplier’s In-Scope Shared Service Centers). This Service Level shall mean, for a given Measurement Window, for the Provider SLA Group, (a) the Provider Aggregate Hold Time divided by (b) the number of calls to Supplier’s In-Scope Shared Service Centers for the Alexian Provider Group or Presence Provider Group (as applicable) for which the caller requested to speak with a Supplier representative during the Measurement Window.  For purposes of calculating this Service Level, “Provider Aggregate Hold Time” means the aggregated total amount of time during the Measurement Window that all callers to Supplier’s In-Scope Shared Service Centers for all of the Eligible Medical Groups in the Provider SLA Group (including “hang-ups”) remained on hold or in the interactive voice response unit after such callers requested to speak with a Supplier representative with respect to the applicable In-Scope Shared Service Centers.
2.2 Service Level 2 - Percentage of Completed Applications received will be processed in less than [*****] days in compliance with Ascension policies and CMS Refund Rules and Regulations. This Service Level shall mean, for the Provider SLA Group, during any Measurement Window, (a) the number of patients who have submitted Completed Applications for financial assistance that were received by Supplier during such Measurement Window for which, in accordance with the Ascension Billing and Collection Policy: (i) the application has been evaluated and a determination has been made to approve or deny the application; (ii) the patient has been notified of the determination; and (iii) Supplier has updated the Athena Platform or Epic Platform, if and as applicable, to adjust balances, within [*****] days or less from Supplier’s receipt of the Completed Application, divided by (b) the number of patients who have submitted Completed Applications for financial assistance that were received by Supplier during such Measurement Window. “Completed Application” means an application for which all required information has been received, including supporting materials, in order for the application to be fully processed by Supplier.
2.3 Service Level 3 – [*****]
2.4 Service Level 4 - [*****]
2.5 Service Level 5 - Patient Experience – Patient Survey Response. This Service Level shall have the meaning mutually agreed upon by the Parties.
.- 27 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


2.6 Service Level 6 – Credit AR Days. This Service Level shall mean, for a given Measurement Window, for each of the Provider SLA Groups: (a) the negative balance accounts receivable as of the last day of the Measurement Window, divided by (b) the Average Daily GPSR for such Measurement Window. “Average Daily GPSR” means (x) the total GPSR for the applicable Measurement Window, divided by (y) the number of calendar days during such Measurement Window. With respect to the Athena Group, the source data for measurement will be the Athena Platform. With respect to the Epic Group, the source data for measurement will be the Crowe RCA. [*****] will not be measured for purposes of this Service Level.
2.7 Intentionally Deleted.
2.8 Service Level 8– Remittance Resolution: Accountable Unpostables and Provider Unposted Cash.
(a)For the Athena Group during any Measurement Window, this Service Level shall mean each of the two equally weighted components:
(1)The result of the following calculation expressed as a percentage:
(x) The result of the calculation as of the last day of each of the most recent three months ended on or prior to the date of measurement:(a) the number of [*****] Remittance Required Unpostables aged greater than [*****] days from the unpostable create date divided by (b) the total number of [*****] Remittance Required Unpostables appearing in the Unpostables dashboard;
divided by
(y) three (the result of such calculation, the “Average Aged >[*****] Remittance Required Percentage”).
(2)The result of the following calculation expressed as a percentage:
(x) The result of the calculation as of the last day of each of the most recent three months ended on or prior to the date of measurement: (a) the number of total [*****] Unpostables aged greater than [*****] days from the unpostable create date divided by (b) the total number of [*****] Unpostables appearing in the Unpostables dashboard;
divided by
(y) three (the result of such calculation, the “Average Aged >[*****] Total Unpostables Percentage”).
“[*****] Unpostables” shall mean those [*****] appropriate groups from the Unpostables dashboard in the [*****] designated by the Parties to measure unidentified remittances that do not contain sufficient information for payments to be processed and posted.
(b)     For Eligible Medical Groups in the Epic Group: this Service Level shall mean, during any Measurement Window, the absolute value of the quotient of (i) the Provider Trailing Period Monthly Average Unposted Cash (as defined below) as of the last day of such Measurement Window, divided by (ii) the Provider Trailing Period Daily Average NPSR as of the last day of such Measurement Window. For purposes of the foregoing:

Provider Trailing Period Monthly Average Unposted Cash” shall mean, the result of (i) the sum of the aggregate amount of Provider Unposted Cash as of the day before the last day of each of the most recent three month ended on or prior to the date of measurement, divided by (ii) three.
.- 28 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


Provider Trailing Period Daily Average NPSR” shall mean, for the Epic Group, for any Measurement Window, the result of (i) the aggregate amount of net patient service revenue generated by the Epic Group during such Measurement Window (as indicated at the time of measurement by the Crowe RCA System) divided by (ii) the number of calendar days during such Measurement Window.
Provider Unposted Cash” shall mean, for the Epic Group, the sum of the balances of all cash deposits related to patient accounts that have not been posted or transferred; provided that certain unposted balances may be excluded by written agreement of the Parties in the event that Supplier did not have sufficient timely information to post or transfer such cash balances.
Ascension shall provide Supplier with, or provide Supplier with direct access to, within [*****] days following the end of each month, with reports setting forth for the Epic Group: (i) the Provider Trailing Period Monthly Average Unposted Cash (including a detailed itemization of the applicable balances of each account holding Provider Unposted Cash) and (ii) the Provider Trailing Period Daily Average NPSR together with all supporting data reasonably necessary for Supplier to verify such amounts and calculations. Additionally, Ascension shall provide (or cause the applicable Eligible Medical Groups within the [*****] Group to provide) Supplier with continuous, direct access to review the balances of each account holding Provider Unposted Cash through PeopleSoft or similar reporting applications.
In the event that Ascension or any Eligible Medical Group changes the manner (including accounting methods, principles or procedures) in which unposted cash is accounted for, or changes any accounting methodology, principles or procedures related to the accounts holding Provider Unposted Cash, then Service Level 8 shall be deemed to be of no effect whatsoever with respect to any such Provider SLA Group or Eligible Medical Group for which such changes have been employed until such time as Supplier and Ascension agree on reasonable modifications to the metrics for Service Level 8 and the Provider Target Level applicable thereto.
2.9 Service Level 9 – [*****]
2.10 Service Level 10 – This Service Level will apply to all existing and new Supplier In-Scope Shared Service Centers - In-Scope Shared Service Centers Abandonment Rate. This Service Level shall mean, for a given Measurement Window, for the Provider SLA Group, (A) the number of calls to Supplier’s In-Scope Shared Service Centers entering the queue that are abandoned after at least 20 seconds in the queue, divided by (B) the total number of inbound calls.
2.11 Service Level 11 – [*****]
2.12 Service Level 12 – [*****]
3.Provider Target Levels.
The target level for each of the Service Levels (a “Provider Target Level”), will be set as follows:
a)Service Level 1 – The Target Level will be set as follows:
[*****][*****]
On and after [*****]
Less than or equal to [*****]
Less than or equal to [*****]
Less than or equal to [*****]
b)Service Level 2 – [*****]
c)Service Level 3 – As mutually agreed by the Parties.
d)Service Level 4 – As mutually agreed by the Parties.
e)Service Level 5 – As mutually agreed by the Parties.
.- 29 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


f)Service Level 6 – Less than or equal to [*****].
g)Service Level 8(a) – The Target Level for each component for each applicable period will be set as follows:
Component[*****][*****]
Average Aged >[*****] Remittance Required Percentage
Less than or equal to [*****]
Less than or equal to [*****]
Average Aged >[*****] Total Unpostables Percentage
Less than or equal to [*****]
Less than or equal to [*****]
a)Service Level 8(b) – [*****] or less.
b)Service Level 9 – As mutually agreed by the Parties.
c)Service Level 10 – Less than or equal to [*****].
d)Service Level 11 – As mutually agreed by the Parties.
e)Service Level 12 – As mutually agreed by the Parties.

4.Changes to Existing Service Levels.
The number of Service Levels will not exceed eleven (11). The Parties will work in good faith during the twelve (12) months prior to the following effective dates to discuss any applicable revisions to the following aspects of the Service Level framework for EMG Services:

(a)effective as of [*****];
(b)effective as of [*****];
(c)effective as of [*****]; and
(d)effective as of [*****].
The baseline reset methodology to be discussed will allow the [*****] for each Service Level [*****], and may reflect or be derived from the following as mutually agreed upon information and factors:
-    External benchmarks; and/or
-    Then-current performance.
Any adjustment to any Service Level resulting from this Section 5 must be mutually agreed, shall apply prospectively only and shall not be applied to any period of time preceding the written agreement of the Parties with respect to such adjustment.
5.Measurement and Reporting.
5.1    Supplier’s performance against the Service Levels will be measured for each Measurement Window as of the Provider SLA Measurement Commencement Date for such Service Level.
.- 30 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


5.2    Supplier will implement automated or other measurement and monitoring tools and procedures reasonably acceptable to Ascension to measure Supplier’s performance against the Service Levels in a manner and at a level of detail approved by Ascension. Supplier will provide Ascension and the applicable Provider SLA Group with access to up-to-date problem management data and other data reasonably requested by Ascension and the applicable Provider SLA Group regarding the status of failures and/or user inquiries.
5.3     If, after the applicable [*****] with respect to a Service Level, Supplier fails to measure its performance with respect to a Service Level so that it is not possible to confirm whether the level of performance specified for the Service Level has been achieved for a given Measurement Window, then, unless such failure to measure was previously excused in writing by Ascension, such failure will be deemed a Provider Service Level Default for the applicable Measurement Window.
5.4 Supplier shall provide to the applicable Provider SLA Groups, as part of Supplier’s monthly performance reports, a set of hard- and soft-copy reports to verify Supplier’s performance and compliance with the Service Levels where data is available monthly.
5.5     Supplier shall provide detailed supporting information for each report to the applicable Provider SLA Groups in machine-readable form suitable for use on a personal computer. The data and detailed supporting information shall be Ascension Health Confidential Information, and the applicable Provider SLA Groups may access such information online, where technically feasible and permissible under Supplier’s applicable third party agreements, at any time.
6.Provider Service Level Credits.
6.1     If Supplier commits a Provider Service Level Default with respect to any Service Level for a Provider SLA Group(s), then Supplier will, subject to Section 2.7, pay or credit Ascension for the amounts described below (each, a “Provider Service Level Credit”). [*****].
6.2    Upon the occurrence of a Provider Service Level Default, Supplier will perform the problem analysis described in Section 8. Supplier will also propose a corrective action plan to improve Supplier’s performance in the upcoming Measurement Window, subject to the approval of the affected Provider SLA Groups. Unless mutually agreed upon by Supplier and the affected Provider SLA Group, the measurement of Supplier’s performance for a Measurement Window will be completed no later than [*****] days after the completion of such Measurement Window.
6.3    If Supplier’s performance within a Measurement Window for such Service Level for any Provider SLA Group does not achieve the applicable Provider Target Level, resulting in a Provider Service Level Default for such Service Level with respect to the applicable Provider SLA Group, then Supplier shall apply a Provider Service Level Credit equal to the product of (i) [*****] divided by the number of Service Levels then in effect with respect to the applicable Provider SLA Group, multiplied by (ii) [*****], for such Measurement Window, which Provider Service Level Credit shall be applied on the [*****] following the applicable Measurement Window (e.g., May 1 for a Provider Service Level Default for the first quarter Measurement Window) for such Provider Service Level Default. If more than one Service Level within a Provider SLA Group has experienced a Provider Service Level Default for any Measurement Window, Supplier will apply the sum of the Provider Service Level Credit amounts for each such Service Level that had Provider Service Level Defaults during such Measurement Window as described in this Section 6.3. There shall be up to [*****] of [*****], as applicable, at risk with respect to such Measurement Window, and Supplier shall in no event be liable for Service Level Credits in excess of such at-risk amount.
.- 31 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


(a)    For Service Level 8(a), Supplier shall calculate and report performance separately for each component, as applicable. If Supplier’s performance does not achieve the Provider Target Level for any component, then the Service Level Credit to be applied will be proportional to the number of the Provider Target Levels not achieved. For example, with respect to Service Level 8(a), if Supplier does not achieve the Average Aged >[*****] Remittance Required Percentage component, but meets the Average Aged >[*****] Total Unpostables Percentage component, then Supplier shall apply [*****] of the Service Level Credit for one Provider Service Level Default calculated in accordance with this Section 6.3 of this Exhibit 3-B.
6.4    Except as otherwise expressly set forth in Section 20.1(b)(ii) of the MPSA, if Supplier’s performance on the Service Level that experienced a Provider Service Level Default achieves the Provider Target Level in the subsequent Measurement Window, the applicable Provider SLA Group will remit the previously paid applicable Provider Service Level Credit on the [*****] following the next Measurement Window (“Provider Earnback”). However, if Supplier’s performance on such Service Level fails to achieve the Provider Target Level during the next Measurement Window, Supplier will no longer have an opportunity to earn back the applicable Provider Service Level Credit.
6.5    The mechanism for applying Provider Service Level Credits and Provider Earnback credits to the [*****].
7.Problem Analysis and Correction.
Supplier shall promptly investigate and correct each failure to meet a Service Level, by (i) promptly investigating and reporting on the causes of the problem; (ii) providing a Root Cause Analysis of such failure as soon as practicable after such failure or at the request of the affected Provider SLA Groups; (iii) correcting the problem as soon as practicable or coordinate the correction of the problem if Supplier does not have responsibility for the cause of the problem; (iv) advising the affected Provider SLA Groups of the status of remedial efforts being undertaken with respect to such problem; (v) demonstrating that the causes of such problem have been or will be corrected on a prospective basis; and (vi) taking corrective actions to prevent any recurrence of such problem. Supplier shall complete the Root Cause Analysis as quickly as possible, but in all events within [*****] days, and shall notify such affected Provider SLA Groups prior to the end of the [*****] day period as to the status of the Root Cause Analysis and the estimated completion date. The Parties shall report on Provider Service Level Defaults at each meeting of the JRB, including any disputes regarding problem analysis and correction steps, and without limiting any obligations of the Parties to implement any other decision of the JRB, each Party shall promptly implement or facilitate implementation of any resolutions determined by the JRB (e.g., Supplier cooperating with any exercise of step-in rights by Ascension as required by Section 4.4 of the MPSA).
8.Windfall Situations; Environmental Changes and Other Issues.
If any of the events described in Section 7.1 or Section 7.2 of Exhibit 4-A-2 occur, and such event significantly affects the Service Level measurement, Supplier’s performance under any Service Level (including the amount of resources required to maintain such performance) or Supplier’s ability to measure its performance with respect to any of the Service Levels, then either Party shall have the right to request that the other Party consider a fair and appropriate adjustment to the affected Service Levels and/or Provider Target Levels. Upon such a request, the Parties will, in good faith, discuss the impact of such event on (i) Supplier’s performance under each such Service Level; (ii) the amount of resources required to maintain performance at or above the applicable Provider Target Levels and (iii) Supplier’s ability to measure such Service Levels, with the outcome to equitably reflect the impact of such event(s).
.- 32 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


With respect to the Athena Group, in the event that the Athena Platform experiences any outage, bugs or other support issue not attributable to Supplier that materially affects Supplier’s ability to meet any Service Levels, as applicable (“Athena Support Issue”), Ascension shall promptly work to resolve the Athena Support Issue. Until such time that the Athena Support Issue is resolved or a reasonable work around is implemented that eliminates the adverse effect of the Athena Support Issue on the Athena Group and Supplier, the impacted Service Levels, as applicable, will be calculated as if failure to meet such Service did not occur due to the Athena Support Issue.

.- 33 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


Addendum 4

Exhibit 3-A to Supplement 26
EMG Incentive Fee (for Presence Provider Group and Alexian Provider Group)


1.Incentive Payments
1.1.General. Supplier will deliver a set of core strategies and management services designed to improve and optimize the revenue cycle operations for the Presence Provider Group or Alexian Brothers Provider Group receiving EMG Services (each, the “Provider Incentive Group”). Ascension shall pay to Supplier Provider Incentive Fees in the form of Incentive Fee Payments subject to, and in accordance with, the terms of this Addendum 4. Whether Supplier qualifies for an Incentive Fee Payment will be determined separately for the Provider Incentive Group by measuring, for such Provider Incentive Group, Supplier’s Actual Performance against a pre-determined and mutually agreed set of Provider Operating Metrics for all of the Eligible Medical Groups in each Provider Incentive Group receiving the EMG Services.
The Incentive Fee Payments will relate to Supplier’s ability to deliver the EMG Services efficiently and in compliance with all applicable rules and regulations.

1.2.Definitions.
For purposes of this Addendum 4, the following terms will have the meanings set forth below:

a)Applicable Platform” means the [*****] Platform, the [*****] or the [*****] as applicable.

b)Contract Year” means a period commencing on the Commencement Date for EMG Services (and, for each subsequent Contract Year, each anniversary thereof) and ending twelve (12) months thereafter.

c)Fiscal Year” means Ascension’s fiscal year, which shall begin on July 1 (or, in the initial Contract Year, the Commencement Date for EMG Services) and end on June 30.

d)Lower Bound Score” means: (i) for any Measurement Period in which the YTD Lift Percentage is less than [*****] and (ii) for any Measurement Period in which the YTD Lift Percentage is greater than or equal to [*****].

e)Measurement Period” means Ascension fiscal quarter.

f)Metric Lift” means, with respect to a Provider Incentive Group for any Measurement Period, the dollar value assigned to the Provider Operating Metric representing increased Cash Collections for the Provider Incentive Group during such Measurement Period for such Provider Operating Metric as compared to the Performance Baseline value for such Provider Operating Metric.

g)NextGen Platform” means a Platform licensed, or otherwise provided, by [*****] (or any successor in interest).

h)Performance Baseline” means, with respect to any Provider Operating Metric for any Provider Incentive Group, the Actual Performance for such Provider Operating Metric with respect to such Provider Incentive Group during the applicable baseline period described in Section 3 below.

i)[*****]

.- 34 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


j)Provider Performance Score” means:

(i)if for any Measurement Period the YTD Lift Percentage for a Provider Incentive Group is greater than or equal to [*****], then the result of the following (expressed as a percentage): the sum of (A) the result of (x) the difference of the YTD Lift Percentage and the Lower Bound Score, divided by (y) the difference of the applicable Upper Bound Score and the applicable Lower Bound Score, multiplied by (z) [*****], and (B) [*****]. An illustrated example of this “[*****]” Provider Performance Score is set forth in Appendix D to Exhibit 3 to the AMG Supplement.

[*****] = Provider Performance Score

For example, a YTD Lift Percentage of [*****] would result in a Provider Performance Score of [*****] since

[*****] = [*****]

or

(ii)if for any Measurement Period the YTD Lift Percentage for such Provider Incentive Group is less than [*****] then the result of the following (expressed as a percentage): (A) the difference of the YTD Lift Percentage and the applicable Lower Bound Score, divided by (B) the difference of the applicable Upper Bound Score and the applicable Lower Bound Score, multiplied by (C) [*****]. An illustrated example of this “[*****]” Provider Performance Score is set forth in Appendix E to Exhibit 3 to the AMG Supplement.

[*****] = Provider Performance Score

For example, a YTD Lift Percentage of [*****] would result in a Provider Performance Score of [*****] since

[*****] = [*****]

Notwithstanding the foregoing, in each case, the maximum Provider Performance Score is [*****] and the minimum Provider Performance Score is [*****].

k)Quarterly Aggregate Lift” means, with respect to a Provider Incentive Group for any Measurement Period, the sum of the Metric Lifts for each Provider Operating Metric during such Measurement Period.

l)Upper Bound Score” means with respect to a Provider Incentive Group: (i) for any Measurement Period in which the YTD Lift Percentage is less than [*****], [*****]; and (ii) for any Measurement Period in which the YTD Lift Percentage is greater than or equal to [*****].

m)YTD Aggregate Lift” means, with respect to a Provider Incentive Group, the sum of the Quarterly Aggregate Lifts for each Measurement Period to date in the applicable Fiscal Year. For example, when calculated at the end of the third fiscal quarter in a Fiscal Year, the YTD Aggregate Lift equals the sum of the applicable Quarterly Aggregate Lifts in each of the first, second, and third fiscal quarters in such Fiscal Year.

n)YTD Cash” means, with respect to a Provider Incentive Group, the aggregate Cash Collections to date for such Provider Incentive Group for the applicable Fiscal Year, for the applicable Provider Incentive Group.

o)YTD Lift Percentage” means, with respect to a Provider Incentive Group, the YTD Aggregate Lift divided by the YTD Cash.
.- 35 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15



2.Operating Metrics Scorecard
2.1.General. Operating Metrics Scorecards will be utilized for each Provider Incentive Group to determine the Provider Performance Score for the Provider Incentive Group for each Measurement Period in order to determine the amount of any Incentive Fee Payment earned by Supplier for such Measurement Period. For Metric 1, Metric 2 and Metric 3, the Operating Metrics Scorecard will be populated with the requisite financial performance data from (i) the Applicable Platforms used by the Eligible Medical Groups for each Measurement Period until the Parties mutually agree that the Crowe RCA System (or to the extent necessary, such other system or method as agreed by the Parties) is ready for use in connection with such Metrics, and (ii) thereafter, the Crowe RCA System (or such other system or method as agreed by the Parties). For Metric 4 and Metric 5, the Operating Metrics Scorecards will be populated with the requisite financial performance data from Supplier’s system of record; provided that Ascension will have the right to approve and audit Supplier’s calculations. The Applicable Platform for each Eligible Medical Group will be the sole source of data for the applicable Operating Metrics Scorecard. Each Operating Metrics Scorecard will also include the supporting information that is used to determine the Actual Performance for each Provider Operating Metric and the overall Provider Performance Scores.
2.2.Metrics. The “Provider Operating Metrics” are comprised of the following five (5) revenue cycle operating metrics, as each is further described and defined in Appendix A to Exhibit 3 to the AMG Supplement. The Provider Operating Metrics will be calculated separately for each Provider Incentive Group.
a.Metric 1: [*****]
b.Metric 2: [*****]
c.Metric 3: [*****]
d.Metric 4: [*****]
e.Metric 5: [*****]
3.Operating Metric Performance Baselines
Ascension and Supplier will calculate the Performance Baselines in accordance with this Section 3 for each Provider Operating Metric in the applicable Operating Metrics Scorecard. The Performance Baseline for each Provider Operating Metric will be as follows:

For the Presence Provider Group:

Metric 1 [*****]
Performance Baseline PeriodFY Q1FY Q2FYQ3FY Q4
Total Baseline
[*****][*****][*****][*****][*****][*****]
[*****][*****][*****][*****][*****][*****]
[*****][*****][*****][*****][*****][*****]

The baseline period for Metric 1 will be [*****]
Metric 2 [*****]
.- 36 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


Performance Baseline Detail
[*****][*****]
[*****][*****]
[*****][*****]

The baseline period for Metric 2 will be Calendar Year [*****]
The metric calculations will set the [*****] of the metric calculation to zero in all periods, and therefore a baseline for the [*****] is not required.

Metric 3 [*****]
Performance Baseline Detail
[*****][*****]
[*****][*****]
[*****][*****]

The baseline period for Metric 3 will be [*****]
Metric 4 [*****]
Performance Baseline value = [*****]
Metric 5 [*****]
Performance Baseline value = [*****]

For the Alexian Provider Group:

Metric 1 [*****]
Performance Baseline PeriodFY Q1FY Q2FYQ3FY Q4
Total Baseline
[*****][*****][*****][*****][*****][*****]
[*****][*****][*****][*****][*****][*****]
[*****][*****][*****][*****][*****][*****]

The baseline period for Metric 1 will be [*****]

Metric 2 [*****]

[*****].
Additionally, the metric calculations will set the change in [*****] of the metric calculation to zero in all periods, and therefore a baseline for the [*****] is not required.
.- 37 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15



Metric 2a [*****]

Performance Baseline Detail
[*****][*****]
[*****][*****]
[*****][*****]

Metric 2b [*****]
Performance Baseline Detail
[*****][*****]
[*****][*****]
[*****][*****]

The baseline for Metrics 2a and 2b will be [*****]
Metric 3 [*****]
Performance Baseline Detail
[*****][*****]
[*****][*****]
[*****][*****]

The baseline period for Metric 1 will be [*****]
Metric 4 [*****]
Performance Baseline value = [*****]
Metric 5 [*****]
Performance Baseline value = [*****]

4.Operating Metric Scorecard Performance
An Operating Metric Scorecard will be generated at the end of each Measurement Period summarizing Supplier’s overall Provider Operating Metrics performance for the Measurement Period for each Provider Incentive Group, including the Provider Performance Score, Quarterly Aggregate Lift, YTD Aggregate Lift, YTD Lift Percentage, and YTD Cash.

5.Timing of Calculation
The Operating Metrics Scorecard for the Provider Incentive Group will be calculated at the end of each Measurement Period. The calculation will be based on the [*****] of the applicable Measurement Period for each Provider Incentive Group, and will [*****] on the first day of each subsequent Fiscal Year [*****]. The Provider Operating Metrics will be measured quarterly, on a cumulative basis within any single Fiscal Year.

.- 38 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15



6.Calculation of Incentive Fee Payments
Supplier shall be eligible for Incentive Fee Payments as calculated pursuant to this Section 6, in accordance with the Operating Metric Scorecard performance.

Incentive Fee Earned Year-to-Date” means, with respect to a Provider Incentive Group for any Measurement Period, an amount equal to the product of:

(i)YTD Cash for such Provider Incentive Group,
multiplied by

(ii)     [*****]

multiplied by

(iii)     the applicable Provider Performance Score for such Provider Incentive Group in such Measurement Period.

Incentive Fee Earned In Period” means, with respect to a Provider Incentive Group for any Measurement Period, an amount equal to the result of:

(i)The Incentive Fee Earned Year-to-Date for such Provider Incentive Group,
less

(ii)The Incentive Fee Earned Year-to-Date for such Provider Incentive Group as of the end of the prior Measurement Period within the same Fiscal Year.
Incentive Fee Payment” means, with respect to a Provider Incentive Group for any Measurement Period, an amount equal to the result of:

(i)The lesser of:
a.The sum of all Incentive Fees Earned In Period for the applicable Measurement Period for such Provider Incentive Group and all previous Measurement Periods within the applicable Fiscal Year
and

b.[*****] for such Provider Incentive Group for such Measurement Period
less
(ii)The sum of all Incentive Fee Payments for such Provider Incentive Group for all previous Measurement Periods within the applicable Fiscal Year.
For the avoidance of doubt a schedule detailing a sample of this calculation has been included in Appendix C to Exhibit 3 to the AMG Supplement and a range of scenarios for the calculation of Provider Performance Scores has been included in Appendix F to Exhibit 3 to the AMG Supplement.

7.Review and Invoicing Process
Step 1:     Operating Metric Scorecards will be provided and distributed by Supplier to Ascension for each Provider Incentive Group in accordance with Section 2.1
.- 39 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


above by the 15th calendar day of the month following the end of each Measurement Period.

Step 2:    Ascension and Supplier will have [*****] days from the delivery of the Operating Metric Scorecards to review such Operating Metric Scorecards for the Provider Incentive Groups, perform audits of Applicable Platform data as appropriate, and work to reach agreement on the Operating Metrics Scorecards for the Measurement Period. In the event that a potential error is identified in an Operating Metrics Scorecard which error may, as determined by either Party, have a material impact on the measurement of the Operating Metrics Scorecard performance for the Measurement Period, the Parties will work to identify the range of impact of the potential error and shall establish a mutually agreed upon plan to review and resolve such potential error, which error will be resolved effective retroactively as the date that the error impacted the applicable measurement. Absent exceptional circumstances, the Parties will work to resolve all such issues within [*****] of discovery of such issue.

Step 3:    Supplier will invoice Ascension for each Incentive Fee Payment no later than [*****] days following the end of the Measurement Period for which the Provider Incentive Fees accrued. The invoice shall not include amounts associated with unresolved potential errors identified in Step 2 above. If any Incentive Fee Payment amount is negative for any particular Measurement Period, then such amount shall be held as a credit against Provider Incentive Fees owed in future Measurement Periods.

Step 4:    Incentive Fee Payments shall be jointly reviewed quarterly by Ascension and Supplier promptly following the delivery of Operating Metric Scorecard results by Supplier to Ascension. To the extent that neither Party delivers written notice of objection to such results within [*****] days following such delivery to Ascension, the performance results and the resulting Incentive Fee Payments shall be final and binding on the Parties.

8.Adjustments to Measurement Metrics
When appropriate, Ascension and Supplier can mutually agree to a Prospective Adjustment (i.e., an adjustment to the calculation of one or more metrics) when market events or actions outside of either Party’s control compromise the ability to accurately compare Actual Performance to Performance Baselines. Any such adjustments shall only take effect on a prospective basis from and after the Measurement Period during which the Parties agree to such adjustments. The Parties agree that a Prospective Adjustments may take into account any prior Measurement Periods affected by such Prospective Adjustment beginning as of the date either Party provides an Adjustment Request and any Measurement Periods thereafter. For the avoidance of doubt, a Prospective Adjustment may affect any Measurement Period during and after the Adjustment Request is made but not any Measurement Periods prior to the Adjustment Request.

The Parties will work in good faith during the twelve (12) months prior to the following effective
dates to discuss any [*****]
[*****]
[*****]

9.Governance Principles
9.1.Code Mapping.
.- 40 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15


a.Ascension will be responsible for mapping the transaction codes and planning codes within the Applicable Platforms to the applicable figures in the Provider Operating Metrics, and shall provide Supplier with sufficient time to review, discuss and concur with such mapping of transaction codes and planning codes before they are implemented.

b.     If Supplier does not agree to any mapping of any transaction code or planning code proposed by Ascension, then the Parties shall seek to resolve the dispute in good faith. However, if the Parties are unable to resolve the dispute, then the issue will be escalated to the Cost Board for resolution.

9.2.    Notification. Supplier agrees to promptly notify Ascension of any proposed changes in the processes or technology under their management that are reasonably likely to impact any of the revenue cycle operating metrics including but not limited to the use of transaction codes or management of accounts receivables. Ascension will have sufficient time to review and discuss the proposed changes before they are implemented and, if requested by Ascension, Supplier will provide an account sampling to ensure that any such proposed changes will be accurate.
9.3.     Records. Supplier and Ascension will maintain a reconciled record of the key assumptions used to derive targets and/or make decisions to support development and management of the Operating Metrics Scorecard.
9.4.    Supplier Access. Ascension shall provide to Supplier access to the Applicable Platform databases to review, reconcile and validate the data used to populate the Operating Metrics Scorecard. Supplier will have the right to audit the Applicable Platform database. In the event the Supplier’s auditor requires information regarding or from the database or access to the database in connection with its audit related to Supplier’s financial or operating controls, Ascension shall reasonably cooperate with Supplier to secure that information for Supplier’s auditors. Any data or database deficiencies will be addressed by Ascension (on behalf of the applicable Eligible Medical Group) in a timely manner.
9.5.    Windfall Situations and Changes in the Environment. In the event that there is a Force Majeure Event, a material change in the environment in which the Eligible Medical Groups are operating their revenue cycles, or a material change in the laws and regulations that apply to Ascension, Supplier, or an individual Eligible Medical Group which significantly impacts the economics of one or more of the Parties or frustrates the ability of a Party to perform its obligations hereunder, through no fault of its own, the applicable Party shall have the right to request that the other Party consider a fair and appropriate adjustment to the Operating Metrics Scorecard. Upon such request, Supplier and Ascension will discuss the impact associated with the change in circumstance, with the outcome to equitably reflect the impact on the Operating Metrics Scorecard. Examples of material matters that could affect one or more metrics on the Operating Metrics Scorecard performance include, but are not limited to, the following:
Payor bankruptcies.
A pattern of services to patients for whom a Eligible Medical Group is not certified by a payor to bill for such services and thus not entitled to reimbursement.
Changes in Self-Pay Discounts and/or changes in Charity Policy.
Material growth or decline in self pay population or patient residual balance after insurance.
Changes in accounts receivable write-off policies or Medicaid Pending aging policies
Implementation of new systems outside the control of Supplier (e.g., new patient accounting system).
Regulatory changes, including changes to the ICD nomenclature (e.g., ICD-11) or changes to the status of Medicaid Expansion in a given state.
.- 41 -
    [*****] Text omitted for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed
156275379.15

Exhibit 31.1


Certification of Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a), as adopted
pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 
I, Joseph Flanagan, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of R1 RCM Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date: November 8, 2022
/s/ Joseph Flanagan    
Joseph Flanagan
Chief Executive Officer
(Principal Executive Officer)



Exhibit 31.2


 
Certification of Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a), as adopted
pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 
I, Rachel Wilson, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of R1 RCM Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date: November 8, 2022
/s/ Rachel Wilson
Rachel Wilson
Chief Financial Officer and Treasurer
(Principal Financial Officer)



Exhibit 32.1

 
Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 
In connection with the Quarterly Report on Form 10-Q of R1 RCM Inc. (the “Company”) for the period ended September 30, 2022 as filed with the Securities and Exchange Commission on or about the date hereof (the “Report”), the undersigned, Joseph Flanagan, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that:
1.the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 8, 2022
/s/ Joseph Flanagan        
Joseph Flanagan
Chief Executive Officer
(Principal Executive Officer)





Exhibit 32.2

 
Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 
In connection with the Quarterly Report on Form 10-Q of R1 RCM Inc. (the “Company”) for the period ended September 30, 2022 as filed with the Securities and Exchange Commission on or about the date hereof (the “Report”), the undersigned, Rachel Wilson, Chief Financial Officer and Treasurer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that:
1.the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 8, 2022
/s/ Rachel Wilson    
Rachel Wilson
Chief Financial Officer and Treasurer
(Principal Financial Officer)